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aim  of  this  thesis  was  to  better  understand  the  KCTD12‐mediated  modulation  of  GABAB  receptor 
signaling as well as to explore new mechanisms of receptor fine‐tuning. 
The  first  part  of  this  thesis  uncovers  the  mechanism  of  GABAB  receptor‐activated  K+  current 





current desensitization. Phosphorylation of serine‐892  (S892)  in GABAB2 by protein kinase A  (PKA) was 
previously described as a rather slow mechanism to regulate GABAB receptor desensitization (Couve et 
al.,  2002).  In  contrast,  KCTD12‐induced  desensitization  of  GABAB  receptor‐activated  K+  currents 
represents a  fast  form of desensitization. We show  that both mechanisms of desensitization  influence 
each  other.  S892  phosphorylation  slows  KCTD12‐induced  K+  current  desensitization  by  rearranging 
KCTD12  at  the  receptor.  In  turn,  KCTD12  promotes  tonic  S892  phosphorylation  by  binding  to GABAB 































































This  thesis  is  based  on  the  following manuscripts  that  are  published  or  in  preparation.  Asterisk  (*) 
indicate equal contributions by the authors. 
 

























In  1950,  Roberts  and  Frankel  described  γ‐aminobutyric  acid  (GABA)  for  the  first  time  as  a  highly 
abundant amino acid  in the brain (Roberts and Frankel, 1950). Later GABA was shown to be the major 
inhibitory  neurotransmitter  in  the  central  nervous  system,  besides  L‐glutamate  being  the  major 
excitatory neurotransmitter in the brain (Curtis et al., 1959). As both neurotransmitters are involved in a 
wide range of neurological processes and functions, an imbalance in excitation and inhibition is often the 
cause  for  neurological  and  psychiatric  disorders,  including  epilepsy,  bipolar  disorders,  depression  or 
anxiety. 








receptors,  nicotinic  acetylcholine  receptors  and  5‐HT3  serotonin  receptors.  They  are  pentameric 
transmembrane receptors that are  formed  from a  repertoire of 16 subunits  (α1‐6, β 1‐3, γ1‐3, δ,  ε, π, 
and  θ)  (Mohler,  2006).  The  subunit  assembly  determines  the  physiology  and  localization  of  GABAA 
receptors. Activation of GABAA receptors results  in neuronal  inhibition as they  increase the membrane 
conductance of the postsynapse thereby decreasing the probability of action potential formation (Olsen 
and  DeLorey,  1999).  GABAA  receptor  ligands  are  commonly  used  as  therapeutics  for  psychiatric  and 
neurological  disorders,  like  anxiety  or  epilepsy  (Foster  and  Kemp,  2006).  Barbiturates  and 
benzodiazepines are two examples of widely used drugs that act anxiolytic, anticonvulsant and sedative 






Metabotropic GABAB  receptors  belong  to  the  class  C  of G  protein‐coupled  receptors  (GPCRs), which 
include calcium‐sensing receptors, metabotropic glutamate receptors, taste receptors type 1 and some 
orphan  receptors  (Foord  et  al.,  2005).  Functional  GABAB  receptors  are  obligate  heteromers  that 
assemble  from  two principal  subunits, GABAB1 and GABAB2  (Jones et al., 1998, Kaupmann et al., 1998, 
White et al., 1998, Kuner et al., 1999, Ng et al., 1999). Receptor heterogeneity  is based on  two splice 
variants of the GABAB1 subunit, GABAB1a and GABAB1b, which differ in their N‐terminus by a pair of sushi 











2005).  Accordingly,  only  correctly  formed  GABAB1/2  heterodimers  translocate  to  the  cell  surface  and 
represent functional receptors. Ligand binding to GABAB1 causes a conformational rearrangement of the 
VFTD dimer, which is required for receptor activation and G‐protein coupling by GABAB2 (Rondard et al., 











Gαs,  Gαi/o, Gαq  and Gα12  (Simon  et  al.,  1991). GABAB  receptors  are  coupled  to Gαi/o‐type G‐proteins 
(Campbell  et  al.,  1993,  Greif  et  al.,  2000).  Free  Gαi/o  inhibits  adenylyl  cyclase,  which  accordingly 
decreases  intracellular cAMP  levels and the activity of PKA.  In presynaptic compartments,  low  levels of 

















Gαi/o‐type G‐proteins. The  α‐subunit  inhibits  the activity of adenylyl  cyclase, which decreases  intracellular  cyclic 
adenosine monophosphate (cAMP) levels. Low cAMP prevents spontaneous neurotransmitter release (Sakaba and 
Neher,  2003,  Rost  et  al.,  2011).  Released  βγ‐subunits  of  the G‐protein  negatively  couple  to  voltage‐gated  Ca2+ 
channels  (VGCC) resulting  in  low  intracellular Ca2+  levels, which  inhibits evoked neurotransmitter release. This,  in 
turn, regulates long‐term potentiation (LTP) processes (Davies et al., 1991, Shaban et al., 2006, Vigot et al., 2006). 
b¦ Activation of postsynaptic GABAB receptors  inhibits adenylyl cyclase and protein kinase A  (PKA), which affects 
gene  regulation,  alleviates  tonic  inhibition  of  TREK2  channels  and  activates  NMDA‐type  glutamate  receptors 
(NMDARs) (Fukui et al., 2008, Deng et al., 2009, Chalifoux and Carter, 2010, Schwirtlich et al., 2010). Released βγ 
opens G protein‐coupled  inwardly  rectifying potassium  (GIRK)  channels  resulting  in  slow  inhibitory postsynaptic 
potentials (IPSPs), less back‐propagating action potentials (APs) and the termination of up states (Scanziani, 2000, 
Koch and Magnusson, 2009, Mann et al., 2009,  Isaacson and Scanziani, 2011). They  further  inhibit VGCCs which 













antibodies  enabled  localization  studies  in  defined  subcellular  compartments  (Kaupmann  et  al.,  1998, 
Kulik  et  al.,  2002,  Lopez‐Bendito  et  al.,  2002,  Kulik  et  al.,  2003).  GABAB  receptors  are  localized  on 
presynaptic  and, more  abundantly,  on  postsynaptic membranes.  Presynaptic  GABAB  receptors  were 
mostly found on extrasynaptic membranes and occasionally over presynaptic membrane specializations 
of glutamatergic and,  to a  lesser extent, of GABAergic  terminals. Their presynaptic expression plays a 




extrasynaptic  compartments  accounts  for  receptor  activation  by  GABA  spillover  from  simultaneously 
active GABAergic cells (Scanziani, 2000). 
The  distribution  of  GABAB  receptors  is  furthermore  regulated  by  the  heterogeneity  of  its  principal 
subunits. Whereas GABAB(1a,2)  receptors  are mainly  localized  to presynaptic  compartments, GABAB(1b,2) 
receptors  are  found more  prominent  in  postsynaptic membranes  (Vigot  et  al.,  2006).  This  subunit‐
specific division of GABAB receptor expression indicates a higher contribution of GABAB(1a,2) receptors to 
heteroreceptor  function  (Guetg et  al., 2009).  In  contrast, both GABAB1  subunits  contribute equally  to 




The  studies of  recombinant GABAB  receptors displayed different  receptor  characteristics  compared  to 
native  GABAB  receptors.  Affinity‐purification  of  native  GABAB  receptor  complexes  followed  by mass 
spectrometry  analysis  revealed  a  number  of  interacting  proteins  that  may  modify  GABAB  receptor 
responses and may account for the discrepancies between native and recombinant receptor responses 
(Bartoi  et  al.,  2010,  Schwenk  et  al.,  2010).  These  studies  identified  members  of  the  K+  channel 
tetramerization  domain‐containing  (KCTD)  protein  family,  namely  KCTD8,  12,  12b  and  16,  to  be 
associated  with  native  GABAB  receptors.  These  cytosolic  proteins  bind  GABAB  receptors  with  their 
conserved N‐terminal  tetramerization  (T1)  domain, which  is  highly  homologous  to  the  T1  domain  of 
voltage‐gated  K+  channels  (Schwenk  et  al.,  2010).  It  contains  a  BTB  (Bric‐a‐brac,  Tramtrack,  Broad‐














mediated  inhibition of voltage‐gated Ca2+ channel  (VGCC) currents  (Schwenk et al., 2010). Accordingly, 
KCTD12  knock‐down  in mice  exhibits  significantly  less  desensitization  of GABAB  receptor‐activated  K+ 
currents confirming the recombinant effects of KCTD12 in vivo (Schwenk et al., 2010). It is interesting to 







Cell  surface expression of GABAB  receptors  is  controlled by  the export of GABAB1  from  the ER. While 
GABAB2  is able  to  independently  translocate  to  the membrane, GABAB1  is  retained  in  the ER via  its ER 
retention  signal.  The  coat  protein  complex  I  (COPI)  recognizes  such  signals  thereby  mediating  the 
retrieval  of  GABAB1  from  the  cis‐Golgi  back  to  the  ER  (Brock  et  al.,  2005).  Some  cases  have  been 
reported,  where  14‐3‐3  proteins  interfere  with  the  ER  retrieval  by  competing  with  this  interaction. 
However, forward trafficking of GABAB1 was shown to take place independent of 14‐3‐3 proteins (Brock 






Once  the  receptors  are  localized  at  the  cell membrane,  prolonged  receptor  activation  initiates  the 
termination of receptor responses to protect the cell from overstimulation. This phenomenon is referred 
to  as  desensitization  (Sodickson  and  Bean,  1996,  Wetherington  and  Lambert,  2002,  Sickmann  and 
Alzheimer, 2003, Cruz et al., 2004). For most GPCRs, this event  includes phosphorylation by G protein‐
coupled  receptor  kinases  (GRKs)  followed  by  an  arrestin‐mediated  internalization  (Ferguson,  2001, 
Gainetdinov et al., 2004).  Internalized receptors are subsequently de‐phosphorylated to be recycled or 
finally degraded in lysosomes. The classical mechanism of GPCR desensitization, however, does not apply 
for GABAB  receptors. Although GRKs  induce desensitization of GABAB  receptors,  this was shown  to be 
independent  of  their  kinase  activity.  GRK4  induces  a  phosphorylation‐independent  GABAB  receptor 
desensitization by directly interacting with the receptor (Perroy et al., 2003, Kanaide et al., 2007, Ando et 





mechanisms,  GABAB  receptor  desensitization  can  be  further  induced  by  phosphorylation‐dependent 
mechanisms.  An  example  is  the  interaction  of  NEM‐sensitive  fusion  (NSF)  protein  with  the  GABAB 
receptor, which promotes protein  kinase C  (PKC)‐mediated  receptor phosphorylation  and  subsequent 
desensitization (Pontier et al., 2006). On the contrary, receptor phosphorylation can even counteract its 
desensitization. The phosphorylation of GABAB2 S783 or S892 by AMP‐dependent protein kinase (AMPK) 









and  effector  coupling.  Phosphorylation  of  S867  in GABAB1  by  the  Ca2+/calmodulin‐dependent  protein  kinase  II 
(CaMKII)  increases  GABAB  receptor  endocytosis  and  inhibits  GABAB  receptor‐mediated  activation  of  G  protein‐
activated  inwardly  rectifying  potassium  channels  (GIRKs)  (Guetg  et  al.,  2010).  AMP‐dependent  protein  kinase 
(AMPK)‐mediated phosphorylation  and protein phosphatase 2A  (PP2A)‐mediated de‐phosphorylation of  S783  in 
GABAB2  promotes  receptor  recycling  and  degradation,  respectively  (Maier  et  al.,  2010,  Terunuma  et  al.,  2010). 






GPCRs are sorted  to endosomes  for  recycling or  to  lysosomes  for degradation. GPCRs are  internalized 
from the cell membrane by constitutive or agonist‐induced endocytosis, the latter allowing for fast signal 










al., 2008, Pooler et al., 2009). GABAB  receptors were  shown  to  internalize as dimers and  their  rate of 
internalization is regulated by the GABAB2 subunit (Hannan et al., 2011). Following internalization, GABAB 
receptors  are  sorted  either  to  endosomes  for  recycling  or  to  lysosomes  for  degradation.  Receptor 







After  endocytosis,  GPCRs  are  either  re‐used  or  degraded.  For  recycling,  receptors  are  sorted  to 
endosomes and subsequently re‐inserted into the membrane. For degradation, receptors are directed to 
lysosomes,  the major  compartment  of  a  cell  for  the  degradation  of membrane  receptors.  Lysosomal 
degradation  is  initiated by  fusion of endocytic vesicles containing  the  receptors with early endosomes 
followed by their maturation to late endosomes. The endosomal sorting complex required for transport 
(ESCRT) machinery binds K63‐linked ubiquitinated proteins and targets them to endosomes (Raiborg and 
Stenmark,  2009).  Finally,  late  endosomes  fuse  with  lysosomes,  where  the  ingested  receptors  are 
degraded  (Futter  et  al.,  1996,  Bright  et  al.,  1997, Mullock  et  al.,  1998, Ward  et  al.,  2000).  GABAB 




et  al.,  2006,  Guetg  et  al.,  2009).  It  is  therefore  not  surprising  that  glutamate  in  turn  regulates  the 
expression of GABAB receptors by controlling their postendocytic sorting  (Vargas et al., 2008, Maier et 
al.,  2010).  Application  of  glutamate  to  cortical  neurons  decreases  the  amount  of  cell  surface GABAB 
receptors  by  shifting  the  balance  from  recycling  to  degradation  (Maier  et  al.,  2010).  Furthermore,  a 






For several years,  lysosomal degradation was  the only known degradation pathway  that  regulates  the 
expression of GABAB receptors. Very recently, Zemoura et al. discovered that cell surface expression of 
GABAB  receptors  is  also  controlled  by  the  proteasomal  degradation  pathway  (Zemoura  et  al.,  2013, 
Zemoura and Benke, 2014). Proteasomal degradation requires the covalent attachment of ubiquitin to 




2002)).  Ubiquitin  is  activated  by  the  ubiquitin‐activation  enzyme  E1  and  transferred  from  E1  to  the 
substrate  by  the  ubiquitin‐conjugating  enzyme  E2.  The  proteasome  recognizes  explicitly  K48‐linked 
polyubiquitinated  proteins  (Chau  et  al.,  1989,  Finley  et  al.,  1994),  whereas  K63‐linked  polyubiquitin 
chains serve as non‐proteolytic signal (Deng et al., 2000). The proteasomal degradation pathway serves 
as  quality  control  of  ER membrane  proteins  or  proteins  that  cross  the  ER membrane.  Abnormal  or 
misfolded  receptors are  removed  from  the ER  through  the ER‐associated degradation  (ERAD)  (Vembar 
and Brodsky, 2008). GABAB receptors are K48‐linked polyubiquitinated on the C‐terminus of the GABAB2 
subunit  and  interact with  components  of  the  ERAD machinery, which  controls  the  amount  of GABAB 
receptors (Zemoura et al., 2013). Finally, proteasomal degradation of GABAB receptors  is controlled by 








and abundant  in all eukaryotic organisms. Multiple  isoforms are  found  in many organisms, with seven 
isoforms  in mammals (β, γ, ε, ζ, η, τ, σ) two of them (β and γ) having a phosphorylated form (α and δ) 
(Aitken  et  al.,  1995).  They  are  expressed  in  almost  all  tissues,  including brain, heart,  liver  and  testes 





than 200 proteins  involved  in almost every cellular process,  like signal transduction, apoptosis, protein 
trafficking,  protein  degradation  or  endocytosis.  Although  14‐3‐3  proteins mostly  recognize  and  bind 

















to  be manifold. A  predominant  function  of  14‐3‐3  proteins  is  the  translocation  of  proteins  from  the 
nucleus to the cytoplasm or from the ER to the cell membrane. 14‐3‐3‐mediated nuclear export to the 











as  shown  for  the  GABAB1  subunit  (Brock  et  al.,  2005).  Another  function  of  14‐3‐3  proteins  is  the 
regulation of protein activity and stability. Binding of 14‐3‐3 can inhibit the activity of proteins, as shown 
for  the  big  mitogen‐activated  protein  kinase  1  (BMK1),  or  enhance  it,  as  shown  for  the  plasma 
membrane H+‐ATPase,  protein  kinase  C,  human  tryptophan  hydroxylase  2,  T‐lymphoma  invasion  and 
metastasis  protein  (Tiam1),  serotonin N‐acetyltranserase  (AANAT)  or  SCFFbx4  (Van Der Hoeven  et  al., 
2000, Obsil et al., 2001, Kanczewska et al., 2005, Winge et al., 2008, Woodcock et al., 2009, Barbash et 
al., 2011). 
The  interaction  of  14‐3‐3  proteins with  a  number of GPCRs  provides  them with  a  pivotal  role  in  the 
regulation  of  signal  transduction.  β1‐adrenergic  receptors  (β1ARs)  deficient  in  14‐3‐3  ε‐binding were 
found to activate Kv11.1 K+ channels in contrast to wild‐type receptors that inhibit these channels (Tutor 
et al., 2006).  It  is suggested that Kv11.1  ‐ also capable of 14‐3‐3 ε binding  ‐ and β1AR compete  for the 
same pool of 14‐3‐3 ε, which regulates the β1AR/Kv11.1 signaling. Another member of the 14‐3‐3 family, 
14‐3‐3  τ, binds  the human  follitropin  receptor  (FSHR)  resulting  in decreased  follitropin‐induced  cAMP 
accumulation (Cohen et al., 2004). 14‐3‐3 θ and ζ bind the calcium‐sensing receptor (CaR) and attenuate 
its Rho kinase signaling likely through masking the CaR binding site for Rho GTPase (Arulpragasam et al., 
2012). The  loss of 14‐3‐3  ζ binding  to  the human  thromboxane  receptor  (TP), on  the other hand, was 
shown  to decrease TR agonist‐induced activation of ERK as 14‐3‐3  ζ  is  thought  to  function as  scaffold 
protein  between  TP  and  Raf‐1  to  ensure  signal  transduction  (Yan  et  al.,  2013).  Finally,  14‐3‐3  ζ was 















antidepressant  behavior  (Schuler  et  al.,  2001,  Gassmann  et  al.,  2004,  Mombereau  et  al.,  2004a, 
Mombereau et  al., 2004b, Mombereau  et  al.,  2005, Vacher  et  al., 2006).  Similarly, overexpression of 
GABAB receptor subunits induces phenotypes like atypical absence epilepsy (Wu et al., 2007, Stewart et 




The  first  part  of  this  study  aims  at  understanding  the  molecular  mechanism  of  KCTD12‐induced 





In  a  second project we  study  the  interplay between  the  slow, phosphorylation‐induced  and  the  fast, 
KCTD12‐induced  desensitization  of  GABAB  receptors.  Slow  desensitization  is  mediated  by  receptor 
activation and subsequent inhibition of protein kinase A (PKA). As PKA phosphorylation of GABAB2 serine‐
892  (S892)  enhances  receptor  stability  at  the  plasma  membrane,  reduced  PKA  activity  promotes 
receptor internalization and desensitization. The proximity of S892 and the KCTD12 binding‐site Y902 on 
GABAB2,  led  us  to  the  hypothesis  that  GABAB2  phosphorylation  might  influence  KCTD12‐induced 
desensitization (2.2). Therefore, we tested S892‐phosphorylation mutants of GABAB2  in their properties 
to activate K+ currents and to bind KCTD12. We further used genetic mouse models to confirm our data 
in vivo. Finally, we  investigated whether  this  regulation might also exist  in  the opposite direction and 
tested the phosphorylation of GABAB2 in the presence and absence of KCTD12. 





(CUL3).  These  binding  studies  revealed  a  functional  effect  of  14‐3‐3  proteins  on  the  expression  of 
KCTD16  as well  as  of  GABAB  receptors.  They  further  seem  to  interfere with  the  binding  of  CUL3  to 
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ActivationofK+channelsby theGproteinbg subunits
is an important signaling mechanism of G-protein-
coupled receptors. Typically, receptor-activated K+
currents desensitize in the sustained presence of
agonists to avoid excessive effects on cellular activ-
ity. The auxiliary GABAB receptor subunit KCTD12
induces fast and pronounced desensitization of
the K+ current response. Using proteomic and elec-
trophysiological approaches, we now show that
KCTD12-induced desensitization results from a dual
interaction with the G protein: constitutive binding
stabilizes the heterotrimericGprotein at the receptor,
whereas dynamic binding to the receptor-activated
Gbg subunits induces desensitization by uncoupling
Gbg from the effectorK+ channel.While receptor-free
KCTD12 desensitizes K+ currents activated by other
GPCRs in vitro, native KCTD12 is exclusively associ-
ated with GABAB receptors. Accordingly, genetic
ablation of KCTD12 specifically alters GABAB re-
sponses in the brain. Our results show that GABAB
receptors are endowed with fast and reversible
desensitization by harnessing KCTD12 that inter-
cepts Gbg signaling.
INTRODUCTION
GPCRs and G-protein-regulated ion channels represent funda-
mental cellular signal transduction systems (Brown and Birn-
baumer, 1990; Dascal, 2001; Dunlap et al., 1987; Pierce et al.,
2002; Wickman and Clapham, 1995). GPCRs activate heterotri-
meric G proteins by catalyzing the exchange of GDP for GTP in
Ga, leading to dissociation of Ga$GTP from Gbg. Released
Ga$GTP andGbg have independent capacities to regulate effec-
tors such as enzymes and ion channels. Gbg released from a
variety of GPCRs directly gates G-protein-activated inwardly
rectifying K+ (GIRK or Kir3) channels (Betke et al., 2012; Lu¨scher1032 Neuron 82, 1032–1044, June 4, 2014 ª2014 Elsevier Inc.and Slesinger, 2010) and voltage-activated Ca2+ channels
(Betke et al., 2012; Tedford and Zamponi, 2006), which influ-
ences neuronal activity throughout the brain. Typical examples
of such GPCRs are the GABAB receptors that are activated by
GABA, themain inhibitory neurotransmitter in the CNS (Chalifoux
and Carter, 2011; Gassmann and Bettler, 2012). Presynaptic
GABAB receptors inhibit voltage-activated Ca
2+ channels to
reduce the release of GABA and other neurotransmitters. Post-
synaptic GABAB receptors activate Kir3 channels and thus
inhibit neuronal activity by local shunting or by generating
hyperpolarizing postsynaptic potentials. Since GABAB receptors
regulate a wide variety of physiological processes in the nervous
system, including neuronal firing, synaptic plasticity, and spon-
taneous network oscillations, the activity of GABAB receptors
needs to be temporally precise. In the continuous presence
of the agonist, GABAB receptors exhibit a time-dependent
decrease in receptor response to avoid prolonged effects on
neuronal activity, a phenomenon referred to as desensitization
(Cruz et al., 2004; Sickmann and Alzheimer, 2003; Sodickson
and Bean, 1996; Wetherington and Lambert, 2002). It is
emerging that the desensitization of GABAB receptor-activated
K+ currents observed in neurons integrates distinct mechanistic
underpinnings. First, protein kinases such as PKA or CaMKII
regulate desensitization by directly phosphorylating the receptor
and influencing its internalization from the cell surface (Couve
et al., 2002; Guetg et al., 2010). These phosphorylation-depen-
dent processes typically operate on timescales of minutes to
hours. Second, the ‘‘regulator of G-protein signaling’’ protein 4
(RGS4) induces a faster form of desensitization that occurs
within seconds of agonist application (Fowler et al., 2007; Mut-
neja et al., 2005). RGS proteins are ‘‘GTPase-activating pro-
teins’’ (GAPs) that promote desensitization by accelerating the
rate of GTP hydrolysis at Ga (Ross and Wilkie, 2000). Third, we
recently reported that the K+ channel tetramerization domain
(KCTD)-containing proteins 8, 12, 12b, and 16 represent a novel
family of proteins regulating GABAB receptor-activated K
+ and
Ca2+ currents (Schwenk et al., 2010). The KCTDs are cyto-
plasmic proteins that constitutively bind to the C-terminal
domain of GABAB2 (Ivankova et al., 2013; Schwenk et al.,
2010), which together with GABAB1 forms obligate heteromeric

























































Figure 1. KCTD12-Induced Desensitization
Is Activity Dependent, Reversible, and Op-
erates Upstream of Kir3 Channels
(A) Representative traces of K+ currents activated
by baclofen and recorded at 50 mV in CHO cells
expressing GABAB receptors and Kir3.1/3.2
channels either with or without (w/o) KCTD12 or
KCTD16. The extracellular K+ concentration was
2.5 mM; scaling for current and time as indicated.
KCTD12 but not KCTD16 induces pronounced
and rapid desensitization of the K+ currents.
(B) Bar graph summarizing the relative desensiti-
zation of baclofen-induced K+ currents. The
relative desensitization was calculated as (1 
(ratio of current amplitude after 60 s versus peak
current)) 3 100. Values are mean ± SD of 60 (w/o
KCTD), 84 (KCTD12), and 8 (KCTD16) experiments.
***p < 0.001; Dunnett’s multiple comparison test.
(C) Recovery of baclofen-activated Kir3 currents
from KCTD12-induced desensitization. After an
initial 25 s application of baclofen to induce
desensitization, baclofen was applied at various
time intervals.
(D) Amplitudes (I) of current responses at various
time intervals normalized to the initial peak ampli-
tude (Imax); data points represented as mean ± SD
of 8 experiments. The line represents fit of a
monoexponential function to the data with a time
constant of 83.6 s.
(E) Representative traces of Kir3 currents activated
either by baclofen or 1-propanol and recorded at
50mV inCHOcells expressingGABAB receptors,
Kir3.1/3.2 channels, and KCTD12. Note that direct
activationofKir3channelsby1-propanol (red trace)
induces largely nondesensitizing currents (14.9%±
5.1%, n = 10), while activation by baclofen (black
trace) induces strongly desensitizing currents
(88.8% ± 5.9%, n = 10, p < 0.001, paired t test).
Inset shows I-V relation determined with a voltage
ramp during application of 1-propanol.
(F) Kir3.2 channels are efficiently activated by 1-
propanol before and after near complete desen-
sitization of the currents by baclofen. See also
Figure S1.
Neuron
Uncoupling of G Protein bg Subunits from Channelsof receptor-activated K+ currents while only KCTD12 and
KCTD12b induce fast and pronounced current desensitization
(Schwenk et al., 2010; Seddik et al., 2012). Desensitization is
due to the particular H1 homology domain in KCTD12 and
KCTD12b as well as the absence of an antagonistic H2 homol-
ogy domain present in KCTD8 and KCTD16 (Seddik et al.,
2012). The mechanism by which the KCTDs regulate GABAB
receptor-activated K+ and Ca2+ currents is unknown.
Here we show that KCTD8, KCTD12, and KCTD16 all constitu-
tively bind to the G protein, which stabilizes the G protein at
the receptor and underlies accelerated K+-current responses.
In addition, selectively KCTD12 binds to the activated Gbg sub-
units at their interface with Kir3 channels, thereby uncoupling
Gbg from the channels. This postreceptor mechanism of desen-
sitization is fully reversible and rendered receptor-specific
through the exclusive association of native KCTD12 protein
with GABAB receptors. Thus, these findings identify a unique re-
ceptor-specific mechanism for fast desensitization of G-protein-
activated K+ currents.RESULTS
KCTD12-Induced Desensitization of GABAB-Activated
Kir3 Currents Is Reversible and Operates Upstream of
the Channel
To study the desensitization of GABAB receptor-activated K
+
currents, we performed whole-cell patch-clamp recordings
from CHO cells expressing GABAB receptors and Kir3 channels
with or without KCTD proteins. Application of the agonist baclo-
fen to KCTD-free or KCTD16-containing GABAB receptors
elicited robust outward K+ currents that slightly, and similarly,
decreased in amplitude during a 1 min application period (Fig-
ures 1A and 1B). In contrast, KCTD12-containing GABAB recep-
tors elicited K+ currents that almost completely desensitized
(Figures 1A and 1B). The time course of KCTD12-induced desen-
sitization was approximated by a double exponential function
with time constants of 1.9 ± 0.3 s (relative contribution to desen-
sitization 42.4% ± 11.2%) and 14.3 ± 2.0 s. The KCTD12-
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Figure 2. Binding of KCTDs to the G Protein
Does Not Require GABAB Receptors
(A) G protein subunits Gao, Gb1, Gb2, and
Gg12 specifically copurify in APs from WT and
Gabbr2/ mouse brain membranes using anti-
KCTD12 or anti-GABAB2 antibodies. Specificity of
the G protein subunit interaction with KCTD12 is
determined by the relative abundance of specific
peptides in APs versus target knockout controls
(rPV) compared to threshold rPV (normalized to 1)
(Schwenk et al., 2012). The number of specific and
total peptides retrieved by mass spectrometry for
any G protein subunit is indicated. Note copur-
ification of G protein subunits in anti-KCTD12 APs
from Gabbr2/ brains in which KCTD12 is not
associated with GABAB receptors.
(B and C) G protein subunits copurify with KCTDs
from membranes of transfected HEK293T cells. In
(B), the Renilla Luciferase-tagged Gao (GaoLUC),
the yellow fluorescent protein-tagged Gb1
(Gb1YFP), and the Venus-tagged Gg2 (Gg2Venus)
were expressed with or without Flag-tagged
KCTD12. In (C),Myc-taggedKCTD8,KCTD12, and
KCTD16 and Venus-tagged Gg2 (Gg2Venus) were
expressed with or without the Flag-tagged Gb
isoforms Gb1 (Gb1Flag) or Gb2 (Gb2Flag). APs were
performed with anti-Flag antibodies and analyzed
by western blot with antibodies against Renilla
Luciferase, Myc, Flag, and GFP. MW, molecular
weight; Venus, variant of GFP. See also Figure S2.
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Uncoupling of G Protein bg Subunits from Channelsbaclofen. After near complete baclofen-induced desensitization,
the responses to subsequent baclofen applications (Figure 1C)
fully recovered with a time constant of 83.6 s (fit to themean, Fig-
ure 1D). To investigate whether KCTD12 directly desensitizes
Kir3 channels, we activated the channels in a G-protein-inde-
pendent manner with 1-propanol (Aryal et al., 2009; Kobayashi
et al., 1999; Lewohl et al., 1999). In the presence of KCTD12,
1-propanol induced K+ currents with negligible desensitization
(Figure 1E). Moreover, 1-propanol effectively, and similarly, acti-
vated Kir3 channels both before and after complete KCTD12-
induced current desensitization obtained by applying baclofen
for 60 s (Figure 1F). Likewise, 1-propanol still activated Kir3
channels during baclofen-evoked KCTD12-induced current
desensitization (Figure S1 available online). Together, these re-
sults demonstrate that KCTD12-induced desensitization is fast,
fully reversible, activity dependent, and operates upstream of
Kir3 channels.
KCTDs Interact with G Protein Subunits
The above results suggest that KCTD12 induces desensitization
at the receptor and/or the G protein. We used a proteomic
approach combining antibody-based affinity purifications (APs)
with high-resolution quantitative mass spectrometry (Mu¨ller
et al., 2010; Schwenk et al., 2012) to address whether G protein
subunits directly interact with KCTD12 in native tissue. For APs,
we equilibrated the entire pool of solubilized KCTD12 protein in
mouse brain membranes with anti-KCTD12 antibodies. To con-
trol the specificity of the APs, we used membrane fractions from
Kctd12 knockout (Kctd12/) mice (Metz et al., 2011) (target KO;
Figure 2A). The anti-KCTD12 antibody copurified GABAB1,
GABAB2 (but no other GPCRs) and the G protein subunits Gao,1034 Neuron 82, 1032–1044, June 4, 2014 ª2014 Elsevier Inc.Gb1, Gb2, and Gg12 (Figure 2A). Copurification of the G protein
subunits was also observed when KCTD12 was not associated
with GABAB receptors (using Gabbr2
/ mice [Gassmann
et al., 2004] for APs; Figure 2A). This suggests that KCTD12
directly interacts with G proteins.
Interactions of KCTD12 with G proteins were confirmed
in APs from HEK293T cells coexpressing combinations of
epitope-tagged KCTD proteins and G protein subunits. FLAG-
tagged KCTD12 copurified the G protein either as a Gabg
trimer or as a Gbg dimer (Figure 2B). Notably, copurification
of individual G protein subunits with KCTD12 either failed
(Gb, Gg) or was very inefficient (Gao). APs with purified recom-
binant KCTD12 and Gb1g2 proteins confirmed that these pro-
teins directly interact with each other (Figure S2). These results
identify the Gbg dimer as the primary interaction partner of
KCTD12 (Figure 2B). Experiments with KCTD8 and KCTD16
confirmed that all KCTD subunits of GABAB receptors bind to
Gbg (Figure 2C).
KCTD12 Dynamically Binds Activated Gbg Subunits and
Prevents Their Interaction with Kir3 Channels
We next tested in transfected CHO cells whether KCTD12 de-
sensitizes K+ currents by directly acting at the G protein. For
this purpose, we activated Kir3 channels in a receptor-indepen-
dent manner with the nonhydrolysable GTP-analog guanosine
50-O-(3-thiotriphosphate) (GTPgS), which we perfused into the
cell via the recording pipette (Figure 3A). By exchanging for
GDP at Ga, GTPgS liberates Gbg and constitutively activates
Kir3 channels (Breitwieser and Szabo, 1988; Dunlap et al.,
1987; Gilman, 1987; Kurachi et al., 1987; Leaney et al., 2004;





































































































































Figure 3. KCTD12-Induced Desensitization Requires Interaction with the Activated G Protein
(A) Representative Kir3 currents activated by intracellular perfusion of GTPgS (0.6 mM) and recorded at 50 mV in transfected CHO cells expressing Kir3.1/3.2
channels with or without (w/o) KCTD12 or KCTD16. Note that KCTD12-induced desensitization only occurs after activation of the G protein by GTPgS and that
channel activation by Gbg is faster than desensitization by KCTD12. Due to the competition of both processes, the peak current is reached earlier and reduced in
amplitude compared to control (KCTD12: 62.8 ± 61.9 pA, n = 13; w/o KCTD12: 128.0 ± 98.8 pA, n = 28; p = 0.025, Student’s t test). KCTD16 fails to desensitize the
current response.
(B) Bar graph summarizing the desensitization of GTPgS-induced responses. The relative desensitization (calculated after 10min of GTPgS perfusion) was similar
in CHO cells expressing KCTD12 without GABAB receptors (w/o GABAB) or together with WT GABAB receptors or mutant Y902A-GABAB2 receptors that do not
associate with the KCTDs (Schwenk et al., 2010). Data are represented asmean ± SD of 28 (WTGABAB, w/o KCTD), 13 (WTGABAB, + KCTD12), 11 (WTGABAB, +
KCTD16), 9 (Y902A-GABAB2, w/o KCTD), 7 (Y902A-GABAB2, + KCTD12), 10 (w/o GABAB, w/o KCTD), and 6 (w/o GABAB, + KCTD12) recordings. ***p < 0.001;
Dunnett’s multiple comparison test and Student’s t test.
(C) Constitutive activation of the G protein with AlF4
 exposes the activity-dependent binding site on Gbg and selectively increases KCTD12 binding to Gbg.
HEK293T cells, expressing Gai1LUC, Gb1Flag, Gg2Venus, and either KCTD12Myc or KCTD16Myc were lysed in the absence or presence of AlF4
. APs were
performed with anti-Flag antibodies and analyzed by western blot with antibodies against Renilla Luciferase, Myc, Flag, and GFP.
(D) Baclofen-induced changes in the BRET ratio determined in CHO cells expressing GABAB receptors, Gao-RLuc, Flag-Gb2, and Venus-Gg2 without (w/o) or
with KCTD12 and KCTD16. Single experiments carried out in parallel are shown. Scheme on the left indicates conformational changes during G protein activation
that are monitored by BRET measurements. The BRET ratio decreases during G protein activation due to conformational rearrangement of the Gao-RLuc and
Venus-Gg2 subunits. After receptor blockade with the antagonist CGP54626, reassociation of the G protein is significantly slowed in the presence of KCTD12.
The BRET recovery phases are shown fitted to a double exponential function (inset).
(E) Bar graph of the changes in BRET ratio determined in experiments as in (D).
(F) Bar graph of the amplitude-weighted mean time constants obtained by fitting the BRET recovery phase to a double exponential function in experiments as in
(D). Data in (E) and (F) are represented as mean ± SD of five experiments. ***p < 0.001; **p < 0.01; Kruskal Wallis test.
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Uncoupling of G Protein bg Subunits from Channelsof KCTDs or in the presence of KCTD16, GTPgS induced slowly
rising inwardly rectifying K+ currents that exhibited modest
desensitization over the 10 min recording period (Figures 3A
and 3B). In contrast, in the presence of KCTD12 the currents
exhibited pronounced desensitization eventually leading to a
decrease in amplitudes close to baseline (Figures 3A and 3B).
Similar results for KCTD12-induced desensitization were
obtained when Kir3 channels were activated by GTPgS in the
presence of either wild-type (WT) GABAB receptors or mutant
Y902A-GABAB2 receptors that are unable to bind KCTD12 (Cor-reale et al., 2013; Schwenk et al., 2010) (Figure 3B). These results
demonstrate that KCTD12-induced Kir3 current desensitization
requires activation of the G protein but does not require assem-
bly of KCTD12 with GABAB receptors. Moreover, since GTPgS is
nonhydrolysable, these experiments show that KCTD12 does
not promote desensitization through GAP activity at Ga (Mutneja
et al., 2005; Ross and Wilkie, 2000). Rather, the results point to
an activity-dependent interaction of KCTD12 with the G protein,
in addition to the constitutive interaction that KCTD12 shares
with KCTD8 and KCTD16 (Figure 2). Indeed, constitutiveNeuron 82, 1032–1044, June 4, 2014 ª2014 Elsevier Inc. 1035
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Figure 4. KCTD12 Occludes the Kir3 Inter-
action Site on Gbg
(A) Scheme illustrating activity-dependent inter-
ference with Gbg binding to Kir3 channels using a
Kir3.4-derived peptide.
(B) Representative traces of Kir3 currents evoked
by two consecutive baclofen applications (first
application was for 15 min, second application for
15 s after a 7 min interval) to CHO cells expressing
GABAB receptors in the absence (top, middle)
or presence (bottom) of KCTD12. Cells were
perfused with control intracellular solution (w/o
Kir3.4 peptide) or with intracellular solution sup-
plemented with 40 mM Kir3.4-peptide (+ Kir3.4
peptide).
(C) Bar graphs summarizing the amplitude ratios
of peak K+ currents recorded during the second
(P2) and first (P1) baclofen application. Data are
represented as mean ± SD of 9 (w/o KCTD, w/o
Kir3.4 peptide), 8 (w/o KCTD, + Kir3.4 peptide),
5 (+ KCTD12, w/o Kir3.4 peptide), and 6
(+ KCTD12, + Kir3.4 peptide) experiments. ***p <
0.001; Student’s t test. Note that KCTD12 coun-
teracts the reduction of the peak amplitude by
the Kir3.4-peptide during the second baclofen
application. See also Figure S3.
Neuron
Uncoupling of G Protein bg Subunits from Channelsactivation of the G protein with AlF4
 selectively increased
KCTD12 binding to Gbg, consistent with an activity-dependent
binding site on Gbg that is unique to KCTD12 (Figure 3C).
We next studied whether KCTD12 and KCTD16 differentially
influence G protein conformational rearrangements during G
protein activation, using bioluminescence resonance energy
transfer (BRET) experiments in transfected CHO cells (Digby
et al., 2006; Frank et al., 2005) (Figures 3D and 3E). Indeed,
KCTD12 but not KCTD16 induced a significant increase in the
magnitude of the BRET change during G protein activation.
Moreover, reassociation of the G protein was slowed in the pres-
ence of KCTD12 (Figures 3D and 3F). Altogether, the data are
compatible with KCTD12 influencing conformational changes
of the G protein and/or increasing steady-state G protein disso-
ciation in an activity-dependent manner.
With native GABAB receptors where GABAB(1,2), KCTD12, and
the G protein reside in close proximity (Schwenk et al., 2010),
constitutive and activity-dependent binding of KCTD12 to Gbg
may be envisaged as follows: receptor activation of the G pro-
tein, which is stabilized at the receptor via constitutive binding
to KCTD12, promotes both activation of Kir3 channels and ac-
tivity-dependent interaction of KCTD12 with Gbg. Competition
between KCTD12 and Kir3 channels for Gbg reduces steady-
state Gbg interaction with the channels, which desensitizes
the current response. Finally, the Ga$GDP subunit displaces1036 Neuron 82, 1032–1044, June 4, 2014 ª2014 Elsevier Inc.KCTD12 from its activity-dependent
binding site on Gbg and reconstitutes
the heterotrimeric G protein, which ren-
ders the desensitization mechanism
reversible. To address whether KCTD12
occludes the channel binding site of
Gbg (Ford et al., 1998; Whorton andMacKinnon, 2013), we used a peptide derived from the Gbg
binding site of the Kir3.4 protein (Figure 4A). This Kir3.4-peptide
inhibits Gbg activation of Kir3 channels with an IC50 of 0.6 mM
(Krapivinsky et al., 1998). Perfusion of the Kir3.4-peptide
(40 mM) into CHO cells expressing GABAB receptors and Kir3
channels resulted in strong desensitization of the K+ currents
during a 15 min baclofen application (Figure 4B, middle). The
peptide-induced desensitization was slowly reversible; a 7 min
period showed recovery of the baclofen response to about
half of the initial peak current amplitude (Figures 4B, middle,
and 4C), while complete recovery was obtained in the absence
of the peptide (Figures 4B, top, and 4C). In the combined pres-
ence of KCTD12 and Kir3.4-peptide, the desensitization was
faster than with the peptide alone (Figure 4B, bottom). However,
a close to complete recovery of the peak K+ current amplitude
was obtained within the 7 min period, showing that KCTD12
significantly counteracted the lasting inhibitory effect of the
Kir3.4-peptide (Figures 4B, bottom, and 4C). The most likely
explanation of these data is that KCTD12 efficiently competes
with the Kir3.4-peptide for binding to activated Gbg. While allo-
steric effects of KCTD12 on Kir3.4-peptide binding cannot be
fully ruled out, we consider this possibility less likely. The Gbg
dimer is assumed to be a relatively rigid scaffold for protein
binding and its X-ray structure remains unperturbed when
bound to various peptides or effectors (Lin and Smrcka, 2011;
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Figure 5. KCTD12 and GRK2 Differ in Their
Binding to Gbg and in the Reversibility of
Desensitization
(A) Representative traces of Kir3 currents evoked
by two consecutive baclofen applications in an
interval of 10 min to CHO cells expressing GABAB
receptors with or without (w/o) GRK2.
(B) Traces of Kir3 currents recorded from GRK2-
expressing cells in the absence (blue) or presence
(gray) of 20 mM gallein.
(C) Bar graphs summarizing Kir3 current desensi-
tization. Data are mean ± SD of 7 (w/o GRK2), 11
(+ GRK2), and 6 (+GRK2, + gallein) experiments.
***p < 0.001; **p < 0.01; Dunnett’s multiple com-
parison test or Student’s t test.
(D) Bar graph summarizing the amplitude ratios of
peak K+ currents recorded during the second (P2)
and first (P1) baclofen application (A). Data are
represented as mean ± SD of 5 (w/o GRK2) and
9 (+ GRK2) recordings. ***p < 0.001; Dunnett’s
multiple comparison test. Note that GRK2-
induced desensitization does not revert during the
10 min period.
(E) Bar graph summarizing the effects of 20 mM
gallein and 20 mMselenocystamine on Kir3 current
desensitization in CHO cells with or without
KCTD12. Data are represented as mean ± SD of
8 (control, w/o KCTD), 18 (+ gallein, w/o KCTD),
10 (selenocystamine, w/o KCTD), 7 (control, +
KCTD12), 15 (+ gallein, + KCTD12), and 6
(+ selenocystamine, + KCTD12) recordings. *p <
0.05; Dunnett’s multiple comparison test. Inset
shows representative traces of baclofen-evoked
Kir3 currents recorded from KCTD12-expressing
cells in the absence (+ KCTD12) or presence of
gallein (+ KCTD12, + gallein). See also Figure S4.
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Uncoupling of G Protein bg Subunits from ChannelsOldham and Hamm, 2006). Moreover, in our experiments,
KCTD12 was unable to displace the Kir3.4 peptide once bound
to Gbg (Figure S3).
Similar to KCTD12, GPCR kinase 2 (GRK2) binds to Gbg and
induces fast desensitization of GPCR-activated Kir3 currents in
heterologous cells (Raveh et al., 2010). Because KCTD12 and
GRK2 share no sequence or structural similarity, we compared
the properties of the desensitization induced by the two
proteins. Expression of GRK2 in CHO cells increased desensi-
tization of baclofen-activated Kir3 currents by 30% (Figures
5A and 5C). In contrast to KCTD12-induced desensitization,
the GRK2-induced desensitization was irreversible within a
10 min period (Figures 5A and 5D). Moreover, the GRK2-
induced desensitization was prevented by gallein (Figures 5B
and 5C), a compound binding with high-affinity to the protein-
protein interaction ‘‘hot spot’’ of Gbg (Lehmann et al., 2008;
Scott et al., 2001). Gallein and selenocystamine (Dessal et al.,
2011), a structurally unrelated compound that also binds to
the ‘‘hot spot,’’ did not prevent KCTD12-induced desensitiza-
tion (Figure 5E). Thus, KCTD12 and GRK2 binding differs inNeuron 82, 1032–10its sensitivity to compounds that bind
to the ‘‘hot spot’’ of Gb. Nonetheless,
as GRK2 and KCTD12 can displace
each other from Gbg (Figure S4), thebinding domains of the two proteins overlap, probably in the
channel-binding area on Gbg.
KCTD12-Induced Desensitization Is Specific for GABAB
Receptors
If KCTD12 induces desensitization by acting at Gbg, it should not
only desensitize GABAB-activated Kir3 currents but also those
activated by other GPCRs, as long as there is free KCTD12 avail-
able tobind toGproteins. Indeed,weobservedKCTD12-induced
desensitization in heterologous cells with various GPCRs. For
example, activation of adenosine A1 (Figure 6A) or mGlu2 recep-
tors (Figures S5A and S5C) in the presence of KCTD12 in trans-
fected CHO cells yielded desensitizing Kir3 currents. Activation
of mutant Y902A-GABAB2 receptors that cannot bind KCTD12
gave rise to strongly desensitizing Kir3 currents in Xenopus oo-
cytes only after injection of KCTD12 cRNA in large excess over
GABAB receptor cRNA (ratio of 32:1; Figure 6B). Under these
conditions, KCTD12 levels are sufficiently high to decrease basal
currents (induced by endogenous or overexpressed exogenous
Gbg; Figures S5F–S5H) and to desensitize Y902A-GABAB244, June 4, 2014 ª2014 Elsevier Inc. 1037
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Figure 6. Receptor Specificity of KCTD12-
Induced Desensitization Depends on the
KCTD12/GABAB Ratio
(A) Left: representative K+ current responses
elicited by 2-chloro-N6-cyclopentyladenosine
(CCPA) in CHO cells expressing adenosine A1
receptors with (+ KCTD12) or without (w/o
KCTD12) KCTD12. Right: bar graph summarizing
desensitization of CCPA-induced K+ currents;
data are represented as mean ± SD of 5 experi-
ments.
(B) GABA-activated Kir3 currents recorded at
50 mV from Xenopus oocytes injected with
cRNA encoding KCTD12 and either WT GABAB2
or mutant Y902A-GABAB2 at the indicated
ratios. Note that mutant receptors only produced
desensitizing responses with a high expression
level of KCTD12, while WT receptors produced
desensitizing responses already at a low
KCTD12 expression level. Y902A-GABAB2 cRNA
expresses slightly less protein than WT GABAB2
cRNA (Figure S5I), showing that the difference in
desensitization is not due to higher expression of
Y902A-GABAB2 than WT GABAB2.
(C) Relative desensitization of K+ currents in Xen-
opus oocytes at different cRNA ratios for KCTD12
and WT GABAB2 or Y902A-GABAB2. Data points
are represented as mean ± SD of 6–11 experi-
ments. Lines are the results of a Hill equation fitted
to the data yielding values for half-maximal effect
and slope factor of 1.01 and 2.34 for WT GABAB2
and 22.5 and 1.06 for Y902A-GABAB2. Inset:
western blots showing expression of KCTD12
protein in oocytes injected with the indicated
cRNA ratios. See also Figure S5.
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Uncoupling of G Protein bg Subunits from Channelsreceptor-activated Kir3 currents (Figures 6B and 6C). At
equimolar amounts of injected KCTD12 and GABAB receptor
cRNA, activation of Y902A-GABAB2 receptors elicited robust K
+
currents that, however, failed to desensitize. This contrasts with
WT GABAB receptors, which exhibited strongly desensitizing
Kir3 currents already at low cRNA ratios (Figures 6B and 6C).
Dose response relations forKCTD12/GABAB2 cRNA ratios versus
Kir3 current desensitization revealed a more than 10-fold differ-
ence between WT and mutant receptors (Figure 6C). Together,
these results suggest that WT GABAB receptors promote desen-
sitization by capturing KCTD12, even at low expression levels,
and juxtaposing it to the activatedGprotein. Accordingly, transfer
of the KCTD-binding domain of GABAB2 to ametabotropic gluta-
mate receptor (mGlu2-GABAB2-CT) endowed this chimera with
rapid and pronounced KCTD12-induced desensitization, similar
to that of GABAB receptors (Figures S5A–S5E).1038 Neuron 82, 1032–1044, June 4, 2014 ª2014 Elsevier Inc.The above results show that the
relative amounts of GABAB receptors
and KCTD12 will determine the recep-
tor specificity of desensitization. Next,
we therefore examined to what extent
KCTD12 protein is associated with
GABAB receptors in the adult mouse
brain. For this purpose, we solubilizedthe complete pool of KCTD12 protein present in brain mem-
brane fractions and separated the solubilized proteins by native
gel electrophoresis (BN-PAGE) and SDS-PAGE. Western blots
of WT brain probed with anti-KCTD12 and anti-GABAB2 anti-
bodies demonstrated that the vast majority of KCTD12 protein
is assembled into high-molecular weight GABAB receptor com-
plexes (Figure 7A, top). The western blot in Figure 7A (enlarged
at shorter exposure time in the inset in Figure 7B) further indi-
cates that KCTD12 only assembles into a fraction of GABAB re-
ceptors with an apparent molecular mass of 0.6 MDa. A minor
fraction of KCTD12 protein, possibly dissociated from GABAB2
during solubilization, focused in the mass range of 0.15 to
0.18 MDa, the expected value for assemblies of KCTD12 tetra-
mers (Schwenk et al., 2010) and Gbg. When using membrane
fractions from Gabbr2/ mice, the entire pool of KCTD12 pro-
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Figure 7. KCTD12 in the Adult Mouse Brain
Is Exclusively Associated with GABAB
Receptors
(A) Two-dimensional gel separations of native
GABAB receptors in membrane fractions prepared
from whole brains of WT and Gabbr2/ mice.
GABAB2 and KCTD12 were revealed on western
blots. Apparent molecular mass (BN-PAGE) and
molecular weight (SDS-PAGE) are as indicated.
Note that KCTD12 coassembles into high-molec-
ular weight GABAB receptor complexes in WT but
not in Gabbr2/ mice. The total amounts of
KCTD12 protein inGabbr2/ andWTmice do not
differ significantly (Figure S6).
(B) Abundance-mass profiles determined by BN-
MS analyses for solubilized GABAB1, GABAB2, and
KCTD12. Each data point represents the amount
determined for the respective protein in one gel
slice (total of 95 slices) normalized to maximum;
symbols are as indicated. Lines are the result of a
mono (red) or double component (blue) Gaussian
function fitted to the data with values for apparent
complex mass peaks of 0.56 MDa (KCTD12), 0.44
MDa, and 0.57 MDa (GABAB2). Note tight coas-
sembly of KCTD12 and a fraction of GABAB re-
ceptors causing a shift in apparent molecular
mass consistent with the weight of KCTD12-Gbg
assemblies. Inset shows western blot of the
2D-PAGE-separated GABAB receptors from (A)
exposed for a shorter period to resolve the
two populations of GABAB receptors. See also
Figure S6.
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Uncoupling of G Protein bg Subunits from ChannelsThus, in the adult mouse brain, KCTD12 almost exclusively as-
sociates with GABAB receptors. This agrees with the results
from anti-KCTD12 APs that failed to identify additional GPCRs
associating with KCTD12 (see above). We further investigated
the GABAB-KCTD12 assembly by combined use of BN-PAGE
and quantitative high-resolution mass spectrometry (BN-MS
[Schwenk et al., 2012]). BN-PAGE slices (400 mm) containing
GABAB receptors from whole-brain preparations were individu-
ally analyzed for the relative molecular abundance of GABAB1,
GABAB2, and KCTD12 proteins. The abundance profiles gener-
ated from 95 consecutive slices showed precise coincidence for
GABAB1 and GABAB2 and identified two major populations of
GABAB(1,2) receptors in the apparent molecular mass range of
0.35 to 0.7 MDa (Figure 7B): one population representing coas-
semblies with KCTD12 had a mass of 0.57 MDa, the otherNeuron 82, 1032–10population had a mass of 0.44 MDa
and is devoid of KCTD12 (and other
KCTDs, data not shown; Figure 7A).
Fitting Gaussian distributions to these
two populations showed that 40% of
GABAB receptors are assembled with
KCTD12, while 60% are free of KCTDs
(Figure 7B). BN-PAGE analysis therefore
supports that in the adult brain KCTD12
exclusively associates with a fraction of
GABAB receptors. This indicates that
GABAB receptors are present in excessof KCTD12 and implies that KCTD12-induced desensitization
is highly GABAB receptor specific.
Altered GABAB Receptor-Activated K
+ Currents in KCTD
Knockout Mice
We previously reported that overexpression of KCTD12 in
cultured hippocampal neurons strongly desensitizes baclofen-
induced K+ currents (Schwenk et al., 2010). We now addressed
whether loss of the KCTDs in hippocampal neurons ofKctd12/
(Metz et al., 2011) and Kctd8/12/16 triple knockout (Kctd8/12/
16/) mice (Metz et al., 2011) reduces desensitization of baclo-
fen-induced K+ currents. Of note, KCTD12b is selectively ex-
pressed in the medial habenula and therefore has no effect in
the hippocampus (Metz et al., 2011; Schwenk et al., 2010).



































































Figure 8. Altered GABAB Receptor-Acti-
vated K+ Currents in Kctd12–/– and Kctd8/
12/16–/– Mice
(A) Representative traces of baclofen-evoked K+
currents recorded from cultured hippocampal
neurons of Kctd12/ (red), Kctd8/12/16 triple
knockout (orange), and WT (black) mice.
(B) Bar graph summarizing the desensitization
observed in neurons of Kctd12/ (red), Kctd8/12/
16/ (orange), and control WT (black) mice. Data
are represented as mean ± SD of 31 (Kctd12/),
23 (WT control of Kctd12/), 13 (Kctd8/12/16/),
and 17 (WT control of Kctd8/12/16/) neurons.
***p < 0.001; *p < 0.05; Student’s t test. Kctd8/12/
16/ neurons exhibit a more pronounced reduc-
tion in desensitization than Kctd12/ neurons.
This may relate to a generally slower G protein/
effector channel coupling (C and D). This may
reduce the basal desensitization, which is KCTD12
independent and determined by the kinetic prop-
erties of the G protein cycle (Chuang et al., 1998;
Leaney et al., 2004; Sickmann and Alzheimer,
2003).
(C) Representative traces of baclofen-evoked K+
currents recorded from neurons of mutant andWT
control mice. Inset shows currents at enlarged
timescale showing the latency period between
start of agonist application (arrow head) and cur-
rent onset (arrows).
(D) Bar graphs summarizing 5%–95% rise time
and latency observed in neurons of mutant and
WT mice (neurons as in B). Data are represented
as mean ± SD. ***p < 0.001; ***p < 0.01; *p < 0.05,
Student’s t test. See also Figure S7.
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Uncoupling of G Protein bg Subunits from Channelsless in cultured hippocampal neurons of Kctd12/ and Kctd8/
12/16/ mice when compared to neurons of WT mice (Figures
8A and 8B). In contrast, adenosine A1 receptor-induced K+ cur-
rents desensitized to a similar extent in Kctd12/ and WT
(Kctd12/: 9.3% ± 3.0%, n = 9; WT: 12.1% ± 4.1%, n = 9; p =
0.124) neurons, consistent with KCTD12 selectively influencing
GABAB receptor signaling. Interestingly, adenosine A1 recep-
tor-induced K+ currents recorded from Gabbr2/ neurons
showed increased desensitization compared to WT neurons
(Gabbr2/: 25.5% ± 8.4%, n = 13; WT, 10.2% ± 4.7%, n = 6,
p < 0.001). Thus, in the absence of GABAB receptors, KCTD12
is ‘‘released’’ in amounts that promiscuously regulate Gbg
signaling of other GPCRs, similar to the results obtainedwith het-
erologous expression of large amounts of KCTD12 (Figures 6).
All KCTDs shorten the rise time of baclofen-induced K+ cur-
rents in heterologous cells (Schwenk et al., 2010). Moreover,
we found that the latency between agonist application and onset
of the K+ current response is significantly shorter in the presence
of KCTDs and dependent on KCTD binding to the receptor (Fig-
ure S7). Accordingly, the rise times of the baclofen-induced K+
currents recorded in Kctd12/ and Kctd8/12/16/ neurons
were significantly longer than those obtained inWT neurons (Fig-
ures 8C and 8D). Of note, Kctd8/12/16/ neurons exhibit a
significantly slower rise time than Kctd12/ neurons, consistent
with all three KCTDs contributing to a shortening of the rise time1040 Neuron 82, 1032–1044, June 4, 2014 ª2014 Elsevier Inc.(Schwenk et al., 2010). In addition, the latency of the current
response was significantly longer in Kctd12/ and Kctd8/12/
16/ neurons than in WT neurons (Figures 8C and 8D). Again,
the latency was longer in Kctd8/12/16/ than in Kctd12/ neu-
rons, consistent with heterologous data showing that multiple
KCTDs can accelerate the onset of the current response (Fig-
ure S7). Native KCTDs therefore promote rapid G protein
signalingwith faster rise times and shorter latency of the receptor
response. Accelerated G protein signaling probably relates to
the constitutive binding of the G protein to KCTD8, KCTD12,
and KCTD16, which stabilizes the G protein at the receptor.
DISCUSSION
This work presents a molecular mechanism for fast and
reversible desensitization of G-protein-mediated K+ current
responses. We show that KCTD12 dynamically interacts with
Gbg released from the activatedGprotein and thus directly com-
petes with Gbg binding to the effector Kir3 channel. Albeit
KCTD12 has the intrinsic ability to inhibit Kir3 currents activated
by numerous GPCRs, the exclusive assembly of KCTD12 into
GABAB receptors in the brain results in a highly receptor-specific
current desensitization. Activity-dependent interaction with Gbg
is unique to KCTD12. However, KCTD8, KCTD12, and KCTD16
are all able to constitutively bind the G protein through
Neuron
Uncoupling of G Protein bg Subunits from ChannelsGbg. Constitutive binding of the KCTDs to both theG protein and
the receptor appears to stabilize the G protein at the receptor
and to accelerate K+ current responses.
A Reversible Mechanism for Fast Desensitization of
GABAB Receptor Responses
The desensitization of GPCR-activated K+ currents that is
observed within seconds of agonist exposure (Sickmann and
Alzheimer, 2002, 2003) is too fast to be explained by classical
mechanisms of desensitization, which typically involve receptor
phosphorylation, uncoupling of the G protein from the receptor,
receptor internalization, and degradation (Evron et al., 2012;
Tsao and von Zastrow, 2000). It emerges that fast desensitiza-
tion is primarily regulated at the postreceptor level. To some
extent, fast desensitization is determined by the kinetic proper-
ties of the G protein cycle, such as the rates of GDP-GTP ex-
change and GTP hydrolysis at Ga (Chuang et al., 1998; Leaney
et al., 2004; Sickmann and Alzheimer, 2003). Accordingly, fast
desensitization is promoted by several proteins acting at the G
protein. These proteins include RGS proteins, which increase
GTPase activity at Ga (Bender et al., 2004; Chuang et al.,
1998; Jeong and Ikeda, 2001; Mutneja et al., 2005; Ross and
Wilkie, 2000), and KCTD12 that shields the Kir3 binding site of
Gbg. Moreover, GRK2 was shown to nonenzymatically induce
fast desensitization of Kir3 currents by scavenging free Gbg
(Raveh et al., 2010). While both KCTD12 and GRK2 induce
desensitization by binding to Gbg, the respective desensitization
mechanisms are profoundly different. KCTD12-induced K+ cur-
rent desensitization is fully reversible, whereas GRK2-induced
desensitization displays poor reversibility (Figure 5). We found
that compounds that bind in the ‘‘hot spot’’ region of Gb (Dessal
et al., 2011; Lehmann et al., 2008) prevent GRK2-, but not
KCTD12-, induced desensitization (Figure 5). This is consistent
with GRK2 binding at the interface of Gbg with Ga (Lodowski
et al., 2003; Tesmer et al., 2005), which sequesters the heterotri-
meric G protein subunits (Tesmer et al., 2005). Moreover, GRK2
probably scavenges free Gbg away from channels (Raveh et al.,
2010), which may contribute to the poor reversibility of the
desensitization mechanism. GRK2, by increasing the refractory
period of the G protein, appears to be better suited to induce
fast and long-lasting desensitization. In contrast, KCTD12, by
avoiding the ‘‘hot spot’’ and specifically targeting the channel
binding site of Gbg, allows for fast desensitization and recovery
of the receptor response.
Receptor Specificity of KCTD12-Induced
Desensitization
Since proteins promoting fast desensitization act at the postre-
ceptor level, fast desensitization is generally expected to lack re-
ceptor specificity. Indeed, the mechanism of KCTD12-induced
desensitization is not intrinsically receptor specific, as shown in
heterologous expression experiments (Figures 6 and S5). Never-
theless, native KCTD12-induced desensitization is exquisitely
GABAB receptor specific. Quantitative proteomic analysis indi-
cates that native KCTD12 is exclusively associated with GABAB
receptors, as no other GPCRs were detected in anti-KCTD12
APs and genetic lack of GABAB2 abolished the appearance of
KCTD12 in high-molecular weight protein complexes (Figure 7).There may be developmental windows, regional cell types, or
pathological conditions where KCTD12 is expressed in excess of
GABAB2 and, therefore, G protein signaling of other GPCRs may
be influenced. High KCTD12 expression levels have been re-
ported during development (Metz et al., 2011; Resendes et al.,
2004) and may also occur in certain neurons (Metz et al., 2011)
or under pathological conditions. Interestingly, KCTD12 has
been linked to schizophrenia (Benes, 2010), bipolar disorder 1
(Lee et al., 2011), depression (Sibille et al., 2009; Surget et al.,
2009), anxiety (Le-Niculescu et al., 2011), and gastrointestinal
tumors (Hasegawa et al., 2013), which may not necessarily entail
an exclusive action of KCTD12 at GABAB receptors.
Implications of G Protein Binding by the KCTDs for
GABAB Receptor Signaling
KCTD12 displays effects on GABAB responses that may not
directly relate to its role in Gbg inhibition. Thus, all KCTDs accel-
erate the rise time (Schwenk et al., 2010) and reduce the latency
(Figure S7) of baclofen-activated Kir3 currents in heterologous
cells. Accordingly, their loss in Kctd8/12/16 triple knockout mice
leads to markedly slower rise times and increased latency of the
K+ currents in cultured hippocampal neurons (Figures 8C and
8D). The KCTD-dependent acceleration of the receptor response
may result from the dual binding of the KCTDs to the receptor and
theGprotein.Pulling together receptorandGprotein shouldover-
come the slow diffusion-limited association between receptor
andGprotein andshift the rate-limiting step inGprotein activation
from receptor/G protein binding to receptor-driven GDP-GTP
exchange, a fasterprocess (Fowler et al., 2007;Ross, 2008).How-
ever, the KCTDs may also speed up G protein signaling at the re-
ceptor by directly acceleratingGDP-GTP exchange, for example,
by promoting the release of GDP from Ga$GDP. We recently re-
ported that KCTD12 additionally promotes surface expression
ofGABAB receptors in neurons (Ivankova et al., 2013). TheKCTDs
therefore influenceGABAB receptor signaling and thus physiolog-
ical processes in several ways. First, KCTD12-induced fast acti-
vation kinetics may be important for a precise timing of pre- and
postsynaptic GABAB receptor influences on synaptic transmis-
sion. Second, KCTD12-induced fast desensitization may serve
to prevent excessive Kir3 channel activity, which can cause intra-
cellular K+ depletion and neuronal apoptosis (Yu et al., 1997) or
generate seizures (Beenhakker and Huguenard, 2010). Third,
the receptor specificity of KCTD12 may provide a means to
avoid promiscuous and potentially adverse interference with the
signaling of other GPCRs (Rives et al., 2009).
EXPERIMENTAL PROCEDURES
Molecular Biology and Cell Culture
The cDNAs encoding WT and mutant proteins used were all verified
by sequencing and had the following GenBank accession numbers: Y10370
(GABAB1b), AJ011318 (GABAB2), AY615967 (KCTD8), AY267461 (KCTD12),
and NM_026135 (KCTD16). The cDNAs encoding the Kir3.1/3.2 concatemer
(Kaupmann et al., 1998) and the adenosine A1 receptor (Ferre´ et al., 2002)
were reported earlier. Cell culturing and transfections were as described in
Biermann et al. (2010), Ivankova et al. (2013), and Schwenk et al. (2010).
Biochemistry
Affinity purifications (APs), two-dimensional BN-PAGE/SDS-PAGE separa-
tions, and western blot analyses were carried out as described in SchwenkNeuron 82, 1032–1044, June 4, 2014 ª2014 Elsevier Inc. 1041
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Uncoupling of G Protein bg Subunits from Channelset al. (2010, 2012). Protein samples for APs were obtained by solubilizing
plasma membrane-enriched protein fractions from whole mouse brains with
ComplexioLyte-47 (CL-47, Logopharm GmbH) at 1 mg protein/ml or by lysing
cultured HEK293T cells or homogenized mouse brains with Nonidet P-40
buffer (100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 20 mM Tris/HCl
[pH 7.4]). AlF4
 (60 mm AlCl3, 10 mm NaF, 10 mm GDP, 10 mM MgCl2) was
freshly prepared as described in Kawano et al. (2007) and incubated in Nonidet
P-40 buffer before lysis of HEK293T cells. Crude membrane preparations
from Xenopus oocytes injected with the indicated cRNA were obtained as
described previously in Schwenk et al. (2010).
Mass Spectrometry
Nano LC-MS/MS analyses were performed on an LTQ-FT Ultra mass spec-
trometer linked to an UltiMate 3000 HPLC as described (Schwenk et al.,
2012). LC-MS/MS data were extracted using the extract_msn utility and
searched against manually assembled databases derived from UniProt
Knowledgebase release 2013/02 (Mus musculus, Rattus norvegicus, and
Homo sapiens) using the Mascot search engine (version 2.3.01; Matrix Sci-
ence) first with a peptide mass tolerance of 15 ppm. After extraction and
mass shift calibration of precursor m/z signals using MaxQuant (Cox and
Mann, 2008), tolerance was reduced to ±5 ppm for final searches.
Relative quantification of proteins was based on peptide peak volumes
(PVs). PVs from individual peptide species were calculated from the respective
LC-MS full-scan m/z signal intensities integrated over time and mass width
either with MaxQuant (protein ratios in Figure 2) or msInspect (profiles in Fig-
ure 7). Alignment of m/z signals between different LC-MS/MS runs and assign-
ment to the peptides identified by Mascot (retention time tolerance: 1 min, m/z
difference threshold: ±2.5 ppm (MaxQuant), ±5 ppm (msInspect) was carried
out by a home-written software tool and manually verified for proteins yielding
less than six peptide PVs.
Protein abundance ratios (rPV; Figure 2) were determined by the TopCorr
method as described in Bildl et al. (2012). Specificity thresholds of APs were
determined from rPV histograms of all proteins detected in the respective
AP/control. Proteins were considered specifically copurified when rPV (mouse
WT versus KO)/threshold (versus KO) > 1. Unless indicated otherwise, only
proteins with rPVs based on at least two protein-specific peptide PVs were
quantified. Protein mass abundance profiles (Figure 7) were determined
from BN-MS analysis as described (Schwenk et al., 2012).
BRET Measurements
BRET measurements were performed in CHO cells stably expressing GABAB1
and GABAB2 and transiently transfected with plasmids encoding Gao-Rluc,
Venus-Gg2, FLAG-Gb2, andmyc-KCTD12 or myc-KCTD16. BRET signals be-
tween Gao-Rluc and Venus-Gg2 in the presence of 5 mM coelenterazine h
(NanoLight Technologies) were measured on an Infinite F500 microplate
reader (Tecan) after receptor activation with baclofen.
Electrophysiology
Experiments on Xenopus oocytes, CHO cells, and cultured hippocampal neu-
ronswereperformedat roomtemperatureasdescribed inSchwenket al. (2010).
Desensitization time constants were derived from double-exponential fits to
the decay phase of Kir3.1/3.2 currents during baclofen application. Curve
fitting and further data analyses were done with pClamp 10 (Molecular De-
vices) and IGOR Pro (version 6.32; Wavemetrics). Latency was determined
in current responses filtered to 20 Hz as the time interval between the agonist
solution reaching the cell surface and the inflection point indicating current
onset (Doupnik et al., 2004). The inflection point was set at the last zero
crossing of the first derivative of the current before the onset. Data are given
as mean ± SD. Statistical significance was assessed using nonparametric t
tests or ANOVA with the Dunnett’s multiple comparison test. Additional infor-
mation is provided in the Supplemental Experimental Procedures.
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SUPPLEMENTAL FIGURE LEGENDS 
Figure S1 (Related to Figure 1). 
Kir3.2 channels can be activated by 1-propanol during KCTD12-induced desensitization. 
Trace of Kir3 current recorded at -50 mV in CHO cells expressing GABAB receptors, Kir3.2 
channels and KCTD12. Note that direct activation of Kir3 channels by 1-propanol is possible 
during KCTD12-induced desensitization of the current evoked by baclofen, showing that 
KCTD12 does not operate at the channel.  
 
Figure S2 (Related to Figure 2). 
Purified recombinant KCTD12 and Gβ1γ2 proteins directly interact with each other. Gβ1γ2 
and KCTD12 proteins were expressed in baculovirus infected Sf21 insect cells and E.coli, 
respectively. The purified proteins were mixed in equimolar amounts, immunoprecipitated with 
KCTD12-specific antibodies and visualized on Western blots. 
 
Figure S3 (Related to Figure 4).  
KCTD12 does not promote unbinding of Kir3.4-derived peptide from Gβγ. (A, B) Traces 
represent Kir3 currents evoked by two consecutive baclofen applications delivered at a 5-minute 
interval to CHO cells expressing GABAB receptors in the absence (A) or presence  of KCTD12 
(B). Prior to the recordings the cells were perfused for 60 minutes with the intracellular solution 
supplemented with 40 μM Kir3.4 peptide. (C) Bar graph showing peak amplitudes (P1) of 
baclofen responses recorded after perfusion of cells with the Kir3.4 peptide relative to peaks of 
control baclofen-evoked currents recorded shortly after establishing of the whole-cell 
configuration. Note a lower sensitivity of the responses to the Kir3.4 peptide in the presence of 
KCTD12, consistent with competition between the peptide and KCTD12 for binding to Gβγ. Data 
are mean ± SD of 7 (w/o KCTD) and 6 (+KCTD12) experiments. *, p < 0.01; Student’s t-test. (D) 
Summary of the amplitude ratios of peak currents recorded during the second (P2) and first (P1) 
baclofen application. KCTD12 does not significantly alter the P2/P1 ratio indicating that it cannot 
rescue pre-inhibited Gβγ by reducing the affinity of Kir3.4-peptide at Gβγ. Data are mean ± SD 
of 5 (w/o KCTD, +KCTD12) experiments. 
 
 
Figure S4 (Related to Figure 5). 
The binding domains of KCTD12 and GRK2 on Gβγ overlap. (A, B) Flag-tagged Gβ1 
(Gβ1Flag) and Venus-tagged Gγ2 (Gγ2Venus) were expressed in the presence of either (A) 
increasing amounts of GRK2 C-terminus (GRK2-CT, 1 - 9 μg of DNA) and equal amounts of 
Myc-tagged KCTD12 or (B) increasing amounts of KCTD12Myc (1 – 9 μg of DNA) and equal 
amounts of GRK2-CT. APs were analyzed by Western blot using antibodies directed at GRK2-
CT, Myc, Flag, and GFP. MW, molecular weight; Venus, variant of GFP; CT, C-terminus. Note 
that GRK2 is more efficient in displacing KCTD12 from Gβγ than vice versa. (C) Kir3 currents 
evoked by two consecutive baclofen applications delivered at 10 minute interval to CHO cells 
expressing GABAB receptors and KCTD12 with (blue) or without (black) GRK2. Note that the 
combined presence of KCTD12 and GRK2 accelerates fast desensitization when compared to 
GRK2 alone (Figure 5). (D) Bar graph summarizing Kir3 current desensitization. Data are mean 
± SD of 6 (w/o GRK2) and 5 (GRK2) experiments. ***, p < 0.001; **, p < 0.01; Student’s t-test. 
(E) Bar graph summarizing the amplitude ratios of peak Kir3 currents recorded during the 
second (P2) and first (P1) baclofen application (panel (C)). Note that during the 10 minute period 
GRK2-induced desensitization does not recover in the presence of KCTD12. This shows that 
KCTD12 does not efficiently interfere with GRK2 mediated desensitization. Data are mean ± SD 
of 5 (w/o GRK2) and 9 (GRK2) recordings. ***, p < 0.001; Dunnett’s multiple comparison test.   
Figure S5 (Related to Figure 6) 
Receptor-specific and receptor-unspecific KCTD12-induced desensitization. (A, B) 
Representative traces of Kir3 currents evoked by fast application of L-glutamate to CHO cells 
expressing WT metabotropic glutamate receptor 2 (mGlu2 WT) or mGlu2-GABAB2-CT, in which 
the C-terminal 58 amino-acid residues of mGlu2 (accession number NM_001105711) were 
replaced with the C-terminal 197 residues of GABAB2. Currents were recorded in the presence 
(+ KCTD12) and absence of KCTD12 (w/o KCTD12). (C) Bar graph summarizing Kir3 current 
desensitization. Note that binding of KCTD12 to mGlu2-GABAB2-CT increases the extent of 
desensitizsation. Data are mean ± SD of 5 experiments for each treatment. ***, p < 0.001; *, p < 
0.01; Student’s t-test. (D) Bar graph shows mean amplitude-weighted time constants obtained 
from a fit of a double exponential function to KCTD12-induced desensitization decay. Note that 
binding of KCTD12 to mGlu2-GABAB2-CT accelerates desensitization of the current response. 
Data are mean ± SD of 5 experiments for each treatment. ***, p < 0.001; Student’s t-test. (E) 
KCTD12 co-immunoprecipitates with mGlu2-GABAB2-CTMyc. Flag-tagged KCTD12 was 
expressed together with either Myc-tagged GABAB2Myc, mGlu2 WTMyc or mGlu2-GABAB2-CTMyc. 
APs were performed with anti-Myc antibodies and analyzed on Western blot with antibodies 
against Myc and Flag. MW, molecular weight. (F) Effect of KCTD12 on basal Kir3 currents 
expressed in Xenopus oocytes. Amplitudes of basal Kir3 currents recorded from whole oocytes 
injected with cRNA encoding GABAB receptors and Kir3.1/3.2 channels in the absence (control) 
or presence of KCTD12, KCTD16 and Gβγ. Bars are mean ± SEM of 6 oocytes for each 
condition; ***, p < 0.001; Mann-Whitney U-test. Note that KCTD12 but not KCTD16 significantly 
reduced basal currents mediated by both endogenous and overexpressed exogenous Gβγ. (G) 
Representative recordings of Kir3 currents elicited by voltage ramps (from -50mV to 30mV). 
Amplitudes recorded at -50 mV are summarized in (F). (H) Effect of overexpressed KCTD12 on 
receptor-activated Kir3 currents in Xenopus oocytes. Representative GABAB-activated Kir3 
currents recorded at -50 mV from Xenopus oocytes injected with cRNA encoding GABAB 
receptors, Kir3.1/3.2, KCTD12 and Gβγ. Note robust KCTD12-mediated desensitization of the 
current response in the presence of overexpressed Gβγ. (I) Membrane fractions of Xenopus 
oocytes injected with the cRNAs encoding WT or Y902A-GABAB2 analyzed by Western blot with 
an anti-GABAB2 antibody. 
 
Figure S6 (Related to Figure 7).  
Total KCTD12 protein levels are not significantly altered in Gabbr2-/- compared to WT 
mouse brains. (A) Western blots of total protein extracts from the brains of a Gabbr2-/- and WT 
littermate mouse. β-actin served as a loading control. (B) Bar graphs summarizing KCTD12 
expression levels in Gabbr2-/- and WT mice, normalized to WT expression levels. Data are mean 
± SD of 3 independent experiments (p = 0.25, Wilcoxon signed-rank test). 
 
Figure S7 (Related to Figure 8)  
KCTD12 and KCTD16 reduce the latency of baclofen-activated Kir3 currents in 
transfected CHO cells. (A) Representative traces of baclofen-evoked currents recorded from 
CHO cells expressing GABAB receptors and Kir3 channels with or without (w/o) KCTD proteins.  
The latency period between start of the agonist application (arrow head) and current onset 
(arrows) is reduced in the presence of KCTD12 and 16. Current and time scale as indicated. (B) 
Bar graph summarizing the latency of baclofen-evoked Kir3 currents observed with WT and 
mutant Y902A-GABAB2 receptors. The latency is only reduced by KCTD12 and KCTD16 in the 
presence of WT receptors. Data are mean ± SD ***, p < 0.001; Student’s t-test.   
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Biochemistry  
Affinity purifications and Western blot analyses were carried out as described (Ivankova et al., 
2013; Schwenk et al., 2012). Briefly, plasma membrane-enriched protein fractions were 
prepared from whole brains of adult WT mice, as well as from Gabbr2-/- and Kctd12-/- mice and 
solubilized for 30 minutes at 4°C with ComplexioLyte47 (CL-47, Logopharm GmbH, at 1 mg 
protein/ml). After clearing by ultracentrifugation (10 min at 150.000 x g), 1.5 ml of solubilizate 
was incubated with 15 µg of immobilized anti-GABAB2 (Schwenk et al., 2010) or anti-KCTD12 
antibodies (Metz et al., 2011) for 2 h on ice. After two brief washes with CL-47, bound proteins 
were eluted in Laemmli buffer. The efficiency of solubilization and purification was controlled by 
Western blot analysis of SDS-PAGE resolved aliquots taken along this procedure. Two-
dimensional BN-PAGE/SDS-PAGE separations were carried out as described (Schwenk et al., 
2012) on linear 3-15% polyacrylamide gradient gels. Excised BN-PAGE lanes were incubated 
for 20 min in Laemmli buffer and placed on top of 10% SDS-PAGE gels. After electro-blotting on 
PVDF membranes the blot was cut horizontally into different molecular weight ranges and 
stained with the indicated antibodies.  
For APs from cultured cells (Figures 2, 3, S4 and S5), HEK293T cells were harvested, 
washed in PBS, and subsequently lysed in a Nonidet P-40 buffer (100 mM NaCl, 1 mM EDTA, 
0.5% Nonidet P-40, 20 mM Tris/HCl, pH 7.4) supplemented with complete EDTA-free protease 
inhibitor mixture (Roche). After rotation for 10 min at 4 °C, lysates were cleared by centrifugation 
at 16,000 × g for 10 min at 4 °C. The lysates were then used for Western blot analysis or 
precleared for 1 h using 30 μl dry volume of a 1:1 mixture of protein-A and protein-G agarose 
(GE Healthcare) for APs. Precleared lysates were immunoprecipitated with mouse anti-Flag 
(F1804, Sigma) or mouse anti-Myc (Figure S5, sc-40, Santa Cruz) antibodies and 10 μl of the 
1:1 protein-A and protein-G agarose mixture, after 3 h of incubation at 4 °C. Lysates and 
immunoprecipitates were resolved using SDS-PAGE, and probed with the primary antibodies 
rabbit anti-Myc (F1804, Sigma, 1:1000), mouse anti-Flag (F7425, Sigma, 1:1000), mouse anti-
Renilla Luciferase (MAB4410, Millipore, 1:2000), rabbit anti-GFP (A11122, Invitrogen, 1:1000) or 
rabbit anti-GRK2-CT (ab32558, Abcam) and peroxidase-coupled secondary antibodies (NA931V 
and NA9340V, Amersham Biosciences, 1:10000). The antibody incubation was in 5% nonfat dry 
milk in PBS containing 0.1% Tween-20. The chemiluminescence detection kit (Pierce) was used 
to identify antibody-labeled proteins.  
For the AlF4- experiment, AlF4- (60 μm AlCl3 (449598, Sigma), 10 mm NaF (215309, 
Sigma), 10 μm GDP (G7127, Sigma) and 10 mM MgCl2 (63064, Fluka)) was freshly prepared 
from powder as described (Kawano et al., 2007) and incubated in Nonidet P-40 lysis buffer 
before lysis of HEK293T cells as described above. 
For determination of total KCTD12 protein levels (Figure S6) mouse brains were washed 
in ice-cold PBS buffer and mouse brain tissue was homogenized in Nonidet P-40 lysis buffer 
using a glass-teflon homogenizer with 20 passes on ice. After rotation for 10 min at 4 °C, 
homogenates were clarified by centrifugation at 16,000 × g for 10 min at 4 °C. The supernatant 
was retained and used for protein determination by Bradford method or Western blot analysis. 
Lysates were resolved using SDS-PAGE, and probed with the primary antibodies rabbit anti-
KCTD12 (Schwenk et al., 2010), rabbit anti-GABAB2 (AGB-002, Alomone, 1:1000) or rabbit anti-
β-actin (4970, Cell Signaling Technology, 1:2000). Band intensity was quantified by ImageJ 
software (National Institute of Health, Bethesda, MD, USA) and depicted in graphical form. 
Histidine tagged human Gγ2 and Gγ1 were subcloned into multigene baculovirus transfer 
vectors (Fitzgerald et al., 2006) and subsequently integrated into the bacmid genome. Virus 
mediated protein expression was conducted by infecting Sf21 insect cells. Cells were harvested 
and lysed with glas potters in homogenization buffer consisting of 10 mM Tris/HCl pH 7,4, 320 
mM Sucrose, 1,5 mM MgCl, 1 mM EGTA, 1 mM TCEP with freshly added protease inhibitors. 
Membrane fractions were isolated by ultracentrifugation (100.000 x g, 30 minutes). Proteins 
were solubilized as described in (Kozasa and Gilman, 1995), purified by Ni-Sepharose (GE 
Healthcare) and size-exclusion chromatography (Superdex 200, GE Healthcare) and thereafter 
dialysed against binding buffer (20 mM Tris/HCl pH 7,4, 150 mM NaCl, 0,1 mM TCEP, 0,15% 
Zwittergent 3-14). His-tagged KCTD12 was expressed in E.coli BL21(DE3) pLysS. Cells were 
lysed by sonication and soluble KCTD12 protein was purified sequentially by IMAC and SEC 
chromatography and dialysed against binding buffer. Equimolar amounts of G proteins and 
KCTD12 were mixed in binding buffer and after 30 min immunoprecipitated with 2 µg 
immobilized KCTD12-specific antibodies. Samples were analysed by Western blot.  
Crude membrane preparations from Xenopus oocytes injected with the indicated cRNA 
were obtained as described previously (Schwenk et al., 2010). Equal amounts of membrane 
proteins were separated on a 10% SDS-PAGE and analyzed by Western blot. 
 
Mass Spectrometry 
Analysis by nano LC-MS/MS was performed as described (Schwenk et al., 2012). Specifically, 
peptide mixtures obtained from tryptic in-gel digestion of protein samples (dissolved in 0.5% (v/v) 
trifluoroacetic acid) were resolved by reverse phase chromatography on an UltiMate 3000 HPLC 
and directly electrosprayed into an LTQ FT Ultra mass spectrometer. Precursor signals (full 
scans) used for quantification were acquired with a target value of 1,000,000 (maximum injection 
time 1 s, spray voltage 2.3 kV; capillary temperature 125°C) and a nominal resolution of 100,000 
(FWHM) at m/z 400 (scan range 370 to 1700 m/z). Up to five data-dependent CID fragment 
spectra per scan cycle were acquired in the ion trap with a target value of 10,000 with dynamic 
exclusion, preview mode for FTMS master scans, charge state screening, monoisotopic 
precursor selection and (+1) charge state rejection enabled. Total MS acquisition times were 
105 min (75 min rising acetonitrile concentration, 30 s dynamic MS/MS exclusion). LC-MS/MS 
data were extracted using the extract_msn utility (grouping tolerance 0.05) and searched against 
(manually assembled databases) derived from UniProt Knowledgebase release 2013/02 (Mus 
musculus, Rattus norvegicus and Homo sapiens) using the Mascot search engine (version 
2.3.01; Matrix Science) first with a peptide mass tolerance of 15 ppm. After extraction and mass 
shift calibration of precursor m/z signals using MaxQuant (Cox and Mann, 2008), tolerance was 
reduced to ± 5 ppm for final searches. One missed trypsin cleavage and common variable 
modifications were accepted for peptide identification. Proteins identified by only one specific 
MS/MS spectrum or representing exogenous contaminations such as keratins or 
immunoglobulins were eliminated.  
Relative quantification of proteins was based on peptide peak volumes (PVs). PVs from 
individual peptide species were calculated from the respective LC-MS full scan m/z signal 
intensities integrated over time and mass width either with MaxQuant (protein ratios in Figure 2) 
or msInspect (http://proteomics.fhcrc.org/CPL/amt/), Computational Proteomics Laboratory, Fred 
Hutchinson Cancer Research Center, Seattle, WA, USA; protein profiles in Figure 7). Alignment 
of m/z signals between different LC-MS/MS runs and assignment to the peptides identified by 
Mascot (retention time tolerance: 1 min, m/z difference threshold: ± 2.5 ppm (MaxQuant), ± 5 
ppm (msInspect) was carried out by a home-written software tool and manually verified for 
proteins yielding less than 6 peptide PVs. Protein abundance ratios (rPV) in AP versus control 
(Figure 2) were determined by the TopCorr method as described (Bildl et al., 2012). Specificity 
thresholds of APs were determined from rPV histograms of all proteins found in the respective 
AP / control. Proteins were considered specifically co-purified when rPV (mouse WT versus KO) 
/ threshold (vs KO) > 1 (Figure 2). Unless indicated otherwise, only proteins with rPVs based on 
at least two protein-specific peptide PVs were quantified. Protein mass abundance profiles (i.e. 
protein abundance ratios of each gel slice sample versus maximum (without calibration of 
molecular abundances, Figure 7) were determined from BN-MS analysis as described (Schwenk 
et al., 2012). Gaussian least square fits to protein profiles were carried out with IGOR Pro 
(version 6.32; Wavemetrics USA). 
 
BRET Measurements 
CHO cells expressing GABAB1 and GABAB2 were transiently transfected with plasmids encoding 
Gαo-Rluc, Venus-Gγ2, FLAG-Gβ2, and myc-KCTD12 or myc-KCTD16 and were seeded into 96-
well microplates (Greiner Bio-One). 24 h after transfection, cells were washed with PBS and the 
measurement was initiated on an Infinite® F500 microplate reader (Tecan) after injection of 5 
µM Coelenterazine h (NanoLight Technologies). 100 µM baclofen was injected after 2 min of 
reading. Luminescence and fluorescence signals were detected sequentially with an integration 
time of 200 ms. The expression of GABAB receptors at the cell surface was controlled with an 
ELISA (Ivankova et al., 2013) and did not differ between experimental conditions. The BRET 
ratio was calculated as the ratio of light emitted by Venus-Gγ2 (530-570 nm) over light emitted 
by Gαo-Rluc (370-470 nm) and corrected by subtracting ratios obtained with the Rluc fusion 
protein alone. The results were expressed in mBRET units. The curves were fitted using 
GraphPad Prism 5.0 (“Plateau followed by one-phase decay”). 
 
Electrophysiology 
Experiments on Xenopus oocytes, CHO cells and cultured hippocampal neurons were 
performed at room temperature as previously described (Schwenk et al., 2010). In two-electrode 
voltage-clamp experiments on oocytes, the extracellular solution was composed as follows 
(mM): 100 KCl, 17.5 NaCl, 10 HEPES, and 1.8 CaCl2 (pH 7.3); solution exchange occurred 
within ~1 s. For experiments with CHO cells and hippocampal neurons cells were continuously 
superfused with an extracellular solution composed of (in mM): 145 NaCl, 2.5 KCl, 1 MgCl2, 2 
CaCl2, 10 HEPES, 25 Glucose; pH 7.3, 323 mOsm. Patch pipettes had resistances between 3-4 
MΩ when filled with intracellular solution composed of (in mM) 107.5 potassium gluconate, 32.5 
KCl, 10 HEPES, 5 EGTA, 4 MgATP, 0.6 NaGTP (LiGTPγS), 10 Tris phosphocreatine; pH 7.2, 
297 mOsm. Series resistance (< 5 MΩ) was compensated by 80%. Kir3 responses were evoked 
by fast application of baclofen (Schwenk et al., 2010) and recorded with an Axopatch 200B 
patch-clamp amplifier (Molecular Devices, USA); filtering and sampling frequencies were set to 1 
kHz and 5 kHz, respectively. Solution exchange occurred within ~12 ms. To establish the 
Kctd8/12/16-/- line single-knockout mice were crossed. Homozygous Kctd8/12/16-/- mice from this 
line were compared with WT mice derived from heterozygous single knockout mice.  
Desensitization time constants were derived from double-exponential fits to the decay 
phase of Kir3.1/3.2 currents during baclofen application. Curve fitting and further data analyses 
were done with pClamp 10 (Molecular Devices, USA) and IGOR Pro (version 6.32; Wavemetrics 
USA). Data are given as mean ± SD. Statistical significance was assessed using non-parametric 
t-tests or ANOVA with the Dunnett's multiple comparison test.  
The Kir3.4-peptide (SMRDEKLCLMFRVGDLR, Biomatik, USA) was dissolved in 
intracellular solution at a final concentration of 40 µM. In experiments with gallein (Tocris 
Bioscience, UK) or selenocystamine dihydrochloride (Sigma-Aldrich, USA), CHO cells were 
preincubated for 30 to 60 minutes at room temperature in extracellular solution containing the 
drug at a concentration of 20 µM. For patch-clamp recording, the drugs were dissolved in 
intracellular solution at a concentration of 20 µM.    
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A B S T R A C T
GABAB receptors assemble from GABAB1 and GABAB2 subunits. GABAB2 additionally associates with
auxiliary KCTD subunits (named after their K+ channel tetramerization-domain). GABAB receptors
couple to heterotrimeric G-proteins and activate inwardly-rectifying K+ channels through the bg
subunits released from the G-protein. Receptor-activated K+ currents desensitize in the sustained
presence of agonist to avoid excessive effects on neuronal activity. Desensitization of K+ currents
integrates distinct mechanistic underpinnings. GABAB receptor activity reduces protein kinase-A
activity, which reduces phosphorylation of serine-892 in GABAB2 and promotes receptor degradation.
This form of desensitization operates on the time scale of several minutes to hours. A faster form of
desensitization is induced by the auxiliary subunit KCTD12, which interferes with channel activation by
binding to the G-protein bg subunits. Here we show that the two mechanisms of desensitization
inﬂuence each other. Serine-892 phosphorylation in heterologous cells rearranges KCTD12 at the
receptor and slows KCTD12-induced desensitization. Likewise, protein kinase-A activation in
hippocampal neurons slows fast desensitization of GABAB receptor-activated K
+ currents while protein
kinase-A inhibition accelerates fast desensitization. Protein kinase-A fails to regulate fast desensitization
in KCTD12 knock-out mice or knock-in mice with a serine-892 to alanine mutation, thus demonstrating
that serine-892 phosphorylation regulates KCTD12-induced desensitization in vivo. Fast current
desensitization is accelerated in hippocampal neurons carrying the serine-892 to alanine mutation,
showing that tonic serine-892 phosphorylation normally limits KCTD12-induced desensitization. Tonic
serine-892 phosphorylation is in turn promoted by assembly of receptors with KCTD12. This cross-
regulation of serine-892 phosphorylation and KCTD12 activity sharpens the response during repeated
receptor activation.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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GABAB receptors are the G-protein coupled receptors (GPCRs)
for GABA, the main inhibitory neurotransmitter in the central
nervous system [1]. GABAB receptors are obligate heteromers
composed of GABAB1 (GB1) and GABAB2 (GB2) subunits. Two GB1
isoforms exist, GB1a and GB1b, which regulate axonal versus* Corresponding author at: Department of Biomedicine, Pharmazentrum,
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http://dx.doi.org/10.1016/j.bcp.2014.07.013
0006-2952/ 2014 The Authors. Published by Elsevier Inc. This is an open access article undendritic distribution of the receptors [2]. In the heteromer GB1
binds GABA while GB2 facilitates surface trafﬁcking and binds the
G-protein [3–6]. GABAB receptors are expressed by most neurons
in the brain and regulate neuronal excitability by modulating the
activity of G protein-gated inwardly rectifying K+ channels (GIRK
or Kir3 channels), voltage-gated Ca2+ channels and adenylyl
cyclase [1,7,8]. To avoid prolonged effects on neuronal activity
in the continuous presence of GABA, GABAB receptors exhibit a
time-dependent decrease in receptor response, a phenomenon
referred to as homologous desensitization [9–12]. GABAB receptor
activity induces homologous desensitization through the inhibi-
tion of adenylate cyclase, which in turn decreases the cAMP-
dependent activity of protein kinase-A (PKA). Since PKA phos-
phorylation of serine-892 (S892) in the C-terminal domain of GB2
increases receptor stability at the plasma membrane, reduced PKAder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. S892 phosphorylation slows KCTD12-induced desensitization of baclofen-activated K+ currents. (A) Scheme highlighting the close proximity of the PKA
phosphorylation-site S892 and the KCTD12 binding-site Y902 in the C-terminal domain of GB2. (B) Representative traces of GIRK currents activated by baclofen (100 mM) and
recorded at 50 mV from CHO-K1 cells expressing GB2-WT, GB1b, GIRK1/2 and KCTD12. Cells were pre-incubated without (Control, black trace) or with 8-Br-cAMP (1 mM,
30 min; grey trace). The desensitization time constants t1 and t2 were derived from double-exponential ﬁts (blue trace) to the decay phase of K
+ currents during baclofen
application. (C) Representative traces as in (B) from CHO-K1 cells lacking KCTD12. (D–F) Representative traces as in (B) from CHO-K1 cells expressing the GB2 mutants S892A
(D), S892E (E) or Y902A (F). (G) Bar graph summarizing the time constant t (amplitude-weighted mean time constant calculated from t1 and t2) of baclofen-induced K
+
current desensitization. Data are means  SD, n = 5–16. *, p < 0.05; **, p < 0.01; ***, p < 0.001; Sidak’s multiple comparison test. (H) Repeated activation of GIRK currents in CHO-K1
cells expressing WT GABAB receptors (GB1,2-WT) together with KCTD12 results in a sharpening of the current response (left; 1st response black, 3rd response red). No sharpening of
the current response upon repeated activation is observed with mutated GABAB receptors (GB1,2-S892A) that cannot be phosphorylated at S892 (right). Baclofen applications were
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Fig. 2. S892 phosphorylation rearranges the receptor/KCTD12 complex. (A) Scheme of the BRET Rluc-KCTD12 donor and GB1a-YFP acceptor pair. (B) BRET donor saturation
curves from HEK293T cells expressing ﬁxed amounts of GB2-WT, GB2-Y902A (both left) or GB2-S892A (right) together with Rluc-KCTD12 and increasing amounts of GB1a-
YFP. Cells were pre-incubated with 8-Br-cAMP (1 mM, 30 min; open circles) to activate PKA. BRET is expressed as milli BRET units (mBU) determined as net BRET  1000. Data
points are means  SD of technical quadruplicates of a representative experiment, n = 4–7. (C) Western blot of lysates of HEK293T cells expressing GB1a-YFP, GB2-WT and Rluc-
KCTD12 in the presence and absence of 8-Br-cAMP (1 mM, 30 min pre-incubation). Activation of PKA does not affect the total amount of GB2 but increases phosphorylation at S892
(GB2-pS892). GB2 runs as two bands on SDS–PAGE, likely due to differences in posttranslational modiﬁcation. The higher molecular weight band appears to be more heavily
phosphorylated at S892. Blots are representative of six independent experiments. Bar graph summarizing the amount of S892 phosphorylation normalized to the amount of GB2 on
the same blot (GB2-pS892 in %). Data are means  SD, n = 6. *, p < 0.05; t test. (D) Co-immunoprecipitation of GABAB receptors with KCTD12 from HEK293T cells expressing GB1a-
YFP, GB2-WT and Rluc-KCTD12 in the presence and absence of 8-Br-cAMP (1 mM, 30 min pre-incubation). Equivalent amounts of GABAB receptors were co-precipitated. Blots are
representative of ﬁve independent experiments. (E) Co-immunoprecipitation of GABAB receptors with KCTD12 from HEK293T cells expressing GB1a-YFP, GB2 (WT, S892A, S892E or
Y902A) and Rluc-KCTD12. Y902A does not bind KCTD12 and was used as a negative control. Blots are representative of three independent experiments.
L. Adelﬁnger et al. / Biochemical Pharmacology 91 (2014) 369–379 371activity facilitates receptor degradation and consequently desen-
sitization of the receptor response [13,14]. This phosphorylation-
dependent mechanism regulates desensitization on the time scale
of several minutes to hours. In addition, faster mechanisms induce
homologous desensitization of the receptor response within
seconds of agonist application. These mechanisms operate at the
G-protein rather than at the receptor. The ‘‘Regulator of G-protein
Signaling’’ (RGS) protein 4 induces desensitization by accelerating
the rate of GTP hydrolysis at the Ga subunit of the activated G-
protein [15–17]. Fast desensitization is additionally induced by the
KCTD proteins 12 and 12b [18,19]. The KCTDs are auxiliaryfor 60-s in intervals of 5 min. (I) Bar graph summarizing experiments as shown in (H). In 
compared to the t of the 1st response (tP1). No change in the desensitization of the curren
(S892A), (ii) with the phospho-mimetic S892E and (iii) when KCTD12 cannot bind to GB2receptor subunits that constitutively associate with the C-terminal
domain of GB2, in which mutation of Y902 to alanine (Y902A)
completely abolishes association [18,20,21]. KCTD12 induces
GABAB receptor-activated K
+ current desensitization by binding
to the bg subunits of the activated G-protein, which interferes
with activation of the effector K+ channel [19]. Of note, this post-
receptor mechanism of desensitization is rendered receptor-
speciﬁc through the exclusive association of native KCTD12
protein with GABAB receptors [19].
Since KCTD12 binds to GB2 in proximity of the PKA
phosphorylation-site S892 (Fig. 1A), phosphorylation of S892experiments with GB2-WT, the t of the 3rd response (tP3) was signiﬁcantly reduced
t response upon repeated activation is seen (i) when S892 cannot be phosphorylated
 (Y902A). Data are means  SD, n = 7–12. **, p < 0.01; t test.
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and vice versa, KCTD12 may inﬂuence S892 phosphorylation. We
therefore addressed whether PKA regulates KCTD12-induced K+
current desensitization. We found that PKA phosphorylation of
S892 reduces KCTD12-induced K+ current desensitization in
heterologous cells and cultured hippocampal neurons. Mechanis-
tically, S892 phosphorylation induces a conformational change in
the GABAB receptor/KCTD12 complex that slows KCTD12-induced
desensitization. Reciprocally, the binding of KCTD12 promotes
phosphorylation of S892, consistent with previous data showing
that KCTD12 stabilizes receptors at the cell surface [21].
2. Material and methods
2.1. Cell lines and cultures of hippocampal neurons
HEK293T and CHO-K1 cells were maintained in DMEM (Life
Technologies, CA, US) supplemented with 10% FBS (GE Healthcare,
Buckinghamshire, UK) at 37 8C with 5% CO2. CHO-K1 cells stably
expressing GB1 and GB2 subunits were cultured as described [22].
Cultured hippocampal neurons were prepared from wild-type
(WT), KCTD12/ [19,23] or GB2-S892A mice on embryonic day
16.5 as described [24].
2.2. Drugs
To activate GABAB receptors, baclofen (Cat.No. 417) was used at
a ﬁnal concentration of 100 mM. To activate PKA, 8-Br-cAMP
(Cat.No. 1140) and forskolin (Cat.No. 1099) were used at a ﬁnal
concentration of 1 mM and 20 mM, respectively. To inhibit PKA,
H89 (Cat.No. 2910) and protein kinase inhibitor-(14-22)-amide
(PKI, Cat.No. 2546) were used at a ﬁnal concentration of 2 mM or
10 mM, and 10 mM, respectively. All reagents were purchased from
Tocris Bioscience, UK.
2.3. Generation of GB2-S892A knock-in mice
The gene targeting construct contained a neomycin resistance
cassette (pRay-2; Genbank accession number U63120) ﬂanked by
two arms of Balb/c GB2 genomic DNA. The S892A mutation in exon
19 was introduced into the 30 arm along with a diagnostic silent
NheI restriction site. The targeting construct was electroporated
into Balb/c embryonic stem cells. Neomycin resistant colonies
were screened for homologous recombination by PCR, and positive
clones conﬁrmed by Southern blot. Positive ES cells were
microinjected into C57BL/6 blastocysts. Chimeric males were
crossed with female Balb/c mice to generate inbred Balb/c mice
heterozygous for the S892A allele. The neomycin cassette in the
S892A allele was then excised by mating heterozygous mice with
Balb/c Cre-deleter mice [25]. Whole brain membranes were probed
with the primary antibodies guinea-pig anti-GB2 (AB5394, 1:2000,
Millipore, Darmstadt, Germany), rabbit anti-GB2-pS892 [13]
(1:2000), rabbit anti-GB1 [26] (1:3000), mouse anti-b-III-tubulin
(T8660, 1:1000, Sigma–Aldrich, MO, US). All animal experiments
were subjected to institutional review and approved by the
Veterinary Ofﬁce of Basel-Stadt.
2.4. Molecular biology
The plasmids encoding HA-GB2, HA-GB2-Y902A, Myc-GB1b,
Flag-GB1a, pRK6-GB1a-YFP, pcDNA3.1-GIRK1/2, Myc-KCTD12,
pIRES-EGFP-KCTD12, Rluc-KCTD12 and Rluc-Gb1 were described
earlier [19,21,27,28]. The HA-GB2-S892A and HA-GB2-S892E
mutations were generated by replacing S892 with alanine or
glutamate, respectively. Lipofectamine 2000 (Life Technologies,
CA, US) was used for transient transfections. For electrophysiologywe co-expressed green ﬂuorescent protein (GFP) or pIRES-EGFP-
KCTD12. The amount of DNA in the transfections was kept constant
by supplementing with pCI plasmid DNA (Promega, WI, US).
2.5. Electrophysiology
CHO-K1 cells and cultured hippocampal neurons were plated
onto ThermanoxTM plastic coverslips (Thermo Scientiﬁc, MA, US) or
poly-L-lysine (P9155, Sigma–Aldrich, MO, US) coated glass cover-
slips, respectively. Experiments with CHO-K1 cells and cultured
hippocampal neurons were performed at room temperature 2–3
days or 1–2 weeks (DIV14-21) after transfection, respectively. Cells
were continuously superfused with an extracellular solution (ECS)
composed of (in mM): 145 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES,
25 glucose; pH 7.3, 323 mosm. Neurons were superfused with ECS
supplemented with (in mM): 10 DNQX, 0.5 TTX, 100 picrotoxin, 5 D-
CPP. Patch pipettes had resistances between 3 and 4 MV when ﬁlled
with intracellular solution (ICS) composed of (in mM): 107.5
potassium gluconate, 32.5 KCl, 10 HEPES, 5 EGTA, 4 MgATP, 0.6
NaGTP, 10 Tris-phosphocreatine; pH 7.2, 295 mosm. To activate PKA
the ICS was supplemented with 250 mM 8-Br-cAMP. Series
resistance (<5 MV) was compensated by 80%. GABAB responses
were evoked by fast application of baclofen and recorded with an
Axopatch 200B patch-clamp ampliﬁer; ﬁltering and sampling
frequencies were set to 1 kHz and 5 kHz, respectively [29].
Desensitization time constants were derived from bi-exponential
ﬁts to the decay phase of GIRK currents during agonist application.
Curve ﬁtting and data analysis were done with pClamp10 software
(Molecular Devices, CA, US). Data are given as mean  SD.
Pharmacological treatments were carried out after DIV15 (neurons)
or 48 h after transfection (CHO-K1 cells). Before recording, hippocam-
pal neurons or CHO-K1 cells were pre-incubated for 30 min with 8-Br-
cAMP, forskolin, PKI and H89 in the ECS.
2.6. Co-immunoprecipitation experiments and drug treatments
Forty-eight hours after transfection, HEK293T cells were
starved for 4 h in DMEM w/o FCS prior to incubation for 30 min
with 8-Br-cAMP. Cells were harvested, washed once with ice-cold
PBS, and subsequently lysed in NETN buffer (100 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40, 20 mM Tris/HCl, pH 7.4) supplemented
with complete EDTA-free protease inhibitor mixture (Hoffmann-La
Roche, Basel, Switzerland) and phosphatase inhibitors 2 and 3
(P5726 and P0044, Sigma–Aldrich, MO, US). After rotation for
10 min at 4 8C, the lysates were cleared by centrifugation at
1000  g for 10 min at 4 8C. Lysates were directly used for Western
blot analysis or immunoprecipitated with anti-Rluc antibody
(MAB4410, Millipore, Darmstadt, Germany) coupled to Dyna-
beads1 Protein-G (10004D, Life Technologies, CA, US). Lysates and
immunoprecipitates were resolved using standard SDS–PAGE and
probed with the primary antibodies guinea-pig anti-GB2 (AB5394,
1:2000, Millipore, Darmstadt, Germany) or guinea-pig anti-
KCTD12 [23] (1:1000) and peroxidase-coupled secondary anti-
bodies donkey anti-guinea pig (A7289, 1:10,000, Sigma–Aldrich,
MO, US). The chemiluminescence detection kit (Thermo Scientiﬁc,
MA, US) was used for visualization. The band intensity on Western
blots was quantiﬁed from non-saturated images using a Fusion FX
Chemiluminescence System (Vilber Lourmat, Witec AG, Lucerne,
Switzerland). GB2 protein sometimes runs as two bands on SDS–
PAGE, depending on the acrylamide concentration of the gel, the
voltage applied across the gel and the electrophoresis time.
Drug treatments of HEK293T cells and cultured hippocampal
neurons were performed 48 h after transfection or at DIV14,
respectively. HEK293T cells were incubated with 8-Br-cAMP for
30 min. Cultured hippocampal neurons were incubated with
H89 for 2 h. Lysates were probed with the primary antibodies
Fig. 3. Binding of KCTD12 to the G-protein bg subunits is modulated by receptor
activation but not by PKA activation. (A) Scheme of the BRET Rluc-Gb1 donor and
Venus-KCTD12 acceptor pair. (B) BRET donor saturation curves from CHO-K1 cells
stably expressing GB1 and GB2 and transiently expressing ﬁxed amounts of Rluc-
Gb1 and Gg2 together with increasing amounts of Venus-KCTD12. Following
receptor activation with baclofen (100 mM, 5 min pre-incubation; grey traces) the
BRET curves were shifted towards higher BRETmax values. Activation of PKA with 8-
Br-cAMP (1 mM, 30 min pre-incubation; open circles) had no effect on the BRET
curves. BRET is expressed as milli BRET units (mBU) determined as net BRET  1000.
Data points are means  SD of technical quadruplicates of a representative
experiment, n = 3.
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Germany) or rabbit anti-GB2-pS892 [13] (1:750) and peroxi-
dase-coupled secondary antibodies donkey anti-guinea pig
(A7289, 1:10,000, Sigma–Aldrich, MO, US) and donkey anti-rabbit
(NA9340, 1:10,000, GE Healthcare, Buckinghamshire, UK). b-III-
Tubulin (T8660, 1:10,000, Sigma–Aldrich, MO, US; peroxidase-
coupled secondary antibody sheep anti-mouse, NA931, 1:10,000,
GE Healthcare, Buckinghamshire, UK) was used to control for
loading and to normalize GB2 and phosphorylated GB2 protein
levels in neurons.
2.7. BRET measurements
BRET measurements were performed as described [19,21].
CHO-K1 cells stably expressing GB1 and GB2 subunits and
HEK293T cells were transiently transfected with plasmids encod-
ing Rluc and YFP fusion proteins and distributed into 96-well
microplates (Greiner Bio-One, Kremsmu¨nster, Austria; coated with
poly-L-ornithine hydrobromide; P3655, Sigma–Aldrich, MO, US) at
a density of 50,000 and 100,000 cells/well, respectively. Twenty-
four hours after transfection, cells were starved for 4 h in DMEM w/
o FCS. After washing, coelenterazine h (5 mM, NanoLight Technol-
ogies, AZ, US) was added with or without 8-Br-cAMP for 30 min.
Luminescence and ﬂuorescence signals were detected sequentially
using an Inﬁnite1 F500 Microplate Reader (Tecan, Ma¨nnedorf,
Switzerland). Baclofen was added 5 min prior measurement. Each
data point represents a technical quadruplicate.
2.8. Data analysis
All data are presented as mean  SD. Statistical signiﬁcance was
assessed using unpaired Student’s t test, one-way ANOVA followed by
Dunnett’s multiple comparison test or two-way ANOVA followed by
Sidak’s multiple comparison test, using Prism 5.04 software
(GraphPad, CA, US). BRET data were analyzed and ﬁtted using a
‘‘one-site speciﬁc binding’’ equation (GraphPad, CA, US).
3. Results
3.1. S892 phosphorylation slows KCTD12-induced K+ current
desensitization
To investigate the effects of S892 phosphorylation on KCTD12-
induced desensitization we performed whole-cell patch-clamp
recordings from CHO-K1 cells expressing KCTD12, GIRK channels
(GIRK1/2) and GB1b together with GB2-WT or the GB2 mutants
S892A (phospho-deﬁcient), S892E (phospho-mimetic) and Y902A
(deﬁcient in KCTD12-binding). Applications of the GABAB receptor
agonist baclofen for 60 s elicited K+ currents with much moreTable 1
Parameters from BRET saturation curves with Rluc-KCTD12 and GB1a-YFP. BRET
donor saturation assays were performed in HEK293T cells transfected with ﬁxed
amounts of GB2-WT or GB2-S892A, Rluc-KCTD12 (donor) and increasing amounts
of GB1a-YFP (acceptor) with and without activation of PKA by pre-incubation with
8-Br-cAMP for 30 min. The BRETmax is the maximal BRET signal obtained for a given
donor/acceptor pair and the BRET50 corresponds to the amount of acceptor needed
to obtain 50% of the BRETmax. Data are presented as the mean  SD of the indicated
number of independent experiments and were derived from data as presented in Fig. 2.
GB2 constructs BRETmax SD BRET50 SD n
GB2-WT 119.0 9.2 0.0037 0.0014 7
GB2-WT, 8-Br-cAMP 132.1* 12.4 0.0042 0.0013 7
GB2-S892A 112.8 3.6 0.0034 0.0008 4
GB2-S892A, 8-Br-cAMP 111.8 4.7 0.0033 0.0004 4
* p < 0.05; compared to GB2-WT; t test.pronounced desensitization in the presence (91.0  3.4%; n = 14;
Fig. 1B) than in the absence of KCTD12 (26.0  7.5%; n = 10; Fig. 1C), as
reported earlier [18]. Approximation of the time-course of the KCTD12-
induced desensitization by a double exponential function yielded time
constants of 1.6  0.4 s (t1; relative amplitude 47.5  15.3%) and
12.9  2.1 s (t2; Fig. 1B) [18,19]. Activation of PKA by pre-incubation of
cells with 8-Br-cAMP for 30 min signiﬁcantly slowed both componentsTable 2
Parameters from BRET saturation curves with Rluc-Gb1 and Venus-KCTD12. BRET
donor saturation assays were performed in CHO-K1 cells stably expressing GABAB
receptors and transiently expressing ﬁxed amounts of Rluc-Gb1 (donor) and Gg2 and
increasing amounts of Venus-KCTD12 (acceptor). To activate GABAB receptors, cells
were pre-incubated with baclofen for 5 min. To activate PKA, cells were pre-
incubated with 8-Br-cAMP for 30 min. The BRETmax is the maximal BRET signal
obtained for a given donor/acceptor pair and the BRET50 corresponds to the amount
of acceptor needed to obtain 50% of the BRETmax. Data are presented as the
mean  SD of the indicated number of independent experiments and were derived
from data as presented in Fig. 3.
GABAB receptor activation BRETmax SD BRET50 SD n
Control, no baclofen 97.9 11.4 0.0490 0.0321 3
8-Br-cAMP, no baclofen 94.3 7.1 0.0517 0.0338 3
Control, baclofen 131.1* 21.9 0.0372 0.0125 3
8-Br-cAMP, baclofen 130.0* 21.9 0.0459 0.0264 3
* p < 0.05; compared to control, no baclofen; compared to 8-Br-cAMP, no
baclofen; t test.
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t2 = 20.8  2.2 s; p < 0.01 and p < 0.001; t test; mean time constant t
shown in Fig. 1G). In contrast, 8-Br-cAMP did not signiﬁcantly inﬂuence
GABAB-activated K
+ currents in the absence of KCTD12 showing that
PKA selectively modulates KCTD12-induced fast desensitization
(Fig. 1C and G). Inhibition of PKA using H89 accelerated desensitization,
suggestive of tonic PKA activity in CHO-K1 cells (t1 = 1.1  0.3 s,
relative amplitude 47.8  19.5%; t2 = 7.2  1.2 s, p < 0.05 and
p < 0.01; t test). 8-Br-cAMP did not inﬂuence desensitization when
expressing GB2-S892A or GB2-S892E instead of GB2-WT (Fig. 1D, E and
G) thus implicating S892 in PKA modulation. Fast desensitization was
not inﬂuenced by PKA when expressing GB2-Y902A (Fig. 1F, G). Of note,Fig. 4. PKA activation slows fast desensitization of baclofen-activated K+ currents in cu
baclofen-activated K+ currents recorded at 50 mV from WT hippocampal neurons. PKA a
grey trace) or H89 (2 mM; dark grey trace). Controls represent recordings from untreate
from double-exponential ﬁts to the decay phase of K+ currents during baclofen applicatio
baclofen-induced K+ current desensitization for the indicated treatments. Data are m
compared to Ctl. Ctl, control; FSK, forskolin; cAMP, 8-Br-cAMP. (C) Representative baclofen
with 8-Br-cAMP (grey trace) or untreated KCTD12/ neurons (control, black trace) as in (A)
baclofen-induced K+ current desensitization for the indicated treatments. Data are meansfast desensitization was already signiﬁcantly slowed (increased t) with
GB2-Y902A compared to GB2-WT in the absence of 8-Br-cAMP
(Fig. 1G). This conﬁrms that assembly of receptors with KCTD12 is
required for PKA regulation of fast desensitization.
Inhibition of PKA accelerates fast desensitization, suggestive of
basal S892 phosphorylation. We therefore investigated whether
repetitive activation of GABAB receptors, which reduces PKA-
dependent phosphorylation of S892 [13], accelerates the KCTD12-
induced desensitization. We recorded K+ currents in response to
repeated baclofen application for 60 s in 5-min intervals. In
experiments with GB2-WT, but not with GB2-S892A, GB2-S892E or
GB2-Y902A, desensitization of the 3rd K+ current response wasltured hippocampal neurons of WT but not of KCTD12/ mice. (A) Representative
ctivity was modulated by pre-incubation for 30 min with 8-Br-cAMP (1 mM; bright
d neurons (black trace). The desensitization time constants t1 and t2 were derived
n (enlarged on the right). (B) Bar graph summarizing the time constants t1 and t2 of
eans  SD, n = 7–35. **, p < 0.01; ***, p < 0.001; Dunnett’s multiple comparison test,
-activated K+ current responses from hippocampal KCTD12/ neurons pre-incubated
. Traces were ﬁtted as in (A). (D) Bar graph summarizing the time constants t1 and t2 of
  SD, n = 5-17, Dunnett’s multiple comparison test, compared to Ctl.
Fig. 5. Basal phosphorylation of S892 is decreased by inhibiting PKA in hippocampal
neurons of WT mice. Western blot of cultured neurons in the presence and absence
of H89 (10 mM, 2 h pre-incubation; left). Inhibition of PKA does not affect the
amount of GB2 protein but decreases the amount of S892 phosphorylation (GB2-
pS892). b-III-Tubulin was used as a loading control. Bar graph summarizing the
amount of phosphorylated S892 (GB2-pS892 in %; right). The total amount of GB2
and GB2-pS892 were normalized to b-III-tubulin on the same blot. Data are
means  SD, n = 6. *, p < 0.05; t test.
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(Fig. 1H, I). In summary, the results show that KCTD12-induced
desensitization of GABAB-activated K
+ currents is regulated by
receptor activity and PKA phosphorylation of S892. Repeated
activation of GABAB receptors results in a sharpening of the receptor
response due to a receptor activity-dependent reduction in S892
phosphorylation.
3.2. S892 phosphorylation rearranges the receptor/KCTD12 complex
It is conceivable that dissociation of KCTD12 from the receptor
underlies the slowing of desensitization in response to PKA
phosphorylation of S892. To test this hypothesis, we used a BRET
assay monitoring the interaction of KCTD12 with GABAB receptors
in living cells [21]. Binding of the donor fusion protein Rluc-
KCTD12 to GB2 allows for speciﬁc BRET to the acceptor fusion
protein GB1a-YFP (Fig. 2A). Expression of increasing amounts of
GB1a-YFP with a ﬁxed amount of Rluc-KCTD12 and GB2-WT
resulted in hyperbolic BRET donor saturation curves, consistent
with a speciﬁc interaction between KCTD12 and GABAB receptors
(Fig. 2B, left). As a control, very low non-speciﬁc linear BRET was
observed between Rluc-KCTD12 and GB1a-YFP in experiments
with GB2-Y902A. When GB2-expressing cells were pre-incubated
with 8-Br-cAMP for 30 min, we still observed a speciﬁc BRET
donor saturation curve. This demonstrates that KCTD12 does not
dissociate from the receptor upon receptor phosphorylation.
However, compared to BRET experiments with untreated cells, the
donor saturation curves in response to PKA activation were
shifted towards higher maximal BRET (BRETmax) values (Fig. 2B,
left, and Table 1). Given that similar amounts of BRET acceptor
were required to reach 50% of the BRETmax signal (BRET50), the
increase in BRETmax most likely reﬂects a conformational
rearrangement in the GABAB receptor/KCTD12 complex and not
a change in the relative afﬁnity of the proteins for one another or
increased levels of GABAB receptors at the plasma membrane.
Western blot analysis demonstrated that 8-Br-cAMP treatment
signiﬁcantly increased phosphorylation of S892 without altering
total GB2 expression levels (Fig. 2C). We next acquired BRET donor
saturation curves for Rluc-KCTD12 and GB1a-YFP in cells
expressing GB2-S892A. As expected, we obtained hyperbolic
BRET donor saturation curves demonstrating a speciﬁc interaction
between KCTD12 and GABAB receptors assembled with GB2-
S892A (Fig. 2B, right). However, 8-Br-cAMP did not alter the
BRETmax and BRET50 values showing that PKA rearranges the
receptor/KCTD12 complex through phosphorylation of S892
(Fig. 2B, right, and Table 1).
The ﬁnding that KCTD12 remains associated with
GABAB receptors when activating PKA was further conﬁrmed in
co-immunoprecipitation experiments showing that similar
amounts of GB2 are associated with KCTD12 in the presence
and absence of 8-Br-cAMP (8-Br-cAMP: 102.8  15.9%, p > 0.05
normalized to without 8-Br-cAMP; t test; n = 5; Fig. 2D). Co-
immunoprecipitation experiments with receptors assembled with
GB2-S892A or GB2-S892E conﬁrmed that phosphorylation of S892 in
GB2 is neither required nor prohibitive for binding of KCTD12
(Fig. 2E).
3.3. PKA does not impair dynamic binding of KCTD12 to the G-
proteins
Since PKA induces a conformational rearrangement in the
receptor/KCTD12 complex, we next investigated whether PKA also
inﬂuences the interaction of KCTD12 with the G-protein [19]. This
can be monitored by BRET between Rluc-Gb1 and Venus-KCTD12
in transfected CHO-K1 cells stably expressing GB1 and GB2
subunits (Fig. 3A). In agreement with KCTD12 dynamicallyinteracting with the G-protein [19], the BRET donor saturation
curves were shifted towards higher BRETmax values following
activation of GABAB receptors with baclofen (Fig. 3B and Table 2).
This agrees with an activity-dependent conformational rearrange-
ment of KCTD12 at the G-protein reported earlier [19]. However, 8-
Br-cAMP did not alter the BRET donor saturation curve between
Rluc-Gb1 and Venus-KCTD12 irrespective of whether GABAB
receptors were activated with baclofen or not (Fig. 3B and
Table 2). These data therefore demonstrate that activation of
PKA does not alter the interaction between KCTD12 and the G-
protein in a measurable way.
3.4. S892 phosphorylation slows KCTD12-induced K+ current
desensitization in cultured hippocampal neurons
We next investigated whether PKA modulates the desensitiza-
tion of GABAB-activated K
+ currents in cultured hippocampal
neurons, which are known to express KCTD12 [18,19,23]. With WT
neurons, K+ currents elicited by 60-s long applications of baclofen
showed a steady-state desensitization of 53.3  9.3% (n = 41,
Fig. 4A). The time course of desensitization was approximated by a
double exponential function with time constants of 1.5  0.3 s (t1)
and 24.4  6.4 s (t2) (Fig. 4B), values that are similar as in earlier
experiments [18,19]. Activation of PKA with 8-Br-cAMP or forskolin
signiﬁcantly increased the fast component t1 of the desensitization,
while inhibition of PKA with H89 or PKI had the opposite effect
(Fig. 4B). Neither activation nor inhibition of PKA had a signiﬁcant
effect on the slow component t2 of the desensitization (Fig. 4B). The
relative contribution of the fast and slow components (t1 and t2,
respectively) to the desensitization did not change with any of the
treatments (t1 of control: 46.5  10.0%; cAMP: 36.3  15.4%; FSK:
40.3  17.8%; H89: 55.7  12.2%; PKI: 47.7  7.7%; p > 0.05; Dun-
nett’s multiple comparison test). These results reveal that PKA
activity speciﬁcally inﬂuences the fast component of baclofen-
induced K+ current desensitization in WT neurons.
In cultured hippocampal neurons of KCTD12/mice [19] t1 but
not t2 was signiﬁcantly increased compared to WT mice (t1 of WT:
1.5  0.3 s; KCTD12/: 2.4  0.9 s; p < 0.001; t2 of WT: 24.4  6.4 s;
KCTD12/: 26.0  8.1 s; p > 0.05; t test; compare Fig. 4B and D).
Neither activation nor inhibition of PKA had a signiﬁcant effect on the
desensitization of baclofen-induced K+ currents in KCTD12/
neurons (Fig. 4D). These data support that the PKA-modulated fast
component of K+ current desensitization in neurons depends on
KCTD12.
Fig. 6. Lack of S892 phosphorylation in S892A knock-in mice accelerates fast desensitization of GABAB-activated K
+ currents. (A) WT and mutated GB2 alleles. The S892 to
alanine mutation (tcc ! gcc) and a silent diagnostic NheI restriction site (gctagc) were introduced into exon 19 using homologous recombination in Balb/c embryonic stem
(ES) cells. Mutated nucleotides are shown in italic. A neomycin marker (neo) ﬂanked by loxP sites (arrowheads) was used for selection of ES cells. Correctly targeted ES cells
(S892A + neo allele) were injected into C57BL/6 blastocysts. A founder mouse was crossed with a Balb/c mouse expressing Cre-recombinase to excise the neomycin cassette,
leaving one loxP site behind (S892A allele). The hybridization probe used in the Southern blot in (B) is indicated. A, alanine; N, NheI restriction sites; S, serine. (B) Southern blot
of NheI cut genomic DNA from correctly targeted ES cells. The probe labels a 15.3 kb fragment for the WT allele and a 4.3 kb fragment for the S892A + neo allele. (C) Western
blot analysis of brain extracts showing that S892A mice express normal levels of GB2, GB1a and GB1b proteins. S892 was phosphorylated in brain extracts of WT but not
S892A mice as shown with an antibody speciﬁc for phosphorylated S892 (GB2-pS892). Brain extracts of GB2-deﬁcient mice (GB2/) [38] conﬁrm the speciﬁcity of the GB2
and GB2-pS892 antibodies. b-III-Tubulin was used as a loading control. (D) Representative GABAB-activated K
+ currents recorded at 50 mV in response to baclofen
application (100 mM) from cultured hippocampal neurons of S892A mice. PKA was activated by pre-incubation for 30 min with 8-Br-cAMP (1 mM; grey trace). Controls
represent recordings from untreated neurons (black trace). The desensitization time constants t1 and t2 were derived from double-exponential ﬁts to the decay phase of K
+
currents during baclofen application (enlarged on the right). (E) Bar graph summarizing the time constants t1 and t2 of baclofen-induced K
+ current desensitization in WT and
S892A neurons. Data are means  SD, n = 5–7. *, p < 0.05; ***, p < 0.001; Sidak’s multiple comparison test.
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Fig. 7. Binding of KCTD12 to GABAB receptors increases S892 phosphorylation. (A)
Lysates of HEK293T cells expressing GB1a and either GB2-WT or GB2-Y902A in the
presence and absence of KCTD12 (up). S892 phosphorylation (GB2-pS892) is
increased in the presence of KCTD12 for GB2-WT, but not for GB2-Y902A. Blots are
representative of ﬁve independent experiments. Bar graph summarizing the
amount of phosphorylated S892 normalized to GB2 protein on the same blot (GB2-
pS892 in %; bottom). Data are means  SD, n = 5. *, p < 0.05; **, p < 0.01; Sidak’s
multiple comparison test. (B) Western blot of lysates from transfected HEK293T cells
expressing the indicated proteins. Phosphorylation of S892 (GB2-pS892) is observed
with GB2-WT and GB2-Y902A but not with GB2-S892A, showing that the pS892
antibody speciﬁcally detects phosphorylation of S892. Note increased phosphorylation
of S892 in the presence of KCTD12 with WT receptors (GB2-WT) compared to mutant
receptors that cannot bind KCTD12 (GB2-Y902A). Blots are representative of three
independent experiments.
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fast desensitization of K+ currents and prevents regulation by PKA
PKA inhibition with H89 or PKI accelerates fast desensitization
of K+ currents in WT hippocampal neurons. Endogenous PKA
activity must therefore provide a high level of basal S892
phosphorylation. Indeed, Western blot analysis of hippocampal
neurons revealed that GB2 is highly phosphorylated at S892
(Fig. 5), which is reduced by inhibition of PKA with H89. We next
addressed whether phosphorylation of S892 in GB2 is essential for
PKA effects on baclofen-induced K+ current desensitization in
neurons. We generated S892A knock-in mice carrying a S892 to
alanine mutation in the GB2 gene using standard gene targeting
techniques (Fig. 6A and B). S892A mice display no overt behavioral
abnormalities. Western blot analysis revealed similar levels of
GB1a, GB1b and GB2 protein in S892A and WT brain extracts
(Fig. 6C). Recordings of baclofen-induced K+ currents from cultured
hippocampal neurons revealed that the desensitization was
signiﬁcantly faster in S892A compared to WT neurons (Fig. 6D
and E). Activation of PKA with 8-Br-cAMP did not signiﬁcantly
increase t1 of the desensitization in S892A neurons, in contrast to
control WT neurons (Fig. 6E). The t2 of the desensitization was
similar in both genotypes and did not change upon activation of
PKA with 8-Br-cAMP (Fig. 6E). The lack of PKA effect in S892A
neurons indicates that S892 phosphorylation is mandatory for
PKA-mediated attenuation of fast desensitization. In summary, our
results show that basal PKA-mediated phosphorylation of S892
slows KCTD12-induced desensitization in neurons.
3.6. Assembly of KCTD12 with GABAB receptors increases S892
phosphorylation
We additionally investigated whether assembly of GABAB
receptors with KCTD12 inﬂuences S892 phosphorylation. We
found that co-expression of KCTD12 with GABAB receptors in
HEK293T cells increases phosphorylation of S892 in WT but not in
GB2-Y902A receptors (Fig. 7). These data reveal that binding of
KCTD12 and phosphorylation of S892 inﬂuence each other.
4. Discussion
4.1. Slow and fast mechanisms of homologous desensitization of
GABAB receptor responses inﬂuence each other
A slow form of homologous desensitization of GABAB receptor
responses relies on the activity-dependent decrease of S892
phosphorylation in GB2 by PKA [13,14]. Here we show that
phosphorylation of S892 by PKA slows KCTD12-induced desensi-
tization, a faster form of desensitization that is induced at the G-
protein rather than at the receptor. We observed a high basal level
of S892 phosphorylation in hippocampal neurons, consistent with
earlier reports [13,30]. Accordingly, KCTD12-induced current
desensitization is signiﬁcantly attenuated in WT hippocampal
neurons compared to GB2-S892A neurons. This may to some
extent explain the moderate desensitization of GABAB-activated K
+
currents in hippocampal neurons, despite a high level of KCTD12
expression [19]. Conversely, KCTD12 promotes S892 phosphory-
lation, which may explain why KCTD12 stabilizes receptors at the
cell surface and increases the magnitude of GABAB receptor
signaling [21]. These results indicate that the mechanism of fast
and slow desensitization inﬂuence each other.
4.2. Interplay of slow and fast desensitization mechanisms
KCTD12 binds to GB2 in close proximity of the PKA
phosphorylation-site S892. In principle, phosphorylation of S892
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would explain the slowing of fast desensitization. However, BRET
analysis and co-immunoprecipitation experiments show that
neither PKA activity nor the phospho-mimetic mutant GB2-
S892E unbind KCTD12 from the receptor. This agrees with earlier
ﬁndings showing that KCTD12 remains associated with the
receptor during receptor activity [21]. However, BRET analysis
revealed that PKA-mediated S892 phosphorylation induces a
conformational change in the receptor/KCTD12 complex without
measurably altering the interaction between KCTD12 and the G-
protein. This suggests that S892 phosphorylation does not stabilize
a receptor/KCTD12 conformation that prevents binding of KCTD12
to Gbg [19]. Since GB2 and KCTD12 both bind to the G-protein the
conformational rearrangement in the receptor/KCTD12 complex
may reduce the rate of G-protein activation [19,27,31–33]. Because
KCTD12-induced desensitization is activity-dependent [19], a
reduction in the G-protein activation rate would slow fast
desensitization.
Conversely, assembly of GABAB receptors with KCTD12
promotes S892 phosphorylation, which may induce a conforma-
tional rearrangement in the cytoplasmic domain of GB2 that makes
S892 more accessible for phosphorylation by PKA. This agrees with
earlier ﬁndings that show that receptors with KCTD12 are more
stable at the cell surface [21].
Overall, the interplay of fast and slow mechanisms of
homologous desensitization will have several effects on GABAB
receptor-activated K+ current responses. Assembly of receptors
with KCTD12 will increase basal S892 phosphorylation and
stabilize receptors at the cell surface [21]. Increased tonic S892
phosphorylation will attenuate KCTD12-induced fast desensitiza-
tion. Conversely, prolonged exposure to agonists will reduce PKA
activity and S892 phosphorylation. This will accelerate KCTD12-
induced fast desensitization and promote slow desensitization due
to receptor degradation. The interplay of the two mechanisms of
desensitization underlies the sharpening of the K+ current
response observed in heterologous cells during repeated receptor
activation. In addition to this homologous regulation of desensiti-
zation, it is possible that other GPCRs regulating cAMP/PKA
signaling modulate GABAB receptor desensitization in a heterolo-
gous manner. Moreover, GABAB receptor desensitization may be
regulated at S892 during neuronal processes in which PKA activity
is altered, such as NMDA-mediated synaptic plasticity, learning
and memory, seizures or during aging [34–37].
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GABAB receptors (GABABRs) are considered promising drug targets for the treatment of mental health
disorders. GABABRs are obligate heteromers of principal GABAB1 and GABAB2 subunits. GABABRs can
additionally associate with auxiliary KCTD8, 12, 12b and 16 subunits, which also bind the G-protein and
differentially regulate G-protein signaling. It is unknown whether the KCTDs allosterically inﬂuence
pharmacological properties of GABABRs. Here we show that KCTD8 and KCTD16 slightly but signiﬁcantly
increase GABA afﬁnity at recombinant receptors. However, KCTDs clearly do not account for the 10-fold
higher GABA afﬁnity of native compared to recombinant GABABRs. The positive allosteric modulator
(PAM) GS39783, which binds to GABAB2, increases both potency and efﬁcacy of GABA-mediated G-
protein activation ([35S]GTPgS binding, BRET between G-protein subunits), irrespective of whether
KCTDs are present or not. Of note, the increase in efﬁcacy was signiﬁcantly larger in the presence of
KCTD8, which likely is the consequence of a reduced tonic G-protein activation in the combined presence
of KCTD8 and GABABRs. We recorded Kir3 currents to study the effects of GS39783 on receptor-activated
G-protein bg-signaling. In transfected CHO cells and cultured hippocampal neurons GS39783 increased
Kir3 current amplitudes activated by 1 mM of baclofen in the absence and presence of KCTDs. Our data
show that auxiliary KCTD subunits exert marginal allosteric inﬂuences on principal GABABR subunits.
PAMs at principal subunits will therefore not be selective for receptor subtypes owing to KCTD subunits.
However, PAMs can differentially modulate the responses of receptor subtypes because the KCTDs
differentially regulate G-protein signaling.
This article is part of a Special Issue entitled ‘GABAergic signaling’.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).mice; A1, adenosine receptor
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GABABRs are the G-protein-coupled receptors (GPCRs) for GABA,
the main inhibitory neurotransmitter in the mammalian brain.
They play important roles in regulating neuronal excitability and
have been implicated in a variety of neurological and psychiatric
disorders (Gassmann and Bettler, 2012). GABABRs activate Gai/o-
type G-proteins that inhibit adenylyl cyclase via Gai/o and gate ion
channels via Gbg. It is well established that presynaptic GABABRs
inhibit voltage-gated Ca2þ channels and neurotransmitter release.
Postsynaptic GABABRs activate inwardly rectifying Kþ channels
(Kir3 channels) that generate slow inhibitory postsynaptic poten-
tials and inhibit neuronal excitability by local shunting.
GABABRs are heteromeric complexes of GABAB1 and GABAB2
subunits (Gassmann and Bettler, 2012). Two predominant GABAB1
subunit isoforms exist, GABAB1a and GABAB1b, which constitute
heteromeric GABAB(1a,2) and GABAB(1b,2) receptors with similarnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
terization of GABAB receptor subtypes assembledwith auxiliary KCTD
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(Brauner-Osborne and Krogsgaard-Larsen, 1999; Green et al., 2000;
Kaupmann et al., 1998). GABAB1 subunits contain the GABA
binding-site while the GABAB2 subunit couples to the G-protein.
GABAB2 allosterically induces a 10-fold increase in agonist binding-
afﬁnity at GABAB1. However, for unknown reasons, recombinant
GABABRs still have a 10-fold lower agonist binding-afﬁnity than the
native receptors (Kaupmann et al., 1998). GABAB1a and GABAB1b
target GABABRs to pre- and postsynaptic compartments, respec-
tively (Biermann et al., 2010; Vigot et al., 2006). We recently
showed that GABABRs can constitutively associate with homote-
tramers of Kþ channel tetramerization-domain (KCTD) containing
proteins. GABABRs assembled with KCTD8,12,12b and 16 constitute
molecularly and functionally distinct receptor subtypes (Schwenk
et al., 2010). The KCTDs are cytoplasmic proteins that simulta-
neously bind to GABAB2 and the Gbg subunits of the heterotrimeric
G-protein (Turecek et al., 2014). Dual binding to receptor and G-
protein allows the KCTDs to stabilize the G-protein/receptor inter-
action, which overcomes the slow diffusion-limited association of
the G-proteinwith the receptor and accelerates G-protein signaling
(Turecek et al., 2014). Furthermore, KCTD12 uncouples Gbg from
effector channels to induce a fast (within seconds) and pronounced
current desensitization (Turecek et al., 2014). The prototypical
synthetic GABABR agonist baclofen is 3e7 fold more potent in
activating Kir3 currents in the presence of KCTD proteins (Schwenk
et al., 2010). Whether this increase in agonist potency in the pres-
ence of the KCTDs relates to an increase in agonist afﬁnity at
GABAB1 or to activity-dependent effects at the G-protein, for
example to an acceleration of the G-protein cycle, is unknown.
The ternary GABABR complex assembled from GABAB1, GABAB2,
KCTD and G-protein subunits offers ample opportunities for allo-
steric regulation. For example, it is well established that the
orthosteric agonist binding-site in GABAB1 is allosterically coupled
to the G-protein binding-site in GABAB2 (Hill et al., 1984; Pin et al.,
2004). Likewise, PAMs (GS39783 and CGP7930) that bind to the
GABAB2 transmembrane domains strongly increase agonist
binding-afﬁnity at GABAB1 (Binet et al., 2004; Dupuis et al., 2006;
Mannoury la Cour et al., 2008; Urwyler et al., 2003). Whether as-
sociation of the KCTDs with GABAB2 and the G-protein also allo-
sterically inﬂuences ligand-binding properties of GABABRs is
unknown.
Herewe report that KCTD8 and KCTD16 slightly increase agonist
binding-afﬁnity at the receptor. However, this increase in agonist
binding-afﬁnity is clearly not reaching the still higher afﬁnity of
native GABABRs. Furthermore, GS39783 increases potency and ef-
ﬁcacy of G-protein activation in the presence and absence of the
KCTDs. In summary, our data indicate that the KCTDs exert mar-
ginal allosteric effects on the GABAB1 and GABAB2 protomers and
primarily inﬂuence receptor signaling by acting at the G-protein. A
conclusion from these experiments is that compounds acting at the
GABAB1 and GABAB2 protomers will not allow to clearly distinguish
receptor subtypes based on KCTD subunits. However, our data also
show that by acting at the G-protein the KCTDs can to some extent
differentially affect allosteric modulation of receptor signaling.
2. Materials and methods
2.1. Plasmids, cell culture and transfection procedure
Plasmids encoding Myc-GABAB1b, Myc-GABAB2, Flag-KCTDs, Kir3.1/3.2 con-
catamers, Renilla reniformis luciferase (Rluc)-tagged Gao and Venus-Gg2 were
described previously (Ayoub et al., 2009; Ivankova et al., 2013; Schwenk et al.,
2010). The plasmid expressing Flag-tagged Gb2 was obtained from the Missouri
S&T cDNA Resource Center and pEGFP-N1 from Clontech. The plasmid expressing
Flag-tagged human adenosine receptor 1 (A1) was a gift from Miriam Peeters
(Center for Basic Metabolic Research, Copenhagen University).
Human Embryonic Kidney 293T (HEK293T) and Chinese hamster ovary K1
(CHO) cells were maintained in Dulbecco's modiﬁed Eagle's medium (DMEM,Please cite this article in press as: Rajalu, M., et al., Pharmacological charac
subunits, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neurophglutamine-free, Invitrogen), supplemented with 10% FCS (Gibco, Life Technolo-
gies) in a humidiﬁed atmosphere of 5% CO2 at 37 C. CHO cells stably expressing
GABAB(1b,2) (CHO-GABAB) were described earlier (Urwyler et al., 2001) and
maintained in DMEM supplemented with 500 mm L-glutamine (Sigma), 40 mg/ml
L-proline (Sigma), 500 mg/ml geneticin (Roche), 250 mg/ml zeocin (Invitrogen) and
10% FCS under identical conditions as HEK293T and CHO cells.
Cultured hippocampal neurons were prepared as described previously (Brewer
et al., 1993). Brieﬂy, embryonic day 16.5 mouse hippocampi were dissected,
digested with 0.25% trypsin (Invitrogen) in 1  PBS solution (Gibco) for 15 min at
37 C, dissociated by trituration, and plated on glass coverslips coated with 1 mg/
ml poly-L-lysine hydrobromide (Sigma) in 0.1 M borate buffer (boric acid/sodium
tetraborate). Neurons were seeded at high density (~550 cells/mm2) and incubated
for 14e21 days in a humidiﬁed atmosphere of 5% CO2 at 37 C. Cultures were grown
in neurobasal medium (Gibco) supplemented with B27 (Invitrogen) and 0.5 mM
L-glutamine.
Lipofectamine 2000 (Invitrogen) was used for all transient transfections of
HEK293T and CHO-GABAB cells. For electrophysiology experiments, CHO-GABAB
cells were splitted at 80e90% conﬂuency 24 h before transfection and plated onto
plastic coverslips (Thermanox, Thermo Fisher Scientiﬁc) at a dilution of 1:5 in
35 mm dishes. CHO-GABAB cells were transfected using 2.5 ml/ml of Lipofect-
amine 2000 as well as 1.75 mg/ml of Kir3.1/3.2 concatamer, 0.625 mg/ml of KCTD
constructs and 0.375 mg/ml of pEGFP-N1 to visualize transfected cells. After 5 h,
the medium was exchanged and the cells were kept in the incubator for addi-
tional 48 h before being used for electrophysiological recordings.
2.2. Viral transduction of CHO cells
For stable expression of Flag-epitope tagged KCTD8 or KCTD12, CHO and
CHO-GABAB cells, were transduced with lentiviral vectors as described earlier
(Lois et al., 2002). Brieﬂy, lentiviruses were produced by cotransfection of
HEK293T cells with the lentiviral target vector FUW (Lois et al., 2002), the HIV-1
packaging vector D8.2 and the VSV-G envelope glycoprotein vector (Oliver
Schlüter, European Neuroscience Institute, G€ottingen). The self-inactivating and
replication-deﬁcient VSV-G pseudotyped viruses were concentrated by ultra-
centrifugation (74,000 g, 90 min, 4 C) of the virus-containing supernatant.
Stable expression of Flag-KCTDs was achieved by transduction of low passage
CHO cells using different concentrations of the virus-containing supernatant to
obtain varying levels of KCTD expression. Pools of CHO cells with equal KCTD-
expression levels were selected by Western blotting of cellular lysates and pro-
teins were detected using an antibody against the Flag-epitope tag (Sigma).
2.3. Radioligand binding assay
Preparation of membranes from HEK293T cells for radioligand binding assays
was performed as described in Galvez et al. (2000). Brieﬂy, culture dishes were
washed twice with ice-cold PBS, 10 mM of HEPES buffer, pH 7.4, was added to the
plates and cells scraped off (BD Flacon). Crude membranes from approximately
ten 15-cm cell culture dishes per point were collected and centrifuged (26,000 g,
20 min). The pellet was re-suspended in 10 ml HEPES buffer, homogenized using
a glass-teﬂon homogenizer (10 strokes) and the suspension centrifuged (38,000 g,
20 min). The pellet was re-suspended in 2 ml of buffer and homogenized (20
strokes). Aliquots were frozen in liquid nitrogen and stored at 80 C for 48 h.
Preparation of membranes from rat cortical neurons as well as mouse brains
for radioligand binding assays was performed as described in Olpe et al. (1990).
Brieﬂy, animals of at least 8 weeks of age were decapitated, the brains removed,
washed in ice-cold PBS and homogenized in 10 volumes of ice-cold 0.32 M su-
crose, containing 4 mM HEPES, 1 m EDTA and 1 mM EGTA, using a glass-teﬂon
homogenizer. Debris was removed at 1000 g (10 min) and membranes centri-
fuged at 26,000 g (15 min). The pellet was osmotically shocked by re-suspension
in a 10-fold volume of ice-cold dH2O and kept on ice for 1 h. The suspension was
centrifuged at 38,000 g (20 min) and re-suspended in a 3-fold volume of dH2O.
Aliquots were frozen in liquid nitrogen and stored at 20 C for 48 h. After
thawing at room temperature, a 7-fold volume of Krebs-Henseleit (KH) buffer (pH
7.4) was added, containing 20 mM Tris-HCl, 118 mM NaCl, 5.6 mM glucose,
4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM KH2PO4 and 1.2 mM MgSO4. Membranes were
washed three times by centrifugation at 26,000 g (15 min), followed by re-
suspension in KH buffer. The ﬁnal pellet was re-suspended in a 5-fold volume
of KH buffer. Aliquots (2 ml) were frozen and stored at 80 C until further use.
On the day of the experiment, the membranes from frozen HEK293T cells or
neurons were thawed, re-suspended in 10 ml of ice-cold dH2O, and centrifuged
at 26,000 g (15 min). The pellet was again re-suspended in 10 ml of ice-cold
dH2O and incubated for 1 h on ice. After one additional round of centrifuga-
tion at 26,000 g (15 min) the ﬁnal pellet was re-suspended in assay buffer
containing 50 mM Tris-HCl buffer (pH 7.7); 10 mM MgCl2, 1.8 mM CaCl2, 100 mM
NaCl, 20 mg of membrane protein, 5 nM of the high-afﬁnity GABABR radioligand
antagonist [3H]CGP54626A (60 Ci/mmol, ANAWA AG, Wangen, Switzerland), in a
ﬁnal volume of 50 ml per point and in the absence and presence of competitor
compound. Protein concentrations for the samples were measured with the
Bradford assay method, using the Bio-Rad protein assay kit and bovine serum
albumin as a standard.terization of GABAB receptor subtypes assembledwith auxiliary KCTD
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polypropylene microplates (Greiner Bio-One) with mild shaking. They were
subsequently ﬁltered using 96-well Whatman GF/C glass ﬁber ﬁlters (Perkin
Elmer), pre-soaked in assay buffer, using a Filtermate cell harvester (Perkin
Elmer). After four washes with assay buffer, the Whatman ﬁlter ﬁbers were dried
for 1 h at 50 C. 50 ml of scintillation ﬂuid (Microscint 20, Perkin Elmer) was
added, the plates were shaken for 1 h and thereafter counted using a Packard
TopCount NXT (Perkin Elmer). GraphPad Prism 5.01 software (Graph Pad, San
Diego, CA) was used for data analysis.
2.4. Western Blotting
For Western Blotting, HEK293T cells were harvested, washed in PBS, and
subsequently lysed in a Nonidet P-40 buffer (100 mm NaCl, 1 mm EDTA, 0.5%
Nonidet P-40, 20 mm Tris/HCl, pH 7.4) supplemented with complete EDTA-free
protease inhibitor mixture (Roche). After rotation for 10 min at 4 C, the ly-
sates were cleared by centrifugation at 16,000  g for 10 min at 4 C. Lysates
were thereafter resolved using standard SDS-PAGE and probed with the primary
antibodies rabbit anti-Myc (Sigma), rabbit anti-GABAB1 (Novartis) and guinea pig
anti-GABAB2 (Millipore). The antibody incubation was in 5% nonfat dry milk in
PBS containing 0.1% Tween-20. The chemiluminescence detection kit (Pierce)
was used for visualization.
2.5. [35S]GTPgS binding assay
[35S]GTPgS binding assays with CHO cell membranes were performed as
described (Urwyler et al., 2001). Brieﬂy, CHO cells were grown to 80e90% con-
ﬂuency in 15-cm culture dishes. Culture dishes were washed twice with ice-cold
PBS and subsequently treated as described for the radioligand binding assay with
membranes of HEK293T cells with the following differences. The ﬁnal pellet was
re-suspended in assay buffer containing 50 mM Tris-HCl buffer (pH 7.7); 10 mM
MgCl2, 1.8 mM CaCl2, 100 mM NaCl, 30 mM guanosine 5‘-diphosphate (GDP,
Sigma), 10 mg of membrane protein, 0.2 nM [35S]GTPgS (Perkin Elmer), in the
absence or presence of GS39783 (10 mM, dissolved in DMSO, a kind gift from K.
Kaupmann, Novartis), in a ﬁnal volume of 200 ml per point. Non-speciﬁc binding
was measured in the presence of unlabeled GTPgS (10 mM, Sigma). To determine
basal [35S]GTPgS binding we used 1 mM of GDP in the assay buffer. Because
maximal binding with GABA alone differed between experiments, the data were
normalized to the maximal effect (Emax) of saturating concentrations of GABA in
the absence of GS39783 (100%) and basal activity without GABA (0%).
For [35S]GTPgS binding assays with mouse brain membranes, mice of at least
8 weeks of age were decapitated, the brains removed and subsequently pro-
cessed as described for the radioligand binding assay with brain membranes. On
the day of the experiment, the frozen membranes were thawed, homogenized in
10 ml ice-cold assay buffer and centrifuged at 20,000 g (15 min). The pellet was
re-suspended in the same volume of cold buffer (50 mM Tris-HCl, pH 7.7, 100 mM
NaCl, 10 mM MgCl2, 1.8 mM CaCl2) and centrifuged twice as above with 30 min of
incubation on ice in between the centrifugation steps. The resulting pellet was
re-suspended, homogenized in assay buffer by using a glass/teﬂon homogenizer
and assayed as described above for CHO cell membranes.
2.6. Bioluminescence resonance energy transfer (BRET) measurements
CHO and CHO-GABAB cells were transiently transfected with plasmids
encoding Gao-Rluc, Venus-Gg2, Flag-Gb2 and Myc-KCTD8, Myc-KCTD12 or
Myc-KCTD16 and seeded into 96-well microplates (Greiner Bio-One). Cells were
washed with PBS 24 h after transfection. BRET was measured in an Inﬁnite® F500
microplate reader (Tecan) after injection of 5 mM Coelenterazine h (NanoLight
Technologies). Baclofen was added at a ﬁnal concentration of 10 mM or 100 mM.
GS39783 was added at the ﬁnal concentration of 10 mM, 5 min prior to mea-
surement. Luminescence and ﬂuorescence signals were detected sequentially
with an integration time of 200 ms. The BRET ratio was calculated as the ratio of
light emitted by Venus-Gg2 (530e570 nm) over light emitted by Gao-Rluc
(370e470 nm) and corrected by subtracting ratios obtained with the Rluc fusion
protein alone. The results were expressed in mBRET units determined as net
BRET  1000. Each data point was obtained using duplicate wells. The curves
were ﬁtted using GraphPad Prism 5.01 software (“Plateau followed by one-phase
decay”).
2.7. Electrophysiology
Kir3 currents were recorded at 30e32 C in artiﬁcial cerebrospinal ﬂuid
containing 145 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 25 mM glucose,
10 mM HEPES, pH 7.3. Patch pipettes were pulled from borosilicate glass capil-
laries (resistance of 3e5 MU) and ﬁlled with a solution containing 140 mM K-
gluconate, 4 mM NaCl, 5 mM HEPES, 2 mM MgCl2, 1.1 mM EGTA, 2 mM Na2-ATP,
5 mM phosphocreatine, 0.6 mM Na3-GTP, at pH 7.25 (adjusted with KOH).
GABABR responses were evoked at 50 mV by fast application of 1e100 mM
baclofen (Ascent Scientiﬁc) with a multiple channel perfusion valve control
system (VC-8, 3 barrels, Warner Instruments). Data were acquired with aPlease cite this article in press as: Rajalu, M., et al., Pharmacological charac
subunits, Neuropharmacology (2014), http://dx.doi.org/10.1016/j.neurophMultiClamp 700B (Molecular Devices), low-pass ﬁltered at 2 kHz and digitized at
10 kHz using a Digidata 1440A interface (Molecular Devices) driven by pClamp
10.3 software. Whole-cell currents were analyzed using Clampﬁt 10.3 software
(Molecular Devices). Data are expressed as mean ± S.E.M. and were analyzed
with GraphPad Prism 5.01 software. EGFP-expressing CHO cells were identiﬁed
via epiﬂuorescence using an FITC ﬁlter set and patched under oblique illumi-
nation optics (BX51WI; Olympus).
2.8. Statistics
Curves for radioligand displacement and [35S]GTPgS binding at different
GABA concentrations were estimated by nonlinear regression. pKI, pEC50
(log10EC50) and Emax values represent the mean ± S.E.M of at least three inde-
pendent experiments. Levels of statistical signiﬁcance were set at *, p < 0.05; **,
p < 0.01 and ***, p < 0.001. Extra sums-of-squares F-tests were used for pKI and
pEC50, using the GraphPad Prism 5.01 software. Two-way ANOVA, followed by a
post hoc Sidak's multiple comparison test was used for Emax. KruskaleWallis test
followed by Dunn's multiple comparison test was used to determine basal [35S]
GTPgS binding and baseline BRET in the absence of agonist.3. Results
3.1. Effects of the KCTDs on GABA binding-afﬁnity at recombinant
and native GABABRs
In order to determine if the KCTDs allosterically inﬂuence
agonist binding-afﬁnity at GABAB1, we transiently expressed
GABAB1b or GABAB(1b,2) in the absence and presence of KCTD8,
KCTD12 or KCTD16 in HEK293T cells. Approximately equal
expression of ectopic GABAB1b and GABAB2 in cells was veriﬁed
using protein extracts from transiently transfected HEK293T cell
membrane fractions (Suppl. Fig. 1). We used [3H]CGP54626A, a
competitive GABABR antagonist (Kaupmann et al., 1997), for radi-
oligand displacement experiments with membranes of transfected
cells. In agreement with earlier studies (Kaupmann et al., 1997,
1998), the afﬁnity of GABA at GABAB1b was ~10-fold lower than at
the GABAB(1b,2) heteromer and ~100-fold lower than at rat cortical
membranes (Fig. 1A). Co-expression of the KCTDs slightly increased
GABA afﬁnity at GABAB(1b,2) (Fig. 1A and Table 1). This increase in
afﬁnity reached signiﬁcance for KCTD8 and KCTD16 but not for
KCTD12 (F-test). These experiments show that binding of KCTD8 or
KCTD16 to GABAB2 exerts a small positive allosteric effect on the
GABA binding-site of GABAB1. The GABA binding-afﬁnity at all re-
combinant GABABR subtypes analyzed here was still signiﬁcantly
lower than the afﬁnity at native receptors (p < 0.001 for rat cortical
membranes vs. KCTD8, KCTD12 and KCTD16; F-test). It is conceiv-
able that in transfected HEK293T cells distinct receptor populations
contribute to the measured GABA binding-afﬁnity. In line with this
HEK293Tcells transiently transfectedwith GABAB1b in combination
with GABAB2 alone or together with KCTD8, KCTD12, or KCTD16
show Hill coefﬁcients of 0.68, 0.77, 0.66 and 0.72, respectively. In
contrast HEK293T cells transiently transfected with GABAB1b alone
or rat cortical membranes exhibit a Hill coefﬁcient close to 1.0
indicative of a single binding site (Table 1). While it cannot be ruled
out that the deviation of the Hill coefﬁcients from 1 and the lower
overall afﬁnity of recombinant receptors compared to native re-
ceptors are caused by overexpression in HEK293T cells it is also
possible that still unknown factors are responsible for the higher
afﬁnity of native receptors. The GABA binding-afﬁnity of full brain
membranes of wild-type (WT) and Kctd8/12/16/ knock-out (3KO)
mice (Turecek et al., 2014) are similar (p ¼ 0.503; Fig. 1B and
Table 2) and rule out a pronounced effect of the KCTDs on the
overall binding afﬁnity in the mouse brain. In summary, the data
show that KCTD8 and KCTD16 exert a small allosteric effect on the
orthosteric agonist binding-site in a recombinant expression sys-
tem but do not signiﬁcantly inﬂuence the overall agonist binding
afﬁnity in native membranes.terization of GABAB receptor subtypes assembledwith auxiliary KCTD
arm.2014.08.020
Table 2
Effect of the KCTDs on [3H]CGP54626A displacement from native GABABRs by GABA.
The binding of the orthosteric ligand [3H]CGP54626A to native GABABRs on brain
membranes of wild-type (WT) or Kctd8/12/16/ knockout (3KO) mice was
measured as described in the Materials and Methods section. Displacement curves
were constructed as illustrated in Fig. 1B. The results shown are means ± S.E.M. from
(N) individual experiments. Results are compared to native GABABRs of wild-type
mice using an Extra sums-of-squares F-test.
GABABR pKi GABA (log M) Hill coefﬁcient N
WT 5.58 (±0.10) 0.80 3
3KO 5.50 (±0.06) 0.86 3
Fig. 1. Effects of the KCTDs on [3H]CGP54626A displacement by GABA. (A) [3H]
CGP54626A displacement curves with membranes of HEK293T cells transiently
transfected with either GABAB(1b,2) alone (black triangles, point up) or GABAB(1b,2) in
combination with KCTD8 (blue triangles, point down), KCTD12 (red diamonds) or
KCTD16 (open green circles). [3H]CGP54626A displacement curves with membranes of
HEK293T cells transfected with GABAB1b alone (gray squares) and with GABABRs in rat
cortical membranes (brown circles) are shown as controls. Displacement of [3H]
CGP54626A (5 nM) was performed with increasing concentrations of GABA. Data
points represent means ± S.E.M. of 3e6 independent experiments, each performed in
quadruplicates. A summary of relevant parameters is given in Table 1. (B) [3H]
CGP54626A displacement curves with brain membranes of wild-type (WT, red circles)
or Kctd8/12/16/ triple KO mice (3KO, blue diamonds). Displacement of [3H]
CGP54626A (5 nM) was performed with increasing concentrations of GABA. Data
points represent means ± S.E.M. of 3 independent experiments, each performed in
quadruplicates. A summary of relevant parameters is given in Table 2.
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GABABRs in [
35S]GTPgS binding experiments
To determine whether the KCTDs inﬂuence allosteric modula-
tion of GABABRs by a PAM we used GS39783 in combination with
the [35S]guanosine 50-O-(3-thio)triphosphate ([35S]GTPgS) binding
assay, a well-established functional assay for GABABRs (UrwylerTable 1
Effect of the KCTDs on [3H]CGP54626A displacement by GABA. The binding of the
orthosteric ligand [3H]CGP54626A to recombinant GABABRs on membranes of
HEK293T cells and native GABABRs on rat cortical membranes was measured as
described in the Materials and Methods section. Displacement curves were con-
structed as illustrated in Fig. 1A. The results shown are means ± S.E.M. from (N)
individual experiments.*, p < 0.05,**, p < 0.01,***, p < 0.001 compared to control
GABAB(1b,2) receptors using an Extra sums-of-squares F-test.
GABABR pKi GABA (log M) Hill coefﬁcient N
GABAB(1b,2) 4.16 (±0.04) 0.68 6
GABAB(1b,2) þ KCTD8 4.43 (±0.07)** 0.77 6
GABAB(1b,2) þ KCTD12 4.27 (±0.04) 0.66 6
GABAB(1b,2) þ KCTD16 4.31 (±0.06)* 0.72 6
GABAB1b homomer 3.07 (±0.03)*** 1.11 3
Rat cortical membranes 5.23 (±0.09)*** 0.91 4
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membranes of CHO-GABAB cells stably expressing GABAB(1b,2) in
the absence or presence of KCTDs. For these experiments, we len-
tivirally transduced CHO-GABAB cells (Urwyler et al., 2001) to
generate two additional cell lines stably expressing GABAB(1b,2)
together with KCTD8 or KCTD12. KCTD12 represents KCTD12 and
KCTD12b that both produce desensitizing Kir3 currents upon re-
ceptor activation. In contrast, KCTD8 represents KCTD8 and KCTD16
that produce largely non-desensitizing currents (Schwenk et al.,
2010). [35S]GTPgS binding assays were performed with mem-
branes of all three cell lines, either in the absence or presence of
10 mM of GS39783 (Fig. 2A). Conﬁrming earlier studies (Urwyler
et al., 2005, 2003), we found that GS39783 signiﬁcantly increased
both potency and efﬁcacy of GABA to stimulate [35S]GTPgS binding
in CHO-GABAB control cells (ø KCTD, Table 3). Similarly, GS39783
signiﬁcantly increased both potency and efﬁcacy of GABA at
membranes of CHO-GABAB cells expressing KCTD8 or KCTD12
(Table 3, F-test for potency, two-way analysis of variance (ANOVA)
with subsequent post-hoc Sidak's multiple comparison test for ef-
ﬁcacy). Of note, the KCTDs did not signiﬁcantly alter the potency of
GABA at GABABRs in the absence of GS39783 when compared to
control CHO-GABAB cells (KCTD8: p ¼ 0.677; KCTD12: p ¼ 0.114).
With GS39783-treated membranes the potency in the presence of
KCTD8 but not KCTD12 was signiﬁcantly but slightly decreased
compared to control cells (KCTD8: p ¼ 0.003; KCTD12: p ¼ 0.876).
This supports that KCTD8 exerts a weak allosteric inﬂuence on the
PAM binding-site or the G-protein binding-site in the presence of
the PAM. Furthermore, the GS39783-induced increase in the efﬁ-
cacy was signiﬁcantly higher in the presence of KCTD8 than in
control or KCTD12-expressing CHO-GABAB cells (Fig. 2A, p < 0.001
for KCTD8 vs. ø KCTD and KCTD8 vs. KCTD12), while there was no
signiﬁcant difference in the increase in efﬁcacy between control
and KCTD12-expressing cells (p ¼ 0.0608 for ø KCTD vs. KCTD12).
The above data indicate that GS39783-modulation of the efﬁ-
cacy of GABABR responses is remarkably large with KCTD8. One
possible explanation for the larger increase in efﬁcacy with KCTD8
is that KCTD8 reduces the efﬁcacy in the absence of GS39783. A
similar phenomenon was reported earlier for partial agonists that
are more amenable to allosteric modulation of GABABRs by PAMs
than full agonists (Mannoury la Cour et al., 2008; Urwyler et al.,
2005). In order to determine if KCTD8 reduces basal G-protein
activation of GABABRs, we performed [35S]GTPgS binding assays in
the absence of agonist, but in the presence of a low GDP concen-
tration (1 mM) (Roberts and Strange, 2005) to facilitate detection of
agonist-independent receptor activity (Strange, 2010). Indeed,
KCTD8 (Fig. 2B) led to a small but signiﬁcant decrease in basal G-
protein activation in the unstimulated state (86% of control CHO-
GABAB cells, p ¼ 0.009), while KCTD12 has no such effect (97% of
control, p ¼ 0.654). This indicates that KCTD8 decreases basal G-
protein activation in the absence of agonist.
In summary, these experiments show that GS39783 increases
agonist potency and efﬁcacy both in the absence and presence of
KCTDs in [35S]GTPgS binding experiments. Together with theterization of GABAB receptor subtypes assembledwith auxiliary KCTD
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Fig. 2. Effects of the KCTDs on allosteric modulation of recombinant GABABRs in [35S]GTPgS binding experiments. (A) GABA-induced [35S]GTPgS binding to membranes of CHO-
GABAB cells stably expressing either GABAB(1b,2) alone (ø KCTD, black triangles, point up) or GABAB(1b,2) in combination with KCTD8 (blue triangles, point down) or KCTD12 (red
diamonds). Filled symbols indicate the absence, empty symbols the presence of GS39783 (10 mM, þGS). Data points represent the stimulation of [35S]GTPgS binding by the indicated
concentrations of GABA above basal binding (0%) normalized to the maximal GABA response in the absence of GS39783 (100%). Data points are means ± S.E.M. of three independent
experiments, each performed in quadruplicates. A summary of relevant parameters is given in Table 3. (B) Summary bar graph of basal [35S]GTPgS binding, performed in the
presence of 1 mM of GDP, in CHO-GABAB cells expressing GABAB(1b,2) without (ø KCTD, black) or with KCTD8 (blue) or KCTD12 (red). One representative experiment out of three is
shown. Results are means ± S.E.M. of quadruplicates. *, p < 0.05 of KruskaleWallis test followed by Dunn's multiple comparison test.
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the KCTDs exert no or little allosteric inﬂuence on allosteric and
orthosteric binding sites in principal receptor subunits. Of note,
KCTD8 reduces the basal level of receptor activity. GS39783 can
overcome reduced G-protein coupling in the presence of KCTD8
and therefore induces a signiﬁcantly larger increase in the maximal
receptor response.3.3. Effects of the KCTDs on allosteric modulation of recombinant
GABABRs in BRET G-protein activation experiments
The [35S]GTPgS binding experiments showed that GS39783 acts
as a PAM in a functional assay in the absence and presence of the
KCTDs. The [35S]GTPgS binding experiments additionally indicated
that KCTD8 reduces basal G-protein activation by the receptor, but
that increased activation can still be obtained in the presence of
GS39783. To corroborate these ﬁndings, we monitored GABABR-
induced G-protein activation in BRET experiments (Digby et al.,
2006; Frank et al., 2005; Turecek et al., 2014). We transiently
transfected CHO-GABAB cells with the donor fusion protein Gao-
Rluc, the acceptor fusion protein Venus-Gg2, Gb2 and each of the
KCTDs. We then determined the magnitude of the BRET changeTable 3
Effects of the KCTDs on allosteric modulation of recombinant GABABRs in [35S]GTPgS
binding experiments. Concentration response curves were measured (Fig. 2) from
membranes of CHO-GABAB cells, stably expressing GABABRs without or with KCTDs,
both in the absence and presence of the positive allosteric modulator GS39783 (GS).
Because the maximal effect of GABA alone differed between experiments, the data
were normalized to the maximal effect (Emax) obtained with saturating concentra-
tions of GABA alone in the absence of GS (100%) and basal activity without GABA
(0%). The results shown are means ± S.E.M from (N) individual experiments.**,
p < 0.01,***, p < 0.001 compared to non- GS-treated control values (Extra sums-of-
squares F-test for pEC50 and two-way ANOVA followed by a post-hoc Sidak's mul-
tiple comparison test for Emax).
pEC50 GABA (- log M) Emax N
ø KCTD 5.3 (±0.1) 97.5 (±7.0) 3
ø KCTD, þGS 6.2 (±0.0)*** 378.4 (±7.3)***
KCTD8 5.2 (±0.2) 100.5 (±15.8) 3
KCTD8, þGS 5.9 (±0.0)** 586.0 (±20.7)***
KCTD12 5.1 (±0.1) 100.0 (±5.9) 3
KCTD12, þGS 6.2 (±0.0)*** 322.8 (±7.0)***
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induced by baclofen (10 mM and 100 mM) in the absence and
presence of GS39783. Of note, baclofen concentrations lower than
10 mM did not lead to measurable changes in BRET.
GS39783 (10 mM) signiﬁcantly increased the magnitude of the
BRET change induced by baclofen in the absence and presence of
KCTDs (Fig. 3AeC). Of note, we recently reported a signiﬁcantly
larger magnitude of the BRET change with KCTD12, which reﬂects
binding of KCTD12 to an activity-dependent binding-site on the bg
subunits of the G-protein (Turecek et al., 2014). This KCTD12-
speciﬁc conformational rearrangement of the G-protein is only
seen with the high concentration of baclofen. Activity-dependent
binding of KCTD12 to bg requires unbinding of Ga from Gbg
(Turecek et al., 2014) and may therefore depend on substantial G-
protein dissociation, offering a possible explanation for the
requirement of a high baclofen concentration. The KCTD12-speciﬁc
increase in the change of BRET is further increased by GS39783.
This indicates that PAMs and KCTD12 affect the G-protein rear-
rangement independent of each other, with KCTD12 primarily
acting at the G-protein (Turecek et al., 2014).
Interestingly, KCTD8, but not KCTD12 or KCTD16, showed a
signiﬁcantly decreased baseline BRET in the absence of baclofen,
which reﬂects the basal G-protein conformation (Fig. 3B and C,
right, also compare traces of KCTD8 with other traces in Fig. 3A). To
determine if the decreased baseline BRET requires binding of
KCTD8 to GABABR, BRET studies were performed with CHO cells
that lacked GABABRs or expressed adenosine receptor 1 (A1). In
these cells KCTD8 did not signiﬁcantly decrease the baseline BRET
levels when compared to controls (p ¼ 0.793 for CHO cells without
GABABR (n¼ 24); p¼ 0.252 for CHO cells expressing A1 (n¼ 27)). In
summary, the BRET measurements support that GS39783 increases
agonist-induced G-protein activation irrespective of the KCTDs.
Moreover, KCTD8 reduces basal G-protein activation when associ-
ated with GABABRs.3.4. Effects of the KCTDs on allosteric modulation of native GABABRs
in [35S]GTPgS binding experiments
[35S]GTPgS binding and BRET studies show that GS39783 acts as
a PAM at recombinant GABABRs assembled with KCTDs. We further
investigated whether GS39783 exerts PAM activity at nativeterization of GABAB receptor subtypes assembledwith auxiliary KCTD
arm.2014.08.020
Fig. 3. Effects of the KCTDs on allosteric modulation of recombinant GABABRs in BRET G-protein activation assays. (A) Representative baclofen-induced changes in the BRET signal
(milli BRET units, mBU) with CHO-GABAB cells co-expressing Gao-Rluc, Venus-Gg2 and Gb2 with or without KCTD8, KCTD12 or KCTD16 in the absence (black) or presence (gray) of
GS39783 (GS, 10 mM, 5 min pre-incubation). (B) Summary bar graph of BRET changes upon 10 mM baclofen application (changes in BRET (DBRET) in % of basal BRET, left) and baseline
BRET (in mBU, right). Data are means ± S.E.M. of eight individual experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; compared to the respective DMSO treatment. #, p < 0.001;
compared to all DMSO treatments. $, p < 0.001; compared to all GS treatments. (C) Summary bar graph of BRET changes upon 100 mM baclofen application (left) and baseline BRET
(right). Data are means ± S.E.M. of 4e7 individual experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001; compared to the respective DMSO treatment. #, p < 0.05; compared to all
DMSO treatments. $, p < 0.01; compared to all GS treatments.
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Table 4
Effects of the KCTDs on allosteric modulation of native GABABRs in [35S]GTPgS
binding experiments. Concentration response curves were measured (Fig. 4) from
brain membranes of wild-type (WT) or Kctd8/12/16/ knockout (3KO) mice, both in
the absence and presence of the positive allostericmodulator GS39783 (GS). Because
the maximal effect of GABA alone differed between experiments, the data were
normalized to the maximal effect (Emax) obtained with saturating concentrations of
GABA alone in the absence of GS (100%) and basal activity without GABA (0%). The
results shown are means ± S.E.M from (N) individual experiments.*, p < 0.05,***,
p < 0.001 compared to non-GS-treated control values (Extra sums-of-squares F-test
for pEC50 and two-way ANOVA followed by a post-hoc Sidak's multiple comparison
test for Emax).
pEC50 GABA (log M) Emax N
WT 5.4 (±0.1) 100.0 (±0.6) 4
WT, þGS 6.3 (±0.1)*** 196.3 (±27.8)*
3KO 5.3 (±0.1) 100.0 (±0.1) 4
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assay andwhole brainmembranes of 3KOmice. Of note, KCTD12b is
only expressed in the medial habenula and does not substantially
inﬂuence biochemical assays in whole brain membranes (Metz
et al., 2011; Schwenk et al., 2010). As expected, GS39783
increased both potency and efﬁcacy of GABA at GABABRs of wild-
type (WT) mice (Perdona et al., 2011; Urwyler et al., 2003)
(Fig. 4). The lack of KCTDs in 3KOmice did not inﬂuence the potency
of GABA in the absence (p ¼ 0.822) or presence of GS39783
(p ¼ 0.464). Furthermore, the lack of KCTDs did not inﬂuence the
ability of GS39783 to increase the efﬁcacy of GABA in 3KO
membranes (p > 0.999) (Table 4). In summary, GS39783 had similar
PAM activity at native GABABRs irrespective of whether KCTDswere
present or not.3KO, þGS 6.4 (±0.1)*** 193.5 (±28.8)*3.5. Effects of the KCTDs on allosteric modulation of GABABR-
activated Kir3 currents in CHO cells
We next analyzed whether GS39783 allosterically modulates
GABABR-activated Gbg signaling in the presence or absence of
KCTDs. Kir3 currents were evoked every 5 min by a 40 s applica-
tion of baclofen (1 mM, ~EC20, Fig. 5A). This was ﬁrst done in the
absence (GS) and then in the presence of GS39783 (þGS, 10 mM,
bath application for 10 min). GS39783 had no effect on holding
currents (Suppl. Fig. 2A) but led to an approximately two-fold
increase of the Kir3 current peak amplitude both in the absence
and presence of KCTDs (Fig. 5A and B). GS39783 accentuated ki-
netic effects of KCTD12 on GABABR signaling described earlier
(Schwenk et al., 2010; Turecek et al., 2014). Speciﬁcally, GS38793
shortened the rise-time and increased the relative desensitization
of evoked Kir3 currents (Fig 5B). The effects of KCTD12 on rise-
time and desensitization are dependent on the baclofen concen-
tration (Suppl. Fig. 2B and C). It is therefore likely that GS39783
shortens the rise-time and increases desensitization in the pres-
ence of KCTD12 by increasing agonist binding-afﬁnity at the re-
ceptor. Interestingly, GS39783 did not signiﬁcantly increase the
plateau current during prolonged KCTD12-induced desensitization
(þGS39783: 19.7 ± 6.2 pA,GS39783: 13.1 ± 6.0 pA, p ¼ 0.055,
Fig. 5A). Since KCTD12 induces desensitization by interfering withFig. 4. Effects of the KCTDs on allosteric modulation of native GABABRs in [35S]GTPgS
binding experiments. Effect of GS39783 on GABA-induced [35S]GTPgS binding to brain
membranes of wild-type (WT, red circles) or Kctd8/12/16/ triple knockout mice (3KO,
blue diamonds). Filled symbols indicate the absence, empty symbols the presence of
GS39783 (10 mM, þGS). Data points represent the stimulation at different GABA con-
centrations above basal binding (0%) normalized to the maximal GABA response in the
absence of GS39783 (100%). Data points are means ± S.E.M. of four independent ex-
periments, each performed in quadruplicates. A summary of relevant parameters is
given in Table 4.
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activity at the receptor may no longer be very effective during
maximal KCTD12-mediated inhibition of Gbg signaling. Altogether
the data are consistent with the PAM potentiating KCTD12-
mediated effects at the G-protein by increasing agonist afﬁnity at
the receptor and hence receptor activation at a given concentra-
tion of agonist.3.6. Effects of KCTDs on allosteric modulation of GABABR-activated
Kþ currents in hippocampal neurons
KCTD8, 12, 12b and 16 are differentially expressed in the brain
(Metz et al., 2011; Schwenk et al., 2010). KCTD12 and 16 expression
is high in the hippocampus while KCTD8 expression is low in this
area. KCTD12b is exclusively expressed in the medial habenula.
Using cultured hippocampal neurons from 3KO mice and control
WTmicewe analyzedwhether GS39783 has similar PAM activity in
the absence and presence of KCTD proteins.
Native Kþ currents exhibit strong run-down after repeated
baclofen application. We therefore studied the modulatory effect of
GS39783 during steady-state application of baclofen. We applied a
low concentration of baclofen (1 mM) for 1 min and then co-applied
GS39783 (10 mM) for an additional minute (Fig 6). Baclofen evoked
Kþ currents exhibited little desensitization. GS39783 increased the
Kþ-current amplitude both inWTand 3KO neurons. This increase in
amplitude was not signiﬁcantly different between 3KO (27 ± 5%)
and WT (40 ± 9%) neurons (p ¼ 0.40). This result conﬁrms that
GS39783 is equally effective as a PAM at native GABABRs with or
without KCTDs.4. Discussion
It is well established that the GABAB1 and GABAB2 subunits of
GABABRs are allosterically coupled through multiple interactions in
their extracellular and transmembrane domains (Monnier et al.,
2011). Likewise, GABABRs undergo allosteric interactions with the
G-protein (Hill et al., 1984; Pin et al., 2004). Constitutive association
of GABABRs with auxiliary KCTD subunits not only generates
molecularly distinct receptor subtypes but also introduces the
KCTDs as novel factors that potentially allosterically regulate the
ternary receptor complex (Gassmann and Bettler, 2012; Schwenk
et al., 2010). The KCTDs bind to both receptor and G-protein,
which inﬂuences the kinetics of the receptor response through
stabilizing the G-protein at the receptor and through direct effects
on G-protein signaling (Turecek et al., 2014). In principle, the KCTDs
could allosterically regulate the receptor through direct effects at
GABAB2 and/or through indirect effects at the receptor-associatedterization of GABAB receptor subtypes assembledwith auxiliary KCTD
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Fig. 5. Effects of the KCTDs on allosteric modulation of GABABR-activated Kir3 currents in transfected CHO cells. (A) Representative traces of GABAB-activated Kir3 currents recorded
at 50 mV from CHO-GABAB cells co-expressing Kir3 channels with or without KCTD proteins. Control traces evoked by 1 mM baclofen (Bac) are shown in gray (- GS), traces evoked
by co-application of 1 mM baclofen þ 10 mM of GS39783 in black (þGS). Pre-incubation with GS39783 by bath was for 10 min. Scaling: 10 pA/10 s. (B) Summary bar graphs showing
the effect of GS39783 on peak amplitude, relative desensitization and rise-time of Kir3 currents. ø KCTD, white; þKCTD8, black; þKCTD12, light gray; þKCTD16, dark gray. Data are
expressed as mean ± S.E.M.; *, p < 0.05, ManneWhitney test on paired data.
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like the KCTDs, bind to GABAB2. PAMs at GABABRs increase both
agonist binding-afﬁnity and efﬁcacy of the receptor response (May
et al., 2007; Urwyler et al., 2003), showing that PAMs modulate
both the orthosteric agonist binding-site and G-protein activation.
PAMs may therefore also inﬂuence interactions between the KCTDs
and the G-protein. In our studies we have addressed whether the
KCTDs allosterically inﬂuence (i) the orthosteric agonist binding-
site, (ii) G-protein activation and (iii) modulation by GS39783.
Our data indicate that the KCTDs exert per se little allosteric inﬂu-
ence on the orthosteric agonist binding-site or on G-protein acti-
vation. This shows that the increase in GABA potency observed in
the presence of KCTDs with receptor-activated Kir3 currentsFig. 6. Effects of the KCTDs on allosteric modulation of GABABR-activated Kþ currents in
native neurons. Representative traces of GABAB-activated Kir3 currents recorded
at50 mV from cultured hippocampal neurons of wild-type (WT, left) or Kctd8/12/16/
triple knockout mice (3KO, right). 1 mM of baclofen (Bac, black bars) was applied for 90 s,
then 10 mM of GS39783 (þGS, gray bars) was co-applied for an additional 90 s. Scaling:
10 pA/1 min.
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afﬁnity but relates to KCTD effects on the G-protein cycle. The ef-
fects on the G-protein cycle are lost in the [35S]GTPgS binding ex-
periments, in which the G-protein cycle is interrupted. Allosteric
regulation of the receptor complex by GS39783 is qualitatively
similar in the absence and presence of the KCTDs. This further
supports that the KCTDs primarily regulate the receptor response at
the G-protein (Turecek et al., 2014). Differential regulation of the
G-protein by the KCTDs, however, causes signiﬁcant quantitative
differences in the modulatory effect of GS39783 on the efﬁcacy of
the receptor response (KCTD8) or the increase in the relative
desensitization of receptor-activated Kþ-currents (KCTD12) in
transfected cells. However, we did not observe signiﬁcant differ-
ences between the modulatory effect of GS39783 on native re-
ceptors inWTand 3KOmice. This is likely due to the fact that native
GABABRs are heterogeneous. Whereas the GABAB1 and GABAB2
protomers are expressed by almost all neurons and glial cells
(Gassmann and Bettler, 2012), the repertoire and abundance of the
KCTDs varies among brain areas, neuronal populations and sub-
cellular sites (Metz et al., 2011; Schwenk et al., 2010). Moreover, a
signiﬁcant fraction of native GABABRs in the brain is devoid of any
KCTDs (Turecek et al., 2014). Thus, it is likely that native GABABRs
assembled with speciﬁc KCTDs are also differentially modulated by
GS39783, similar to the GABABRs reconstituted with KCTDs in
transfected cells, but that the responses of individual receptor
populations are masked in the overall response of different re-
ceptor populations.
The agonist binding experiments show that the KCTDs fail to
increase agonist binding-afﬁnity at recombinant GABABRs to the
level of native receptors. This suggests that other factors are
responsible for the higher agonist binding-afﬁnity of native
GABABRs. Candidate factors are additional binding partners of
GABABRs (Schwenk et al., 2010) or posttranslational modiﬁcationsterization of GABAB receptor subtypes assembledwith auxiliary KCTD
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the GABAB1 and GABAB2 subunits (Couve et al., 2002; Guetg et al.,
2010; Kuramoto et al., 2007).
KCTD8 reduces basal G-protein activation in the [35S]GTPgS
binding assay. Reduced basal G-protein activation can to some
extent be overcome with GS39783, which induces a larger increase
in efﬁcacy with KCTD8 than with the other KCTDs. A similar phe-
nomenon has been observed with partial agonists that are more
amenable to allosteric modulation by PAMs than full agonists. This
was for example shown with GABABRs (Mannoury la Cour et al.,
2008; Urwyler et al., 2005) and mGlu2 receptors (Schaffhauser
et al., 2003). This supports that a less efﬁcacious G-protein
coupling e either due to the effects of a partial agonist or the
presence of KCTD8 e allows for a bigger total increase in efﬁcacy in
the presence of the PAM. Consistent with a unique effect of KCTD8
on basal G-protein activation we selectively observed a change in
the basal BRET between G-protein subunits in the combined
presence of KCTD8 and GABABRs. KCTD8, when associated with
GABABRs, therefore likely induces a conformational change in the
G-protein that reduces basal G-protein activation by the receptor.
Of note, the BRETexperiments allow for the ﬁrst time to distinguish
KCTD8 and KCTD16 in a functional assay system.
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ABSTRACT 
GABAB receptors are the G-protein coupled receptors (GPCRs) for GABA, the main inhibitory 
neurotransmitter in the central nervous system. As they are crucial for numerous neuronal 
processes, the activity of GABAB receptors needs to be temporally precise. The principal GABAB 
receptor subunits associate with auxiliary subunits, the K+ channel tetramerization domain-
containing proteins KCTD8, 12 and 16. In this study, we found that KCTD16, but not KCTD8 or 12, 
binds to 14-3-3 proteins. The binding is mediated by the C-terminal H2-domain of KCTD16 and 
regulates the expression of KCTD16 in a 14-3-3 isoform-specific manner. 14-3-3 ε promotes KCTD16 
stability and tetramer formation whereas 14-3-3 γ promotes lysosomal degradation of KCTD16. 
Additionally, the interaction to KCTD16 enables 14-3-3 proteins to modulate the expression of the 
GABAB2 subunit. Using a protein-fragment complementation assay, we found that the Gα-signaling of 
GABAB receptors is changed as a consequence of KCTD16 and 14-3-3 co-expression. We further 
identified cullin3 as a new interaction partner of KCTD16 and show that this interaction is affected by 
14-3-3 proteins. We propose that GABAB receptors are substrates of the KCTD16-cullin3 complex. 
This provides a mechanism of how cell surface GABAB receptors can be targeted for lysosomal 
degradation, which is regulated by 14-3-3 proteins. 
 
INTRODUCTION 
Functional GABAB receptors are heterodimers that consist of GABAB1 and GABAB2 subunits. Whereas 
GABA binds to the GABAB1 subunit, surface-targeting and receptor signaling is mediated by the 
GABAB2 subunit (Couve et al., 2000, Calver et al., 2001, Bettler et al., 2004, Pin et al., 2004). GABAB 
receptors couple to Gαi/o-type G-proteins and modulate the activity of adenylyl cyclase, G protein-
gated inwardly rectifying K+ channels and voltage-gated Ca2+ channels (Luscher and Slesinger, 2010, 
Chalifoux and Carter, 2011, Gassmann and Bettler, 2012). As GABAB receptor activity is fundamental 
for numerous neuronal processes, like synaptic plasticity or neuronal firing, its activity has to be 
precisely controlled. Receptor signaling is regulated at different time points of receptor maturation 
including the export from the endoplasmic reticulum, receptor desensitization, endocytosis and 
degradation (Benke et al., 2012). For functional GABAB receptors localized in the cell membrane, 
posttranslational modifications have a major impact on receptor signaling. Phosphorylation of GABAB 
receptors controls receptor stability, induces endocytosis, and differentiates between receptor 
recycling and degradation (Couve et al., 2002, Fairfax et al., 2004, Guetg et al., 2010, Maier et al., 
2010, Terunuma et al., 2010, Adelfinger et al., 2014). Additionally, the binding of other proteins to 
GABAB receptors can contribute to the extent of receptor activity. The auxiliary receptor subunits 
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KCTD12 and 12b, for instance, induce fast desensitization of GABAB-activated K+ currents, whereas 
KCTD8 decreases the basal G-protein activation of GABAB receptors (Schwenk et al., 2010, Rajalu et 
al., 2014). Further, members of the 14-3-3 protein family were found to be associated with GABAB 
receptors and to modulate GABAB receptor signaling. Although 14-3-3 proteins are dispensable for 
surface trafficking of GABAB receptors, they are capable of dissociating the GABAB1/2 receptor 
heterodimer and thereby impairing its signaling (Couve et al., 2001, Brock et al., 2005, Laffray et al., 
2012). 
In this study, we show that the interaction between KCTD16 and distinct members of the 14-3-3 
family leads to changes in KCTD16 and GABAB2 subunit expression. 14-3-3 γ binding promotes 
lysosomal degradation of KCTD16, whereas 14-3-3 ε binding stabilizes KCTD16 by increasing the 
affinity for KCTD16-tetramer formation. Moreover, we found that the interaction of KCTD16 with 14-
3-3 proteins regulates the Gα-signaling of GABAB receptors. Using a protein-fragment 
complementation assay, we show that KCTD16 together with 14-3-3 ε increases GABAB-mediated 
PKA inhibition, whereas KCTD16 together with 14-3-3 γ leads to a disinhibition. Together, we propose 
that KCTD16 is a cullin3 substrate adaptor that controls the amount of cell surface GABAB receptors, 
which in turn is regulated in a 14-3-3 isoform-dependent manner. 
 
MATERIAL AND METHODS 
Generation of expression plasmids - All KCTD cDNAs contained an N-terminal tag of three c-Myc 
epitopes and were cloned as described earlier (Seddik et al., 2012). To generate KCTD12-16H2Δ39 (2-
16H2Δ39) and KCTD16Δ39 (16H2Δ39), a stop codon was inserted in KCTD12-16H2 and KCTD16 after 
residue Leu388. To generate KCTD16Δ60 (16H2Δ60), a stop codon was inserted in KCTD16 after 
residue Thr367. To generate KCTD12-16H2ΔN (12-16H2ΔN) and KCTD16ΔPEST (16ΔPEST), residues 
Pro280 to Cys314 in KCTD12-16H2 and residues Gly300 to Thr333 in KCTD16 were excised, 
respectively. The constructs KCTD12-16H2 (12-16H2), KCTD16ΔH2 (16ΔH2), KCTD16H2 (16H2) and 
KCTD12-16H2Δ60 (12-16H2Δ60) were described earlier (Seddik et al., 2012). The plasmids HA-14-3-3 
γ and HA-14-3-3 ε were purchased from Addgene (Cambridge, MA, US). The plasmids RlucF1-RegPKA, 
RlucF2-CatPKA and RlucF2-RegPKA were a kind gift of E. Stefan (Montreal, Canada).  
Cell culture - COS-1 cells were maintained in DMEM (Life Technologies, CA, US) supplemented with 
10% FBS (GE Healthcare, Buckinghamshire, UK) at 37°C with 5% CO2. CHO-K1 cells stably expressing 
GABAB1 and GABAB2 subunits were cultured as described (Urwyler et al., 2001). Lipofectamine 2000 
(Life Technologies) was used for transient transfections. The amount of DNA in transfections was 
kept constant by supplementing with pCI plasmid DNA (Promega, WI, US). 
Co-immunoprecipitation, Western blot analysis and Native PAGE - For co-immunoprecipitations, COS-
1 cells were harvested, washed once with ice-cold PBS, and subsequently lysed in NETN buffer (100 
mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 20 mM Tris/HCl, pH 7.4) supplemented with complete 
EDTA-free protease inhibitor mixture (Hoffmann-La Roche, Basel, Switzerland). After rotation for 10 
min at 4°C, the lysates were cleared by centrifugation at 1000 x g for 10 min at 4°C. Lysates were 
directly used for Western blot analysis or immunoprecipitated. Lysates and immunoprecipitates were 
resolved using standard SDS-PAGE. All antibodies used for Western blot and immunoprecipitations 
are listed in Suppl. Table 1. 
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To study KCTD16 degradation, COS-1 cells were incubated with the following compounds for 18 h: 
Chloroquine diphosphate (100 μM, 4109, Tocris), Epoxomicine (2 μM, 324801, Millipore), MG132 (10 
μM, M7449, Sigma Aldrich). 
Native PAGE experiments were carried out as instructed by the manufacturer (Bio-Rad, CA, US). 
Briefly, cell lysates were prepared as for SDS-PAGE. Non-reducing sample buffer was composed of: 
62.5 mM Tris-HCl, pH 6.8, 40% (v/v) glycerol, 0.01% (w/v) bromophenol blue. The running buffer was 
composed of: 2.5 mM Tris, 19.2 mM glycine. 4-15% Mini-PROTEAN® TGXTM Gels and a HMW Native 
Marker Kit was purchased from Bio-Rad (456-1083S and 17-0445-01). 
BRET measurements - BRET measurements were described earlier (Ivankova et al., 2013, Adelfinger 
et al., 2014). Briefly, COS-1 cells were transiently transfected with plasmids encoding Rluc-
KCTD16/YFP-KCTD16 or Rluc-KCTD12/YFP-KCTD12 with or without HA-14-3-3 ε. Six hours after 
transfection, cells were distributed into 96-well microplates (Greiner Bio-One, Kremsmünster, 
Austria) at a density of 50,000 cells/well. Twenty-four hours after transfection, cells were washed 
and incubated in PBS containing 5 μM coelenterazine H (NanoLight Technologies, AZ, US) for 20 min 
at RT. Luminescence and fluorescence signals were detected sequentially using an Infinite® F500 
Microplate Reader (Tecan, Männedorf, Switzerland). Each data point represents a technical 
quadruplicate. 
Protein-fragment complementation assay - The PCA assay was performed as described earlier (Stefan 
et al., 2007). CHO-K1 cells stably expressing GABAB1 and GABAB2 subunits grown in 12-well plates 
were transfected with RlucF1-RegPKA and RlucF2-CatPKA (or RlucF2-RegPKA), myc-KCTD16 and HA-
14-3-3 ε or γ. Six hours after transfection, cells were distributed into 96-well microplates. Fourty-
eight hours later, cells were washed and incubated in PBS containing 10 μM forskolin and 5 μM 
coelenterazine H (NanoLight Technologies, AZ, US) for 20 min at RT. The increase in bioluminescence 
following baclofen injection (100 μM; 0417, Tocris Bioscience, UK) was recorded on an Infinite® F500 
Microplate Reader (Tecan) with an integration time of 1 s. The curves were normalized to the point 
of injection and to the non-activatable control (RlucF1-RegPKA + RlucF2-RegPKA).  
Data analysis – All data are presented as mean ± SEM. Statistical significance was assessed with the 
unpaired Student’s t test using Prism 5.04 software (GraphPad, CA, US). BRET data were analyzed and 
fitted using a “one-site specific binding” equation (GraphPad). 
 
RESULTS 
KCTD16 associates with 14-3-3 proteins through its C-terminal H2-domain 
14-3-3 proteins are known binding partners of the GABAB receptor (Couve et al., 2001, Brock et al., 
2005, Laffray et al., 2012). Here, we observed that other members of the 14-3-3 family interact with 
members of the KCTD protein family, which are auxiliary subunits of the GABAB receptor. A schematic 
illustration of the three auxiliary subunits of the GABAB receptor is shown in Fig. 1A. We found that 
KCTD16 but not KCTD12 associates with 14-3-3 proteins (Fig. 1B). It is interesting to note that 14-3-3 
ε and γ were identified as KCTD16 interacting proteins but not 14-3-3 ζ (data not shown), which was 
shown to bind the GABAB1 subunit. As KCTD16 contains the H2-domain which is absent in KCTD12, it 
is conceivable that 14-3-3 proteins bind to this domain. To test this hypothesis, we used a chimeric 
protein, in which the H2-domain of KCTD16 was fused to the C-terminus of KCTD12 (12-16H2), and a 
deletion mutant, in which the H2-domain was removed from KCTD16 (16ΔH2). As predicted, both 14-
3-3 ε and γ bound 12-16H2 but not 16ΔH2 (Fig. 1B). Moreover, the H2-domain itself (16H2) was 
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sufficient to bind the 14-3-3 proteins although the binding efficiency was strongly reduced (Fig. 1C). 
To investigate whether 14-3-3 proteins interact in general with H2-domains, we tested KCTD8, 
another H2 domain-containing KCTD protein, for interaction with 14-3-3 ε and γ. In contrast to 
KCTD16, KCTD8 was not able to associate with both 14-3-3 ε and γ (Fig. 1D). Together, these data 
show that KCTD16, but not KCTD8 or 12, interacts with 14-3-3 ε and γ through its C-terminal H2-
domain. 
In order to map the minimal binding site of KCTD16 for 14-3-3 proteins, we co-expressed truncations 
of the chimeric 12-16H2 protein in COS-1 cells for co-immunoprecipitation studies. Whereas the 
deletion of the N-terminal part of the H2-domain of 12-16H2 (deletion of amino acid residues 328-
362; 12-16H2ΔN; Fig. 2A) did not affect the interaction with 14-3-3 ε or γ (Fig. 2B), deletions of the C-
terminal part of the H2-domain of 12-16H2 affected the binding properties to 14-3-3 proteins (Fig. 2B 
and C). It was of interest to see that the deletion of the last 60 amino acid residues in 12-16H2Δ60 
abolished the binding to both 14-3-3 isoforms, whereas the deletion of the last 39 amino acid 
residues in 12-16H2Δ39 interfered with the binding to 14-3-3 ε but not to 14-3-3 γ. As 14-3-3 
proteins mostly bind to phosphorylated serines/threonins, we mutated selected serines/threonins, 
which are present within the C-terminal part of the H2-domain of KCTD16 but not in the H2-domain 
of KCTD8. However, the mutation of T369, S375 or S379 to alanine did not prevent the binding of 14-
3-3 proteins (data not shown). These data indicate that 14-3-3 binding to KCTD16 is either 
phosphorylation-independent or that 14-3-3 binding is ensured by more than one binding site. 
 
14-3-3 binding regulates KCTD16 protein expression 
To assess the functional relevance of such interaction, we measured the expression levels of KCTD16 
in the presence of 14-3-3 proteins. We observed that 14-3-3 protein co-expression affected the 
expression levels of the interaction partner KCTD16. Whereas 14-3-3 ε increased the protein levels of 
KCTD16, 14-3-3 γ decreased the expression of KCTD16 (Fig. 3A). These effects were dependent on 
direct interaction since both 14-3-3 isoforms did not affect protein levels of KCTD12 (Fig. 3B). 
Furthermore, the protein levels of KCTD16 truncation mutants were changed only if they were able 
to bind 14-3-3 proteins. The expression of the KCTD16 truncation mutant 16H2Δ39, which lacks the 
last 39 amino acid residues of the H2-domain equivalent to 12-16H2Δ39 and binds 14-3-3 γ but not 
14-3-3 ε, is regulated exclusively by 14-3-3 γ (Fig. 3C). On the other hand, the expression level of the 
KCTD16 truncation mutant 16H2Δ60, which lacks the last 60 amino acid residues of the H2-domain 
equivalent to 12-16H2Δ60 and binds neither 14-3-3 isoforms, was unaffected by 14-3-3 co-
expression (Fig. 3D). Together, these data show that direct binding is obligatory for 14-3-3 ε and γ to 
regulate the expression levels of KCTD proteins. 
 
14-3-3 γ shifts the degradation of KCTD16 from the proteasome to the lysosome 
14-3-3 proteins are well known to regulate the degradation of their binding partners (LeBron et al., 
2006, Kasahara et al., 2010). Therefore, we investigated whether decreased protein levels of KCTD16 
in the presence of 14-3-3 γ correspond to increased degradation of KCTD16. To test this hypothesis, 
we incubated COS-1 cells expressing either KCTD16 alone or together with 14-3-3 γ with inhibitors of 
the lysosome, chloroquine (CHQ), or proteasome, epoxomicine (EPO) or MG132 (MG). In cells co-
expressing KCTD16 and 14-3-3 γ we observed a down-regulation of KCTD16 to ~55% which was 
inhibited in the presence of lysosome inhibitor (w/o vs. CHQ; Fig. 4A and B). In contrast, incubation 
4 
 
with proteasome inhibitors did not prevent the reduction in KCTD16 expression induced by 14-3-3 γ 
(~30-40% down-regulation of KCTD16 in the presence of DMSO, EPO and MG). These data suggest 
that 14-3-3 γ promotes KCTD16 degradation through the lysosome. It is interesting to note that in 
the absence of 14-3-3 γ the expression of KCTD16 increased ~2 fold when applying EPO or MG (Fig. 
4C), which indicates proteasomal degradation of KCTD16. The expression of KCTD16 was unchanged 
upon CHQ incubation. 
 
14-3-3 ε increases the stability of KCTD16 and its affinity to form tetramers 
The ability of proteins to form dimers or oligomers is a well described mechanism to control protein 
stability and activity (Mateu, 2002, Li et al., 2006, Freeman et al., 2013). As KCTD proteins are a 
family of tetramerizing proteins, we investigated whether increased expression levels of KCTD16 
induced by 14-3-3 ε correlate with higher stability of KCTD16 resulting from enhanced 
tetramerization. We used BRET donor saturation assays to study the formation of KCTD16 homo-
tetramers. Binding of the donor fusion protein Rluc-KCTD16 to the acceptor fusion protein Venus-
KCTD16 induces specific BRET that allows studying the affinity and degree of tetramerization. 
Expression of increasing amounts of Venus-KCTD16 with a fixed amount of Rluc-KCTD16 results in 
hyperbolic BRET donor saturation curves (Fig. 5A, up), consistent with KCTD16 being able to form 
tetramers as described earlier (Schwenk et al., 2010). When co-expressing fixed amounts of 14-3-3 ε 
we could still observe a specific BRET donor saturation curve suggesting that 14-3-3 ε does not 
prevent KCTD16 tetramer formation. However, compared to experiments without 14-3-3 ε, the BRET 
donor saturation curves were shifted towards (i) lower half-maximal BRET (BRET50) and (ii) lower 
maximal BRET (BRETmax). The BRET50 reflects how much BRET acceptor is required to reach 50% of the 
BRETmax signal. Therefore, a left shift of the BRET donor saturation curve, as observed, is indicative 
for an increased affinity between the donor fusion protein and the acceptor fusion protein. At the 
same time, the decreased BRETmax likely reflects a conformational rearrangement in the KCTD16 
tetramer upon 14-3-3 ε binding. To test whether these effects arise specifically from direct 
interaction between KCTD16 and 14-3-3 ε, we conducted the same BRET donor saturation curves 
with Rluc-KCTD12 and Venus-KCTD12. As expected, we obtained hyperbolic BRET donor saturation 
curves confirming that also KCTD12 forms tetramers (Fig. 5A, down). In the presence of 14-3-3 ε, the 
BRET donor saturation curves were neither shifted in BRETmax nor in BRET50 suggesting that 14-3-3 ε 
specifically increases the affinity to form tetramers for its binding partner KCTD16 but not for non-
interacting KCTD proteins. 
To address the question whether 14-3-3 ε increases the amount of KCTD16 tetramers, we co-
immunoprecipitated myc-KCTD16 with flag-KCTD16 in the presence and absence of 14-3-3 ε. Myc- 
and flag-tagged KCTD16 were enriched in the input as well as in the immunoprecipitation (Fig. 5B), 
which suggests that 14-3-3 ε increases the amount of tetramerized KCTD16. Additionally, we 
performed Native PAGE experiments to study if (i) KCTD16 per se exists as monomer and (ii) if 14-3-3 
ε co-expression raises the amount of KCTD16 tetramers relative to KCTD16 monomers. Under native 
conditions, co-expression of 14-3-3 ε increased the amount of KCTD16 tetramers (Fig. 5C). However, 
KCTD16 seems to exist exclusively as tetramer as no monomer signal was observed. Altogether, 





KCTD16 links 14-3-3 proteins to GABAB receptors, which consequently regulates the expression of the 
GABAB2 subunit 
Distinct 14-3-3 isoforms, ζ and η, are known interactors of the GABAB1 subunit (Couve et al., 2001, 
Brock et al., 2005, Laffray et al., 2012). Still, no 14-3-3 isoforms were yet shown to interact with the 
GABAB2 subunit. Based on our findings that 14-3-3 ε and γ are binding partners of KCTD16, we asked 
the question whether the same 14-3-3 isoforms associate with the GABAB2 subunit as well or 
whether they are part of the receptor complex solely in the presence of KCTD16. We found that both 
14-3-3 ε and γ did not directly interact with the GABAB2 subunit (Fig. 6A, up). However, when KCTD16 
was co-expressed, 14-3-3 ε and γ were able to co-precipitate both KCTD16 and the GABAB2 subunit 
(Fig. 6A, bottom) indicating that they are part of the receptor complex in the presence of KCTD16. 
Furthermore, when co-expressing KCTD16, both 14-3-3 isoforms regulated the expression of the 
GABAB2 subunit in the same way as they regulate the expression of KCTD16 (Fig. 6B). These data 
suggest that 14-3-3 ε and γ are part of the GABAB receptor/KCTD16 complex and that they 
simultaneously regulate the expression of KCTD16 and GABAB2. 
 
14-3-3 proteins regulate the Gα-signaling of GABAB/KCTD16 receptors  
Cell surface targeting of GABAB receptors is a precisely regulated process (Margeta-Mitrovic et al., 
2000, Calver et al., 2001, Pagano et al., 2001). Whereas GABAB1 homodimers are retained in the ER 
through their ER retention signal, GABAB1/2 heterodimers reach the cell surface and form functional 
receptors. The expression of the GABAB2 subunit determines therefore the rate of functional 
receptors at the cell membrane. To test if 14-3-3 proteins control the level of functional membrane 
GABAB receptors we investigated whether the signaling of GABAB receptors is changed in the 
presence of 14-3-3 proteins. The Gα-signaling of GABAB receptors can be monitored by a protein-
fragment complementation (PLC) assay in which split variants of the Renilla luciferase are fused to 
the regulatory (R) and the catalytic (C) subunit of the protein kinase-A (PKA) (Fig. 7A). High 
bioluminescence corresponds to inactive PKA composed of an R/C subunit heterodimer. High 
intracellular cAMP levels induce the dissociation of the R subunit from the C subunit leading to the 
activation of PKA, which accordingly corresponds to low bioluminescence. As GABAB receptors are 
Gαi/o-coupled receptors, applying baclofen to CHO-K1 cells stably expressing GABAB1 and GABAB2 
subunits results in PKA inhibition and hence to an increase in bioluminescence (Fig. 7B). Co-
expression of 14-3-3 ε, KCTD16 or KCTD16 together with 14-3-3 ε significantly increased the Gα-
signaling of GABAB receptors (Fig. 7C). In contrast, co-expression of KCTD16 together with 14-3-3 γ 
decreased the Gα-signaling of GABAB receptors whereas co-expression of 14-3-3 γ alone was without 
effect. These data suggest that 14-3-3 proteins regulate the expression of functional GABAB receptors 
at the cell surface to control GABAB receptor signaling in the presence of KCTD16.  
 
14-3-3 proteins affect the binding of KCTD16 to CUL3 
Some members of the KCTD protein family were reported to bear cullin adaptor function (Bayon et 
al., 2008, Azizieh et al., 2011, Correale et al., 2011, De Smaele et al., 2011, Balasco et al., 2014). It was 
not shown yet that the GABAB receptor interacting KCTD proteins 8, 12 and 16 share this function. To 
answer this question we expressed KCTD 8, 12 and 16 (KCTD16 alone and in the presence of 14-3-3 ε 
or γ) in COS-1 cells and performed immunoprecipitations against endogenous CUL3. We found that 
CUL3 was able to co-precipitate KCTD8 as well as KCTD16 (Fig. 8A). In the presence of 14-3-3 ε and γ, 
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the intensity of co-precipitated KCTD16 with CUL3 was greatly reduced (Fig. 8B). When normalizing 
the amount of co-precipitated KCTD16 to the input of KCTD16 it becomes obvious that 14-3-3 ε 
almost fully blocks KCTD16-CUL3 binding (Fig. 8C). Together, these data suggest that KCTD16 serves 
as substrate adaptor for CUL3 and that this function is regulated by 14-3-3 proteins. 
 
DISCUSSION 
Members of the KCTD protein family (8, 12, 12b, and 16) were reported to be auxiliary subunits of 
the GABAB receptor with KCTD12 being the most studied KCTD protein. It has been suggested that 
KCTD12 renders GABAB-mediated signaling more precisely as it promotes fast desensitization of 
GABAB-mediated responses but at the same time increases cell surface expression and stability of 
GABAB receptors (Schwenk et al., 2010, Ivankova et al., 2013, Adelfinger et al., 2014). KCTD8 was 
recently shown to reduce the basal G-protein activation mediated by GABAB receptors but not by 
other GPCRs like adenosine receptors 1 (Rajalu et al., 2014). Here, we identified members of the 14-
3-3 protein family as a class of interaction partners that specifically bind to KCTD16, which might help 
to elucidate the function of KCTD16 on GABAB receptor signaling. The 14-3-3 isoforms ε and γ bind to 
the H2-domain of KCTD16 with each 14-3-3 isoform occupying a distinct binding site. Mutations of 
single serines or threonines in the H2-domain of KCTD16 did not abolish 14-3-3 interaction 
suggesting that 14-3-3 proteins have more than one binding site on KCTD16. Additionally, more 
studies are needed to elucidate whether 14-3-3 binding to KCTD16 is phosphorylation-dependent or -
independent. Both 14-3-3 isoforms are associated specifically with the H2-domain of KCTD16 as they 
did not interact with KCTD8, which contains a H2-domain as well. The finding that the H2-domain 
harbors binding sites for other proteins - and 14-3-3s may not be the only binding partners - provides 
a first functional implication of the H2-domain besides its antagonizing effect on fast desensitization 
of GABAB-activated K+ currents (Seddik et al., 2012). 
Moreover, we found that 14-3-3 binding affects the expression level of KCTD16. 14-3-3 proteins are 
well studied regulators of many eukaryotic proteins (for a review see (van Heusden, 2005)). They 
were shown to modulate protein localization, degradation, stability and activity as well as protein-
protein interactions. This study shows that the co-expression of 14-3-3 γ shifts KCTD16 degradation 
from the proteasome to the lysosome. This switch might be mediated by 14-3-3 γ masking the PEST 
sequence that is localized in the H2-domain of KCTD16 (Suppl. fig. 1). The PEST sequence is a signal 
peptide responsible for protein degradation (Rogers et al., 1986) and would explain why KCTD16 
shows a very low basal expression compared to KCTD12 or KCTD8 that do not contain such a 
sequence. Furthermore, it may be possible that 14-3-3 binding promotes the translocation of KCTD16 
from the cytosol to the plasma membrane. Consequently, cytosolic KCTD16 would be rapidly 
degraded by the proteasome while membrane located KCTD16 - probably part of the GABAB receptor 
complex - would be degraded by the lysosome. This model would agree with earlier findings that 
KCTD proteins remain associated with the GABAB receptor during internalization (Ivankova et al., 
2013). 
On the other hand, 14-3-3 ε seemed to have a positive effect on KCTD16 expression. Co-expression 
of 14-3-3 ε strongly increased protein levels of KCTD16. This observation was not exceptional as 14-3-
3 proteins were not only shown to affect the degradation of their binding partners but also to 
increase the stability or activity of their binding partners (Zheng et al., 2003, Winge et al., 2008, 
Woodcock et al., 2009, Barbash et al., 2011). SCFFbx4 activity, for example, is higher when interacting 
with 14-3-3 proteins as a result of augmented SCFFbx4 dimerization. Other 14-3-3 binding partners, 
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like AANAT and tryptophan hydroxylase, were found to form oligomers or contain dimer interfaces 
(Mockus et al., 1998, Khalil et al., 1999, Tenner et al., 2007) which might indicate that also these 
proteins are more stable upon 14-3-3-mediated dimerization although this is not proven yet. The 
results from BRET donor saturation assays in this study suggest that the effect of 14-3-3 ε on KCTD16 
expression is mediated by enhancing the affinity of KCTD16 to form tetramers. In this assay, 14-3-3 ε 
did not elevate KCTD16 expression levels, yet shifting the binding curves for KCTD16 tetramers 
towards lower BRET50 values. The lack of 14-3-3-mediated changes in KCTD16 levels might result as 
this assay was performed 24 h after transfection compared to the expression or co-
immunoprecipitation studies that were done 48 h after transfection. Co-immunoprecipitations and 
Native PAGE experiments support the hypothesis of 14-3-3 ε enhancing KCTD16 self-assembly 
(stronger signals of co-precipitated KCTD16 in Figure 5B and of tetrameric KCTD16 in Figure 5C). The 
detection of non-denatured KCTD16 in the presence of 14-3-3 ε reveals a defined signal at the height 
of ~220 kDa correlating to the height of a KCTD16 tetramer while the signal is more diffuse towards 
bigger complexes in the absence of 14-3-3 ε. This suggests that KCTD16 is able to build higher forms 
of multimers but the formation of distinct tetramers is promoted by 14-3-3 ε. Native PAGE 
experiments further indicate that KCTD16 forms exclusively multimers due to the lack of monomeric 
KCTD16 in Figure 5C. 
Until now, KCTD16 could not be assigned to a distinct function in GABAB signaling. This study reveals 
that KCTD16 serves as linker between the GABAB receptor and 14-3-3 proteins, which enables the 
regulation of GABAB2 expression mediated by 14-3-3 proteins. This regulation very likely affects the 
number of cell surface receptors as the Gα-mediated signaling of GABAB receptors was found to be 
altered upon KCTD16 and 14-3-3 co-expression. The results of the PKA PCA assay are in accordance 
with the results of the Western blot analysis. In the presence of KCTD16, 14-3-3 ε up-regulates 
GABAB2 expression as well as GABAB receptor-mediated PKA inhibition while 14-3-3 γ has the 
opposite effect. However, co-expression of 14-3-3 ε alone already increased the Gα-signaling of 
GABAB receptors. In contrast to 14-3-3 γ, which forms both homodimers and heterodimers 
preferentially with 14-3-3 ε, 14-3-3 ε does not form homodimers but heterodimers with most other 
14-3-3 isoforms (Chaudhri et al., 2003). As CHO cells endogenously express 14-3-3 proteins (Feng et 
al., 2000, Rowland et al., 2011), heterodimerization of 14-3-3 ε with other 14-3-3 isoforms might give 
unspecific effects. Furthermore, GABAB receptors containing KCTD16 showed more inhibition of PKA 
compared to receptors without KCTD16 (Fig. 7B-C). This result might indicate that either 
endogenously expressed 14-3-3 ε is sufficient to display the same effect as overexpression of 14-3-3 
ε or that KCTD16 alone increases the amount of cell surface GABAB receptors. Previous data show 
already a slight increase in cell surface GABAB receptors when co-expressed with KCTD16 (Ivankova 
et al., 2013). The Gα-signaling of GABAB receptors containing KCTD16 is not potentiated in the 
presence of 14-3-3 ε, which would indicate that PKA is already fully inhibited by GABAB receptors in 
the presence of either KCTD16 or 14-3-3 ε. 
KCTD proteins belong to the family of BTB (bric-a-brac, tramtrak and broad complex)/POZ (poxvirus 
zinc finger) domain-containing proteins. Some of those members have been shown to serve as 
substrate adaptors for cullin ubiquitin ligases. KCTD5, 6, 7, 11 and 21 were identified to interact with 
CUL3, one of seven cullins that is known to bind BTB proteins (Furukawa et al., 2003, Geyer et al., 
2003, Pintard et al., 2004, Bayon et al., 2008, Canettieri et al., 2010, Azizieh et al., 2011, Correale et 
al., 2011, De Smaele et al., 2011, Balasco et al., 2014). Here we show that KCTD16, and further 
KCTD8, is able to bind CUL3 which suggests a role for KCTD16 as a substrate adaptor for CUL3. 
However the substrate is not known yet, it is tempting to postulate that GABAB receptors might be 
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the substrate for the CUL3-KCTD16 complex as some steps of GABAB receptor degradation are still 
unknown. GABAB receptor degradation is initiated through two major pathways. Newly synthetized 
receptors in the ER are degraded by the endoplasmic reticulum-associated degradation (ERAD) 
(Zemoura et al., 2013). Misfolded GABAB receptors are K48-linked polyubiquitinated on GABAB2-
K767/771 by the ERAD E3 ubiquitin ligase Hrd1 and constitutively directed to proteasomal 
degradation. The ERAD-mediated degradation of GABAB receptors determines the cell surface 
expression of functional receptors as it limits the forward trafficking of receptors to the plasma 
membrane. Cell surface GABAB receptors on the other hand are constitutively internalized via the 
dynamin- and clathrin-dependent pathway to be recycled in endosomes or eventually degraded in 
lysosomes (Grampp et al., 2007, Grampp et al., 2008). The phosphorylation of distinct sites on 
GABAB1 and GABAB2 determines whether GABAB receptors are directed to endosomes or lysosomes 
(Guetg et al., 2010, Terunuma et al., 2010). However, it is not known yet how GABAB receptors are 
designated for lysosomal degradation. In general, K63-linked polyubiquitination was shown to 
stimulate endocytosis and subsequent degradation (Galan and Haguenauer-Tsapis, 1997). The 
analysis of the brain ubiquitome revealed two putative ubiquitination sites on the GABAB2 subunit 
(Na et al., 2012). One of them, K771, was already confirmed to be K48-linked polyubiquitinated as 
described above (Zemoura et al., 2013). The other site, K800, has not been studied yet and it is 
possible that this site is K63-linked polyubiquitinated to serve as a signal for lysosomal degradation. 
In principal, K63-linked polyubiquitination can be achieved by CUL3 (Jin et al., 2009, Han et al., 2010), 
which would fit to our hypothesis that GABAB receptors are substrates of CUL3. 
In conclusion, we propose that the complex formation of KCTD16 with 14-3-3 proteins determines 
the localization and fate of KCTD16 and the amount of functional GABAB receptors in the cell surface 
(Fig. 9). In the absence of 14-3-3 proteins and GABAB receptors, KCTD16 is mostly localized in the 
cytosol and rapidly degraded by the proteasome via its PEST-sequence. In the presence of GABAB 
receptors, KCTD16 is part of the receptor complex and located at the cell surface. 14-3-3 proteins 
may strengthen this interaction by either promoting the translocation of KCTD16 from the cytosol to 
the cell membrane or by stabilizing the binding through conformational changes. Dependent on the 
14-3-3 isoform, GABAB receptors and KCTD16 are either stabilized or degraded. 14-3-3 γ enhances 
lysosomal degradation of the GABAB-KCTD16 complex by cullin-mediated ubiquitination of the GABAB 
receptor. In contrast, 14-3-3 ε binding to KCTD16 stabilizes the GABAB-KCTD16 complex. It promotes 
KCTD16 stability by increasing the affinity for KCTD16 tetramer formation while at the same time 
interfering with the binding of KCTD16 to CUL3. This in turn increases cell surface GABAB receptor 
levels resulting in elevated receptor signaling. Together, this model would show for the first time 
how cell surface GABAB receptors are regulated by their auxiliary subunit KCTD16 and how they are 
targeted to lysosomes for degradation. It further includes that the lysosomal degradation of GABAB 
receptors is highly dependent on the expression pattern of KCTD proteins as well as 14-3-3 proteins. 
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FIGURE 1. KCTD16 associates with 14-3-3 proteins through its C-terminal H2-domain. Direct cell 
lysates (input) and co-immunoprecipitations of COS-1 cells transfected with 14-3-3 proteins and wild-
type or chimeric KCTD proteins. KCTD proteins were immunoprecipitated with myc-, flag- or KCTD 
specific-antibodies as indicated. (A) Schematic figure showing the full-length KCTD proteins 12, 8, and 
16 with their T1-, H1-, and H2-domain. KCTD12 lacks the H2-domain. The BTB/POZ domain is 
indicated in blue. (B) 14-3-3 γ and ε co-precipitate with KCTD16 but not with KCTD12. The addition of 
the H2-domain of KCTD16 to KCTD12 (myc-12-16H2) results in 14-3-3 binding, whereas the deletion 
of the H2-domain in KCTD16 (myc-16ΔH2) leads to 14-3-3 un-binding. (C) The isolated H2-domain of 
KCTD16 (myc-16H2) is sufficient to bind 14-3-3 proteins. The asterisk likely indicates an unspecific 
signal in the input that is absent in the immunoprecipitation. (D) 14-3-3 proteins bind specifically to 
the H2-domain of KCTD16 as they do not interact with KCTD8. IP, immunoprecipitation. 
FIGURE 2. Mapping of 14-3-3 binding sites in the H2-domain of KCTD16. Direct cell lysates (input) 
and co-immunoprecipitations of COS-1 cells transfected with 14-3-3 proteins and chimeric KCTD 
proteins. KCTD proteins were immunoprecipitated with myc- or KCTD12 specific-antibodies as 
indicated. (A) Schematic figure showing the chimeric KCTD proteins. The H2-domain of KCTD16 was 
added to the C-terminus of KCTD12 (12-16H2). Based on this construct, the following deletion 
mutants were generated: 12-16H2Δ60 (Δ416-475), 12-16H2Δ39 (Δ437-475) and 12-16H2ΔN (Δ328-
362). (B) 14-3-3 γ and ε co-precipitate with the N-terminal deletion mutant (12-16H2ΔN) but not with 
the mutant lacking half of the H2-domain (12-16H2Δ60). (C) 14-3-3 γ, but not 14-3-3 ε, co-
precipitates with the C-terminal deletion mutant 12-16H2Δ39. IP, immunoprecipitation. 
FIGURE 3. 14-3-3 proteins regulate the expression level of KCTD16. Direct cell lysates of COS-1 cells 
transfected with 14-3-3 proteins and KCTD16 (A), KCTD12 (B), 16H2Δ39 (C) or 16H2Δ60 (D). The 
binding of 14-3-3 ε increases the expression of its interaction partner KCTD16 (A), whereas the 
binding of 14-3-3 γ decreases the expression of its interaction partners KCTD16 (A) and 16H2Δ39 (C). 
Binding-deficient KCTDs, like KCTD12 (B), 16H2Δ39 (deficient in 14-3-3 ε binding, C) or 16H2Δ60 
(deficient in 14-3-3 ε and γ binding, D) do not show changes in expression upon 14-3-3 protein co-
expression. Blots are representative of 3-4 independent experiments. Bar graphs on the right 
summarize the amount of KCTD expression (in %) normalized to the loading control actin on the 
same blot. Data are means ± SEM, n = 3-4. *, p < 0.05; **, p < 0.01; t test. 
FIGURE 4. 14-3-3 γ promotes lysosomal degradation of KCTD16. Direct cell lysates of COS-1 cells 
expressing KCTD16 with and without 14-3-3 γ. Cells were untreated (lane 1 and 2, w/o, as a control 
for CHQ) or treated for 18 h with the lysosome-inhibitor chloroquine (100 μM, lane 3 and 4, CHQ), 
DMSO (lane 5 and 6, as a control for EPO and MG) or the proteasome-inhibitors epoxomicine (2 μM, 
lane 7 and 8, EPO) or MG132 (10 μM, lane 9 and 10, MG). Adding the lysosome-inhibitor blocks 14-3-
3 γ-mediated knock-down of KCTD16 expression. Increased total ubiquitin levels ensure the 
effectiveness of the treatment. Blots are representative of four independent experiments. The bar 
graph summarizes the amount of KCTD16 expression (in %) normalized to the loading control actin 
on the same blot. Data are means ± SEM, n = 4. *, p < 0.05; **, p < 0.01; t test. 
FIGURE 5. 14-3-3 ε increases the affinity for KCTD16 to form tetramers. (A) BRET donor saturation 
curves from COS-1 cells expressing fixed amounts of Rluc-KCTD16 and increasing amounts of Venus-
KCTD16 (up) or fixed amounts of Rluc-KCTD12 and increasing amounts of Venus-KCTD12 (down) in 
the presence (open circles) and absence (filled circles) of 14-3-3 ε. 14-3-3 ε affects the binding 
properties of KCTD16 - but not KCTD12 - to form tetramers. BRET is expressed as milli BRET units 
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(mBU) determined as net BRET × 1000. Data points are means ± SEM of technical quadruplicates of a 
representative experiment, n = 5-8. (B) Direct cell lysates (input) and co-immunoprecipitations of 
COS-1 cells expressing flag- and myc-KCTD16 with and without 14-3-3 ε. In the presence of 14-3-3 ε, 
the amount of co-immunoprecipitated myc-KCTD16 with flag-KCTD16 is increased. (C) Native PAGE of 
cell lysates from COS-1 cells expressing myc-KCTD16 with and without 14-3-3 ε. The amount of 
KCTD16 tetramers is increased when 14-3-3 ε is co-expressed. KCTD16 can be detected in a high 
molecular weight complex. 14-3-3 ε can be detected as monomer and in a high molecular weight 
complex. A short (left) and long (right) exposure of the immunoblot against myc is shown. IP, 
immunoprecipitation; IB, immunoblot. 
FIGURE 6. KCTD16 links 14-3-3 proteins to GABAB receptors, which leads to changes in GABAB2 
expression. Direct cell lysates (input) and co-immunoprecipitations (A) and direct cell lysates (B) of 
COS-1 cells transfected with 14-3-3 proteins and GABAB2 (GB2) with and without KCTD16. 14-3-3 
proteins were immunoprecipitated with myc- or HA-antibodies as indicated. (A) 14-3-3 proteins do 
not directly interact with GABAB2 (up) but are part of the GABAB receptor complex in the presence of 
KCTD16 (down). (B) 14-3-3 proteins slightly decrease the expression of GABAB2 in the absence of 
KCTD16. In the presence of KCTD16, 14-3-3 proteins show the same regulation of GABAB2 expression 
as observed for KCTD16 expression. Blots are representative of 6-14 independent experiments. The 
bar graphs on the right summarize the amount of GABAB2 expression normalized to the loading 
control actin on the same blot. Data are means ± SEM, n = 6-14. *, p < 0.05; t test. 
FIGURE 7. 14-3-3 proteins affect the Gα-signaling of GABAB receptors. (A) Scheme of the protein-
fragment complementation assay. Split variants of the Rluc-donor are fused to the regulatory and the 
catalytic subunit (R and C) of the protein kinase A (PKA). High bioluminescence results from low PKA 
activity due to the tetrameric structure of the kinase. Increasing intracellular cAMP levels caused by 
forskolin (FSK) activates PKA leading to a dissociation of R and C, which results in low 
bioluminescence. (B) Real-time kinetics (normalized to control Reg/Reg) in response to baclofen (100 
μM) of Reg/Cat recorded from CHO-K1 cells stably expressing GABAB1 and GABAB2 and transiently 
expressing pCI-empty (w/o), 14-3-3 ε, 14-3-3 γ, KCTD16 or the combinations KCTD16 + 14-3-3 ε, and 
KCTD16 + 14-3-3 γ. Increased PKA inhibition is detected with 14-3-3 ε, KCTD16 and KCTD16 + 14-3-3 
ε. Decreased PKA inhibition is detected with KCTD16 + 14-3-3 γ. Changes in bioluminescence are 
expressed in relative luminescence (in % of Reg/Reg). One representative experiment is shown. (C) 
The bar graph summarizes the changes of Reg/Cat (in % of Reg/Reg). Data are means ± SEM, n = 4. *, 
p < 0.05; **, p < 0.01; t test. 
FIGURE 8. KCTD16-CUL3 interaction is reduced in the presence of 14-3-3 proteins. (A) Direct cell 
lysates (input) and co-immunoprecipitations of COS-1 cells expressing KCTD proteins and 14-3-3 
proteins as indicated. Endogenous CUL3 was immunoprecipitated with a cullin3-specific antibody. 
KCTD16 and KCTD8 co-precipitated with CUL3. The amount of co-precipitated KCTD16 is decreased in 
the presence of 14-3-3 proteins. IP, immunoprecipitation. (B) The bar graph summarizes the amount 
of co-precipitated KCTD16 (in %). Data are means ± SEM, n = 2. 
FIGURE 9. Degradation pathway of cell surface GABAB receptors and KCTD16. KCTD16 is a cytosolic 
protein that is rapidly degraded by the proteasome (1). Degradation is mediated by the PEST 
sequence in the H2-domain of KCTD16. The binding of 14-3-3 proteins masks the PEST sequence in 
KCTD16, which inhibits proteasomal degradation of KCTD16 (2). KCTD16 harbors the function as an 
adaptor protein for cullin3 (CUL3). The binding of the KCTD16-CUL3 complex to GABAB receptors (3) 
leads to ubiquitination and subsequent degradation of the receptor (4). This process is limited by low 
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expression of KCTD16 due to its rapid proteasomal degradation. Binding of 14-3-3 γ to KCTD16 
promotes the lysosomal degradation of GABAB receptors (5). As KCTD16 constitutively binds to 
GABAB receptors, its degradation is shifted from the proteasome to the lysosome. The binding of 14-
3-3 ε to KCTD16 enhances the stability of the GABAB/KCTD16 complex by interfering with the 
KCTD16-CUL3 complex (6). 
SUPPL. FIGURE 1. KCTD16 contains a PEST sequence. (A) Schematic figure showing the PEST 
sequence in KCTD16 and its conservation throughout different species. The PEST sequence was 
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Table 1. Parameters from BRET saturation curves with Rluc-KCTD16/YFP-KCTD16 and Rluc-
KCTD12/YFP-KCTD12. 
BRET donor saturation assays were performed in COS-1 cells transfected with fixed amounts of HA-
14-3-3 ε and Rluc-KCTD16/12 (donor) and increasing amounts of YFP-KCTD16/12 (acceptor). The 
BRETmax is the maximal BRET signal obtained for a given donor/acceptor pair and the BRET50 
corresponds to the amount of acceptor needed to obtain 50% of the BRETmax. Data are presented as 
the mean ± SEM of the indicated number of independent experiments and were derived from data as 
presented in Fig. 5A. ***, p < 0.001 *, p < 0.05; compared to KCTD16, w/o 14-3-3 ε; t test. 
  BRETmax ± SEM BRET50 ± SEM n 
 KCTD16, w/o 14-3-3 ε 1267.0 30.3 0.03317 0.00571 8 
 KCTD16, + 14-3-3 ε 1096.0*** 18.4 0.01681* 0.00326 8 
 KCTD12, w/o 14-3-3 ε 900.5 24.4 0.02522 0.00535 5 





SUPPLEMENTARY TABLE 1: Antibody information 
Antibody information Application and corresponding figure 
Antibody and 
species 
Product # and Supplier IP WB 
anti-myc 
(mouse) 
sc-40, Santa Cruz 1-1.5 μg (Protein G-Agarose 
or Dynabeads Protein-G) 
Figures: 1D-E, 2B-D, 3B 
1:1000 
Figures: 2B, 3B-C, 4A-
D, 5, 6C, 7, 8 
Suppl. fig. 1C 
anti-myc 
(rabbit) 
C3956, Sigma Aldrich 1 μg (Dynabeads Protein-G) 
Figures: 3C 
1:1000 




MMS-101P, Covance n/a 1:1000 




RHGT-45A-Z, ICL 1 μg (Dynabeads Protein-G) 
Figures: 1D-E 
1:1000 
Figures: 2B, 2D, 3B 
anti-HA 
(rat) 
11867423001, Roche n/a 1:1000 
Figures: 2C, 4D, 5, 6B-
C, 7, 8 
anti-flag 
(mouse) 
F1804, Sigma Aldrich 1-1.2 μg (Protein G-Agarose 
or Dynabeads Protein-G) 





F7425, Sigma Aldrich n/a 1:1000 
Figures: 1E, 2D, 6B 
anti-actin 
(mouse) 
MAB1501, Millipore n/a 1:1000 
Figures: 4D, 5, 7 
anti-actin 
(rabbit) 




Suppl. fig. 1C 
anti-KCTD16 
(rabbit) 




















sc-629, Santa Cruz n/a 1:1000 
Figures: 4B 



















AB5394, Millipore n/a 1:2000 
Figures: 1D-E,  







GABAB receptors play a  fundamental role  in modulating the synaptic transmission of  inhibitory signals. 
Presynaptic GABAB receptors suppress evoked and spontaneous neurotransmitter release from synaptic 
clefts  by  inhibiting  voltage‐gated  Ca2+  channels  and  adenylyl  cyclase.  Postsynaptic  GABAB  receptors 
decrease  neuronal  excitability  by  activating  G  protein‐coupled  inwardly  rectifying  potassium  (GIRK) 
channels, which underlies  the  generation of  slow  inhibitory postsynaptic potentials.  It  is  therefore of 
high  importance  to  explore mechanisms  that  precisely  control  the  activity  of  these  receptors. Great 
interest lies in the fine‐tuning of GABAB receptor‐mediated signaling that allows slight changes in signal 
intensity dependent on  localization, compartmentalization and complex composition. The discovery of 
auxiliary GABAB  receptor  subunits was  already  a  significant  progress  in  elucidating  the  discrepancies 
between  recombinant  and  native  GABAB  receptor  responses.  And  yet,  a  lot  more  mechanisms  of 
receptor regulation are most  likely unexplored until today. This dissertation aims to better understand 
the  KCTD12‐induced  K+  current  desensitization  and  to  describe  new  mechanisms  that  regulate  the 
signaling of GABAB receptors. 





additional  activity‐dependent  binding  to  Gβγ  besides  its  constitutive  binding.  The  activity‐dependent 
binding  interferes with  the  interaction  of Gβγ  to  the GIRK  channel  leading  to  the  inactivation  of  the 
channel and the termination of the  ion flux.  Interestingly, there are two additional mechanisms of fast 
desensitization  of  GABAB‐activated  K+  currents  that  are mediated  by  other  proteins  acting  at  the  G‐
protein. Regulators of G‐protein signaling (RGS) promote desensitization by binding to Gα and enhancing 
the GTPase activity  (Chuang et al., 1998, Ross and Wilkie, 2000,  Jeong and  Ikeda, 2001, Bender et al., 
2004, Mutneja et al., 2005). On the other hand, GPCR kinase 2 (GRK2) induces desensitization by binding 
to Gβγ similar to KCTD12 (Raveh et al., 2010, Turecek et al., 2014). The desensitization induced by GRK2 
differs  to  the one  induced by KCTD12  in  its  irreversibility. GRK2 scavenges  free Gβγ  from channels by 
binding to the “hot spot” region of Gβ, which sequesters the heterotrimeric G‐protein and renders the 







A  further  observation  in  this  study  was  the  acceleration  of  GABAB  receptor  responses  induced  by 
KCTD12. Generally, the association between receptor and G‐protein  is slow and  limited by diffusion. As 







it precisely  times  the activation kinetics and  the desensitization of GABAB  receptor  responses. KCTD12 







The  second  part  of  this work  describes  the  interplay  between  two mechanisms  that  regulate GABAB 





receptor  desensitization  but  as well  the  fast  type  of  receptor  desensitization.  S892  phosphorylation 
rearranges KCTD12  at  the  receptor  thereby  slowing KCTD12‐induced desensitization. This observation 
was evident in heterologous cells as well as in hippocampal neurons, where knock‐in mice with a S892 to 
alanine  mutation  show  an  accelerated  K+  current  desensitization  compared  to  wild‐type  mice.  The 
assembly of KCTD12 with  the  receptor  in  turn  increases  tonic S892 phosphorylation promoting GABAB 
receptor  stability  in  the  cell  surface.  These  results  indicate  that  the  mechanism  of  slow  and  fast 
desensitization influence each other. 
Hippocampal GABAB receptors desensitize only moderately despite a high expression of KCTD12, which 
might  be  explained  by  the  above  described  phosphorylation‐dependency  of  GABAB  receptor 
desensitization  and  a  high  tonic  activity  of  PKA  in  the  hippocampus  (Couve  et  al.,  2002).  As  GABAB 
receptors are negatively coupled to adenylyl cylase and thereby decrease PKA activity, repeated receptor 
activation  sharpens  the  K+  current  response  due  to  a  feedback  loop  to  its  own  phosphorylation.  In 
addition  to  this homologous  regulation of desensitization, other GPCRs  that  stimulate  the  cAMP/PKA 
signaling  might  regulate  GABAB  receptor  desensitization  in  a  heterologous  manner.  Furthermore, 






MUPP1 was  shown  to  affect  the  signaling of 5‐HT2CRs  and GABAB  receptors, whereas 14‐3‐3 proteins 








KCTD12‐induced  K+  current  desensitization  is  activity‐dependent,  a  conformational  rearrangement 
between the GABAB receptor and the G‐protein upon S892 phosphorylation might reduce the rate of G‐
protein  activation  and  thereby  its  kinetics.  The  physiological  relevance  of  the  phosphorylation‐








to  contribute  significantly  to  the  kinetic of  individual  slow  IPSPs. However,  activation of postsynaptic 
GABAB receptors usually requires the concerted action of multiple interneurons or repetitive stimulation 
(Dutar  and Nicoll,  1988,  Isaacson  et  al.,  1993,  Scanziani,  2000,  Kulik  et  al.,  2006)  and  it  is  therefore 
important  to  consider  desensitization  during  sustained  activation.  Given  that  KCTD12‐mediated 
desensitization  persists  for  seconds  (Turecek  et  al.,  2014),  it  is  expected  that  repetitive  activation  of 
GABAB receptors, as  it  is occurring during  in vivo firing pattern, will produce slow  IPSPs with a reduced 
amplitude. While  further work  is needed to  investigate whether  the  temporal  regulation of K+ current 
desensitization  by  KCTD12  influences  physiological  processes,  the  present  results  provide  the  first 
evidence that this mechanism is controlled by second messenger kinases. 
The  third  part  investigates  the  allosteric  influence  of  auxiliary  KCTD  subunits  on  pharmacological 
properties of GABAB receptors. KCTDs bind to both receptor and G‐protein. Therefore, it is possible that 
they  allosterically  regulate  the  signaling  of  GABAB  receptors.  KCTDs  as  well  as  positive  allosteric 




2007).  Here we  show  that  both  effects  of  GS39783  are  independent  on  the  presence  of  the  KCTD 
proteins.  In  general,  all  KCTDs  had  almost  no  allosteric  influence  on  G‐protein  activation  or  on  the 
orthosteric agonist binding‐site, which supports that the KCTDs mainly modulate the receptor response 
at the level of the G‐protein. Furthermore, we found that GABAB receptor associated KCTD8 reduces the 







The  fourth part  focuses on new protein‐protein  interactions within  the GABAB  receptor  complex  and 
their  potential  to  influence  receptor  signaling.  This work  revealed  that  the  auxiliary  GABAB  receptor 
subunit  KCTD16  interacts with  two members  of  the  14‐3‐3  protein  family,  ε  and  γ.  14‐3‐3  proteins 
regulate  the  expression  of  KCTD16  by  promoting  lysosomal  degradation  (mediated  by  14‐3‐3  γ)  and 
enhancing the dimerization and stabilization of KCTD16 (mediated by 14‐3‐3 ε). Additionally, the GABAB2 
expression  is modulated by  14‐3‐3 proteins when  KCTD16  is  co‐expressed  resulting  in  altered GABAB 
receptor signaling as observed in an assay that monitors PKA activity. 14‐3‐3 proteins furthermore seem 
to  interfere  with  the  interaction  between  KCTD16  and  cullin3  (CUL3),  another  newly  described 
interaction. 
The auxiliary GABAB  receptor  subunits were  first described  in 2010 and  the  research  to uncover  their 
functions  is still ongoing (Schwenk et al., 2010). Until now, the best described member of this family  is 
KCTD12.  In contrast to KCTD12, which was shown to drastically affect GABAB receptor signaling and G‐
protein  activation,  an  important  function  for  KCTD16  was  not  shown  so  far.  The  current  study 
characterizes  a  protein‐protein  interaction  specific  for  KCTD16  and  gives  a  first  impression  about  its 
importance  for  the  signaling  of  GABAB  receptors.  KCTD16  binds  14‐3‐3  proteins with  its  H2‐domain. 





H2‐domain of KCTD16. This sequence  is described to promote rapid protein degradation. Although  it  is 
still  under  investigation  whether  this  sequence  is  functional  in  KCTD16,  it  would  explain  the  poor 
heterologous  expression  of  KCTD16  and why  its  expression  is  improved  by  the  deletion  of  the  H2‐
domain. Future experiments will determine the half‐life of KCTD16 and will compare the stability of wild‐
type KCTD16  to a KCTD16 mutant  that  lacks  the PEST sequence. The observation  that KCTD16 protein 
levels  increase  in  the presence of proteasomal  inhibitors support  the hypothesis of a PEST‐dependent 
degradation  of  KCTD16.  However,  co‐expressing  14‐3‐3  γ  redirected  the  degradation  pathway  for 
KCTD16  from  the proteasome  to  the  lysosome. Taking  into account  that cytosolic proteins are mainly 
degraded by the proteasome and membrane‐bound proteins by the lysosome, we propose the following 
model.  In  the  absence  of  14‐3‐3  γ,  KCTD16  is  located  in  the  cytosol  and  is  rapidly  degraded  by  the 
proteasome, which is initiated by the PEST‐sequence. The binding of 14‐3‐3 γ to KCTD16 masks the PEST 
sequence  and  translocates  KCTD16  to  the membrane  to  facilitate  GABAB  receptor  interaction.  Once 
bound to the GABAB receptor, the whole receptor complex is degraded by the lysosome as we also see 
decreased  GABAB2  levels  in  the  presence  of  14‐3‐3  γ.  The  potential  underlying  mechanism  will  be 
discussed in the last paragraph of this chapter. 
Whereas  the  above mentioned mechanism  is  defined  for  cell  types  or  brain  areas  of  high  14‐3‐3  γ 
expression,  areas  of  high  14‐3‐3  ε  expression  show  increased  stability  of  both  KCTD16  and  GABAB 
receptors. 14‐3‐3 ε stabilizes KCTD16 by masking the PEST‐sequence on one hand (as 14‐3‐3 γ) and by 
promoting  the  tetramerization  of  KCTD16  on  the  second  hand.  All  KCTDs  contain  a  tetramerization 
domain and were shown to bind the GABAB receptor in a ratio of 4:1, which confirms their ability to form 




exclusively  form tetramers or whether their  functionality depends on tetramer  formation. The present 
study  suggests  that  KCTD16  does not  exist  as monomers but  forms  higher‐order  oligomers.  14‐3‐3  ε 
further  stabilizes  the  GABAB  receptor  itself  (only  when  KCTD16  is  co‐expressed)  by  elevating  the 
expression levels of GABAB2. The following paragraph will also aim to address this mechanism. 
The  impact of  the KCTD16/14‐3‐3  interaction on  the  signaling of GABAB  receptors  is at  this  stage  still 
under  investigation.  First data already  indicate  that KCTD16  together with 14‐3‐3 proteins affects  the 
expression of GABAB receptors and their signaling through Gα. This suggests a change in the number of 
functional  GABAB  receptors  at  the  plasma membrane.  Still,  it  is  necessary  to  further  underline  this 
hypothesis by quantifying the amount of membrane‐bound GABAB receptors by cell surface ELISA. The 
question arises how this regulation is achieved. We found that KCTD16 interacts with CUL3, a member of 
the  cullin‐RING  ubiquitin  ligase  family.  Other  members  of  the  KCTD  family  were  already  shown  to 









inhibition of degradation. On  the other hand, 14‐3‐3  γ would drive  the  lysosomal degradation of  the 
GABAB receptor/KCTD16 complex as  its binding to KCTD16  is not mutually exclusive with the binding of 
CUL3. To validate these hypotheses,  it  is necessary  to show that CUL3 exists  in a complex with GABAB 




also  regulate  the  signaling of  their  interaction partners. An ongoing project,  in  collaboration with  the 
group  of  Jan  Siemens,  focuses  on  the modulation  of  TRPV1  sensitization  by  GABAB  receptors.  The 
capsaicin  receptor TRPV1  is a nonselective  cation  channel  that  is mainly expressed  in  somatosensory, 
nociceptive  neurons  (Caterina  et  al.,  1997).  TRPV1s  are  sensitive  to  noxious  stimuli  and  initiates 
protective reflexes to prevent tissue damage. Sensitization of TRPV1, which manifests in a low activation 
threshold  of  receptors,  leads  to  hyperalgesia  and  pain  hypersensitivity  (Caterina  et  al.,  2000). 
Antagonists that block TRPV1 have analgesic properties but concurrently produce hyperthermia (Julius, 
2013).  Drugs  that  prevent  or  counteract  the  sensitization  of  TRPV1  are  therefore  a more  promising 
approach for pain therapy. Current data of this project reveal so far that activation of GABAB receptors 















suppresses  desensitization  of  gamma‐aminobutyric  acid  type  B  receptor‐mediated  signaling  by 
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